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ABSTRACT 
 
DEVELOPMENT OF TOPICAL OPHTHALMIC IN SITU GEL-FORMING 
ESTRADIOL DELIVERY SYSTEM INTENDED FOR THE PREVENTION OF AGE-
RELATED CATARACTS 
 
 
By 
Udaya K. Kotreka 
August 2011 
 
Dissertation supervised by Moji Christianah Adeyeye, Ph.D. and Vicki Davis, Ph.D. 
The increased risk of cataracts in aging women versus men, the reduced risk in 
women on hormone replacement therapy, and studies in animal models suggest that 
estrogen may protect lens transparency. To use estrogen for cataract prevention, we 
hypothesized that an ophthalmic estradiol in situ gel-forming formulation would be more 
effective for inducing lenticular estrogen responses without undesired uterine stimulation 
associated with systemic delivery. The following aims tested this hypothesis: 1) to 
develop an ophthalmic in situ gel-forming estradiol (E2) delivery system that is stable and 
safe; 2) to determine if ocular estrogen formulation was more effective than systemic 
therapy in inducing cataracts and activating estrogen-regulated genes in ERΔ3 mice, 
while minimizing systemic side effects in the estrogen-responsive uterus; 3) to determine 
  v 
ocular safety and to estimate ocular and systemic drug bioavailability of the formulation 
in rabbits.  
An in situ gel-forming estradiol solution eye drop containing gellan gum polymer 
was developed as it offers a unique advantage of solution for easy handling which then 
undergoes a sol-gel transition in the presence of tear fluid in the eye to prolong drug 
contact time and enhance ocular bioavailability. Pre-formulation studies identified 
excipients that provided acceptable characteristics of clarity, isotonicity, and sterility to 
the ocular formulation. Using design of experiments approach, an optimized formulation 
with desirable viscoelastic and drug release characteristics was identified. In ERΔ3 mice, 
estrogen-dependent cataracts occurred earlier at lower doses for ophthalmic versus 
systemic delivery. Further, gene expression and uterotrophic studies demonstrated that 
ocular estrogen therapy was more effective than systemic delivery in stimulating an 
estrogen-regulated gene in the ER3 lens and in minimizing systemic absorption as 
evidenced by little to no rodent uterine stimulation. Additionally, the in vivo studies in 
rabbits demonstrated that the optimized estradiol formulation was practically non-
irritating to the eyes with maximal ocular drug absorption and minimal systemic drug 
bioavailability. Accelerated stability study indicated that the formulation was stable with 
a tentative shelf-life of 2 years assigned to the product. 
In summary, the developed ophthalmic estradiol formulation has the desired 
safety profile, stability, and ocular bioavailability required for future testing in animals 
and humans for cataract prevention.   
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CHAPTER I  
INTRODUCTION 
 
I.A. Statement of the Problem 
Cataracts are a leading cause of blindness affecting millions of people across the 
globe (Rucker CW, 1965; Taylor et al., 2001).
 
Recently, the protective effect of estrogen 
in reducing cataracts risk has been demonstrated in various epidemiological and pre-
clinical studies (Bigsby et al., 1999; Davis et al., 2002; Chen et al., 2004; Benitez del 
Castillo et al., 1997; Cumming RG and Mitchell P, 1997; Worzala et al., 2001; Fletcher, 
2010). 17β-estradiol (E2) is the most potent estrogen that occurs naturally in the human 
body. Epidemiological studies carried out to investigate the role of age and gender on the 
prevalence of cataracts indicated the possible role of estradiol in retarding cataract 
formation in women receiving hormone replacement therapy (Benitez del Castillo et al., 
1997; Cumming RG and Mitchell P, 1997; Worzala et al., 2001; Lindblad et al., 2010). 
Prevalence of cataracts in postmenopausal women was higher relative to men of similar 
age due to the low levels of estrogen after menopause (Livingston et al., 1994; Klein et 
al., 1998). Therefore, the reduced risk observed in post menopausal women receiving 
hormone replacement therapy suggests a possible role of the female hormone, estrogen, 
in retarding cataract formation.  
Studies done in various rodent models to investigate the relationship between 
estrogen deficiency and cataract formation have provided further evidence towards the 
protective effect of estrogen against loss of lens transparency (reviewed in Worzala et al., 
2001). Despite current availability of estrogen supplements in the form of oral (Lokind et 
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al., 1996; Haiharan et al., 2006), buccal (Kitano et al., 1998), vaginal (Bachman G, 1998), 
nasal (Al-Ghananeem et al., 2002), and transdermal formulations (Loftsson T and Bodor 
N, 1989; Variankaval et al., 2002), many women are hesitant to take them due to high 
risk of breast and endometrial cancers associated with high systemic levels of estrogen 
and its metabolic product estrone (Colditz et al., 1995; Kerdelhué and Jolette, 2002; 
Haiharan et al., 2006; Longcope et al., 1985; Lokind et al., 1996). Therefore a non-oral 
and non-systemic route of estrogen delivery that will limit the amount of drug that is 
systemically available will be advantageous in reducing the side effects. 
 
The recent discovery of estrogen receptor (ER) in rat, bovine, and human retina 
and rat, canine, and human lens suggests that eye can respond directly to estrogen 
(Johansson and Oehman, 1985; Zhang et al., 2003; Colitz et al., 2009). Estradiol (E2) is 
the most potent form of estrogen which acts by regulating the transcription of estrogen-
responsive genes.  It is a lipophilic drug with poor aqueous solubility (0.03mg/L at 25C) 
and high permeability (logP of 3.94) (Loftsson et al., 2002). Given the evidence 
supporting the protective role of estrogen in cataracts reduction, E2 delivered by 
ophthalmic route will be able to permeate cornea and interact with the estrogen receptors 
(ER) locally in the eye and delay or prevent the onset of cataracts at much lower doses 
compared to systemic delivery. Ocular estrogen therapy would also offer an attractive 
alternative to surgery which, so far, is the only available treatment for cataracts. 
 
Drug delivery to ocular mucosa for local treatment is associated with great 
possibilities, but often also with many obstacles. The physiological constraints imposed 
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by the protective mechanisms of the eye lead to low absorption of drugs (Davies NM, 
2000). The most common way to deliver drugs to the eye is to instill an aqueous solution 
of the drug into the eye. The bioavailability of a drug introduced in this way is often very 
low, typically <5%, depending on its physicochemical properties (Nanjawade et al., 
2007). Such low bioavailability is attributed to extensive precorneal drug loss by 
nasolachrymal drainage. The rapid elimination of the instilled drug often results in a short 
duration of therapeutic effect and, consequently, the need for a frequent dosing regimen 
(Bourlais et al., 1998). Also, systemic absorption of E2 solution drained through the 
nasolachrymal duct may increase the risk for undesirable side effects (e.g., breast cancer, 
endometrial cancer, etc.). Ocular therapy would be significantly improved if the 
precorneal residence time of E2 could be increased. The best way of doing so is by 
designing in situ gel-forming drug delivery systems that are conveniently administered 
into the eye as a liquid; whereafter, they undergo a transition into a gel brought about by 
the presence of stimuli-responsive polymers. 
An in situ gel-forming solution delivery system combines the advantages of a 
solution, being patient convenient, with the favorable residence time of a gel. Due to their 
viscoelastic properties, these gels resist ocular drainage leading to longer contact times 
and duration of action. Parameters that can change and trigger this sol-gel phase 
transition include pH or temperature or ionic strength of the tear fluid. Numerous types of 
stimuli-responsive polymers used in ocular drug delivery systems have been reviewed 
previously (Mundada and Avari, 2009). Of all these systems, gellan gum-based in situ gel 
systems have been shown to significantly prolong the ocular contact time of the drug in 
animal and human studies (Carlfors et al., 1998; Schenker et al., 2000). The gellan 
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systems form clear gels in the presence of mono (Na
+
, K
+
) and divalent (Ca
2+
) cations of 
the tear fluids with good in situ gelling characteristics at as low as 0.1%(w/v) polymer 
concentration (Paulsson et al., 1999). A key challenge in the development of a sterile 
ophthalmic in situ gel-forming solution lies in the ability to ensure that the formulation 
has acceptable characteristics of sterility, clarity, tonicity, drug release, viscoelasticity, 
and stability. E2 being a biopharmaceutical classification system (BCS) class-II drug, its 
delivery by ocular route as an in situ gel-forming solution is also limited by its poor 
aqueous solubility.  
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I.B. Hypothesis and Objectives 
The project is based on the central hypothesis that a safe and stable in situ gel-
forming topical ophthalmic 17-estradiol (E2) drug delivery system, with appreciable 
ocular absorption in order to stimulate estrogen responses but less systemic absorption, 
can be developed for future testing for its efficacy in the prevention of age-related 
cataracts. 
 
Given the central hypothesis, the objectives were to: 
1) Perform pre-formulation and formulation development of ion-activated in situ 
gel- forming E2 eye drops 
2) Identify the optimum formulation with desirable product performance 
characteristics using statistical design of experiments 
3) Establish pre-clinical in vivo safety of the developed E2 ophthalmic formulation 
and capacity to induce known estrogen response in ER∆3 transgenic mouse 
4) Evaluate in vivo ocular safety and estimate ocular and systemic drug 
bioavailability from the optimized formulation in rabbits 
5) Evaluate stability of the optimized in situ gel-forming E2 ophthalmic formulation 
according to ICH Q1A (R2) guidelines 
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I.C. Literature Review 
I.C.1. Cataracts: What is it? 
A cataract is defined as a clouding of the eye's natural lens.  In normal eyes, the 
lens focuses the incident light on the retina to activate photoreceptors and cause vision. In 
cataractous eyes, due to the clouding of lens the incident light is scattered causing blurred 
vision. It is the leading cause of blindness in the world and affects nearly 20 million 
people at or above age 40 year in US alone (Rucker CW, 1965; Taylor et al., 2001). The 
factors that lead to cataract formation include aging, diabetes mellitus, cigarette smoking, 
elevated body mass index, UV light, and alcohol use (Ellwein and Urato, 2002; Worzala 
et al., 2001). Since age is the single greatest factor, every one is at risk of developing 
cataract. The age-related cataracts are classified as cortical, nuclear, and posterior sub-
capsular based on their anatomical location in the lens of the eye. 
 
I.C.2. Cataracts: Treatment Options and Impact on Society 
I.C.2.1. Surgery for the treatment of cataracts 
 Surgical treatment to replace the cataractous lens with a synthetic lens is the only 
means currently available to treat cataracts. The surgery is a cure; however, implantation 
of a synthetic lens may only temporarily restore vision as residual cells associated with 
the lens capsule often grow to form new opacities called secondary cataracts, a risk often 
associated with elderly patients. In these patients, the loss of sight that occurs is 
physically and psychologically disabling due to the loss of independence. The World 
Health Organization (WHO) estimates that in 2020, approximately 75 million individuals 
will suffer from vision problems related to cataracts with a projected economical cost of 
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$110 billion dollars in the United States (Ellwein and Urato, 2002). Despite such a huge 
burden on economy there are currently no available treatments that delay or prevent 
incidence of cataracts. It was also reported that a modest delay of only 14% in the rate of 
cataract development would delay the onset of cataract by a decade and reduce the 
number of surgeries by 50% (Javitt et al., 1996). 
 
I.C.2.2. Alternative treatment for cataracts: Role of estrogens 
Numerous epidemiological studies carried out to investigate the role of age and 
gender in the incidence of cataracts suggests protective role of estrogen against cataracts. 
These studies associated the higher prevalence of cataracts in women after menopause 
relative to men of similar age to the low levels of estrogen after menopause (Livingston 
et al., 1994; Leske et al., 2004; Fletcher, 2010). Cataracts are observed as a common side 
effect in women on the anti-estrogen cancer therapy, tamoxifen (Greaves et al., 1993; 
Gail et al., 1999; Reeder et al., 2007; Li et al., 2008), which suggests that inhibition of 
estrogen action may result in the loss of lens transparency. Blue Mountain Eye Study 
(BMES) and Beaver Dam Eye Study (BDES) established a correlation between cataract 
incidence and the age at puberty and menopause in women. It was observed that women 
with late age of puberty and/or earlier onset of menopause had greater risk for cataracts 
and vice versa; these findings suggest that a shorter lifetime exposure to endogenous 
estrogens might increase the risk of age-related cataracts (Cumming and Mitchell, 1997; 
Klein et al., 2000).  Also, the evidence that postmenopausal women on hormone 
replacement therapy (HRT) experienced lower risk for cortical cataracts suggested a 
possible role of the female hormone, estrogen, in retarding cataract formation. 
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In conjunction with epidemiological evidence, the protective effect of estrogen 
against loss of lens transparency in cataracts is also seen in animal models (Bigsby et al., 
1999; Hales et al., 1997; Davis et al., 2002).  In an in vivo rodent model, ovariectomized 
rats were treated with a cataractogenic compound, methylnitrosourea (MNU) to induce 
cataracts that simulate morphological changes associated with age-related cataracts in 
humans. Estrogen treatment significantly lowered the incidence of methylnitrosourea 
(MNU)-induced cortical cataracts compared to untreated ovariectomized rats (Bigsby et 
al., 1999; Roy et al., 1989). In addition, the type of estrogen used also influenced the 
efficacy in inhibiting lens opacities, with the weaker estrogen, estrone, being less 
effective in reducing the incidence of cataracts than the more potent estrogen, 17-
estradiol (E2).  In another rodent model, transforming growth factor (TGF)--induced 
sub-capsular cataracts in cultured rat lenses were reduced when the potent form of 
estrogen, 17-estradiol, was administered to the rat before lens culture (Hales et al., 
1997; Chen et al., 2004). Based on the evidence of epidemiological studies and laboratory 
tests in rodent models, it is suggested that estrogen is protective; however, little is known 
on how estrogen exerts protection against cataract development.  
Classical mechanism of estrogen action involves binding to estrogen receptors 
(ER) in the cell nucleus to form dimers that bind to an estrogen response element (ERE) 
and regulating the transcription of estrogen-responsive genes. Accordingly, if estrogen 
provides protection in the lens against the development of age-related cataracts, more 
than likely its actions will be mediated through its receptors. The two subtypes of ER that 
are known to exist currently are ER and ER. ERα was the first estrogen receptor 
identified and cloned in 1986 (Green et al., 1986). The second ER, ERβ, was identified in 
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1996 (Kuiper et al., 1996). Nuclear estrogen receptors have been identified in ocular 
tissues (Ogueta, 1999; Bigsby, 1999; Wickham 2000; Cammarata, 2004). ER receptor 
transcripts were detected for ERα in lenses from rat and rabbits (Bigsby, 1999; Wickham, 
2004) and for ERβ in rat lenses (Bigsby, 1999). Further, ERα and ERβ messages were 
detected in human lens epithelial cells (Cammarata, 2004) and ERα protein was detected 
in the human lens (Ogueta, 1999). Expression of ER receptors in the lens of rodent 
animals and humans suggest the potential of estrogen to act directly via estrogen 
receptors expressed in the lens.  
To test if lack of estrogen receptor or inhibition of estrogen signaling mechanism 
could lead to cataract development, Davis and colleagues developed an ERΔ3 mouse 
model to investigate estrogen inhibition (Davis et al., 2002). ERΔ3 mice express the 
ERΔ3 receptor, a dominant negative variant of ERα, resulting from the in-frame deletion 
of exon3 by alternative splicing.  The region of the ERα receptor translated from exon 3 
is part of the DNA-binding domain. Deletion of this region results in the receptor lacking 
the second zinc finger while all other domains of ERα such as ligand-dependent 
dimerization domain remain intact. In this transgenic model, morphological changes 
associated with cortical cataracts are spontaneously developed in adult female, but not 
male, ERΔ3 mice due to inhibition of estrogen action via estrogen activation of the 
dominant negative estrogen receptor. But, cataracts were not observed in adult female 
mice if they are ovariectomized before, but not after the onset of puberty. In addition, 
spontaneous cortical cataracts were observed in male and ovariectomized female ERΔ3 
mice treated with exogenous estrogen, 17β-estradiol (E2),  but not in ovariectomized mice 
treated with vehicle; which suggest that eliminating exposure to estrogens can prevent 
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cataracts in ERΔ3 mice (Kirker and Davis, unpublished). These results also indicate that 
estrogen is required to activate ERΔ3 repressor to dimerize and, thus, inhibit the activity 
of the wild-type ER. The major mechanism for dominant negative activity occurs through 
the formation of heterodimers; that is, the ERΔ3 dominant negative variant could bind to 
and form a complex with wild-
1994; Bollig and Miksicek, 2000). Based on in vitro studies, these specific ERΔ3:ERα 
heterodimers do not possess the ability to bind to an ERE and/or transactivate an estrogen 
responsive gene (Wang and Miksicek, 1991; Yen and Chin, 1994). These data agree with 
studies in women showing estrogen is protective, since women would not have the ER3 
inhibitor present in their eyes to inhibit estrogen action in the lens. In addition to estrogen 
receptor-dependent mechanisms, the actions of estrogens in the eye may also occur by 
estrogen receptor-independent mechanisms, where estradiol acts as an anti-oxidant 
(Wang et al., 2003). For example, estrogen has been shown to provide neuroprotection 
and protection against macular degeneration by acting as a free-radical scavenger, which 
does not require an estrogen receptor (Prokai et al., 2003). 
Kirker and Davis (unpublished data) also observed E2 binding sites in the nuclear, 
cytosolic, and membrane fractions of both the wild-type mouse and human lens, which 
suggests that estrogen can bind directly to receptors present in the lens. If it binds to these 
high affinity receptors, estrogen has the potential to regulate its downstream signaling 
mechanism critical for the maintenance of lens transparency. In addition, E2 was capable 
of stimulating the expression of several genes (pax6, six3, sox2, tcfap2a, and pdgfa) 
known to influence development, proliferation, and differentiation in the lenses of the 
ERΔ3 mice, which further substantiates the evidence that estrogen possess actions in 
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lens.  Since ERΔ3 receptors are also expressed in the retina, a known ocular tissue that 
influences lens cell proliferation, the protective nature of E2 in the lens may be a result of 
E2 action in the neighboring cells at the retina which in turn induces changes that are 
observed in the cells of the lens. 
Since E2 can bind to its receptors in the lens and is protective against cataracts, the 
current work attempts to develop a topical ophthalmic E2 delivery system and evaluate its 
capacity to induce known estrogen responses in ERΔ3 mouse relative to systemic E2 
therapy.  ERΔ3 cataract model will be used to evaluate different estrogen therapies for 
cataract development after estrogen exposure and also to investigate the regulation of 
estrogen-induced genes in the lens. If topical estrogen therapy remains safe and 
efficacious, it will pave the way for testing the potential of estrogen for cataract 
prevention. 
 
I.C.3. 17β-estradiol (E2): Drug Profile 
I.C.3.1. Chemical structure 
17β-estradiol or estradiol (Figure I.1.) is a white crystalline powder, chemically 
described as estra-1, 3, 5(10)-triene-3, 17β-diol. It has an empirical formula of C18H24O2 
and molecular weight of 272.39.  
 
Figure I.1: Chemical structure of 17β-estradiol (E2) 
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I.C.3.2. Clinical pharmacology 
The main actions of estrogen drug products are to regulate the transcription of 
estrogen-responsive genes. Estrogens diffuse through cell membranes, distribute 
themselves throughout the cell, bind to and activate the nuclear estrogen receptor, a 
DNA-binding protein which is found in estrogen-responsive tissues. The activated 
estrogen receptor binds to specific DNA sequence called estrogen response elements 
(ERE) and modifies the transcription of estrogen-regulated genes (Figure I.2). Estrogen 
receptors have been identified in tissues of the reproductive tract, breast, pituitary, 
hypothalamus, liver, and bone of women and also in human lens and retina (Couse and 
Korach 1999; Gustafsson, 1999; Ogueta, 1999; Cammarata, 2004; Zhang et al., 2003). 
 
                      
Figure I.2: Estradiol (E2) mechanism of action (Reproduced with permission from  
Elsevier) 
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Estrogens are important in the development and maintenance of the female 
reproductive system and secondary sex characteristics. By a direct action, they cause 
growth and development of the uterus, fallopian tubes, and vagina. With other hormones, 
such as pituitary hormones and progesterone, they cause enlargement of the breasts 
through promotion of ductal growth, stromal development, and the accretion of fat. 
Estrogens are intricately involved with other hormones, especially progesterone, in the 
processes of the ovulatory menstrual cycle and pregnancy, and affect the release of 
pituitary gonadotropins. They also contribute to the shaping of the skeleton, maintenance 
of tone and elasticity of urogenital structures, changes in the epiphyses of the long bones 
that allow for the pubertal growth spurt and its termination, and pigmentation of the 
nipples and genitals (Couse and Korach, 1999). 
Estrogens occur naturally in several forms. The primary source of estrogen in a 
normally cycling adult woman is the ovarian follicle, which secretes 70 to 500 
micrograms of estradiol daily, depending on the phase of the menstrual cycle. This is 
converted primarily to estrone, which circulates in roughly equal proportion to estradiol, 
and to small amounts of estriol. After menopause, most endogenous estrogen is produced 
by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral 
tissues. Thus, estrone, especially in its sulfate ester form, is the most abundant circulating 
estrogen in postmenopausal women. Although circulating estrogens exist in a dynamic 
equilibrium of metabolic interconversions, estradiol is the principal intracellular human 
estrogen and is substantially more potent than estrone or estriol at its receptors. 
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I.C.3.3. Clinical pharmacokinetics 
Absorption 
Estrogens used in therapy are well absorbed through the skin, mucous 
membranes, and gastrointestinal tract. When applied for a local action, absorption is 
usually sufficient to cause systemic effects. Circulating estrogens modulate the pituitary 
secretion of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating 
hormone (FSH) through a negative feedback mechanism. Estrogens act to reduce 
elevated levels of these hormones seen in postmenopausal women. 
Distribution 
The distribution of exogenous estrogens is similar to that of endogenous 
estrogens. Estrogens are widely distributed in the body and are generally found in higher 
concentrations in the sex hormone target organs. Estrogens circulate in the blood largely 
bound to sex hormone binding globulin (SHBG) and albumin.  
Metabolism 
Exogenous estrogens are metabolized in the same manner as endogenous 
estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic 
interconversions. These transformations take place mainly in the liver. Estradiol is 
converted reversibly to estrone, and both can be converted to estriol, which is the major 
urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and 
glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and 
hydrolysis in the gut followed by re-absorption. In postmenopausal women, a significant 
proportion of the circulating estrogens exist as sulfate conjugates, especially estrone 
sulfate, which serves as a circulating reservoir for the formation of more active estrogens.  
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Excretion 
Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and 
sulfate conjugates. 
 
I.C.4. Estradiol (E2) Topical Ocular Drug Delivery System 
As discussed in I.C.2.2, estrogens (with E2 being the most potent endogenous 
estrogen) are shown to be protective in preventing cataracts. However, many women are 
concerned about estrogen treatments due to the potential risk with breast cancer, 
endometrial cancer, etc., associated with drug delivery systems that lead to high systemic 
levels of estrogen, such as through the oral (Lokind et al., 1996; Haiharan et al., 2006), 
buccal (Kitano et al., 1998), vaginal (Bachman G, 1998), nasal (Al-Ghananeem et al., 
2002), and transdermal formulations (Loftsson T and Bodor N, 1989; Variankaval et al., 
2002) routes. In addition, since the lens is an avascular tissue, delivery via systemic 
routes would be expected to be less efficient. Hence, a topical ocular delivery of estrogen 
that will allow localized interactions with ER receptors in the lens to elicit known 
estrogen responses would be a more efficient way to treat cataracts. Such a localized 
delivery will reduce drug dose and frequency of administration leading to lower systemic 
drug levels and incidence of side effects associated with it. However, before an ocular 
formulation can be developed, it is important to understand the anatomy of the eye.  
 
I.C.4.1. Anatomy of the eye 
 A schematic representation of the human eye is depicted in Figure 1.3. In ocular 
delivery, the physiological constraints imposed by the protective mechanisms of the eye, 
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like short pre-corneal residence time of the solutions due to constant lachrymal drainage 
usually results in low absorption of drugs and, consequently, a short duration of the 
therapeutic effect.  The faster washing by tear fluid in response to body‘s reflex defense 
mechanism also results in frequent administration. Moreover, systemic absorption of the 
drug drained through the nasolachrymal duct may result in some undesirable side effects 
particularly in the case of estradiol formulations. Among the factors that limit ocular 
absorption is the relatively impermeable nature of the corneal barrier. Nevertheless, the 
barrier also serves to reduce undesired systemic absorption and side effects associated 
with many drugs. 
 
 
Figure I.3: Schematic representation of the human eye (Ludwig et al., 2005) 
(Reproduced with permission from Elsevier). 
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 The cornea consists of three membranes, the epithelium, the endothelium, and 
inner stroma which are the main absorptive barriers. The epithelium composed of 
lipophilic cellular layers acts as barrier to ion transport. The tight junctions of epithelium 
serve as a selective barrier for small molecules and prevent diffusion of macromolecules 
via the paracellular route. The stroma beneath the epithelium is a highly hydrophilic layer 
making up 90% of the cornea. The more lipophilic the drug is, the more resistance there 
is to cross the stroma and the more hydrophilic a drug, the more resistant the transport 
across the epithelium. Hence, physicochemical drug properties, such as lipophilicity 
(Rojanasakul et al., 1992), solubility (Schoenwald and Huang, 1983), molecular size and 
shape (Liaw and Robinson, 1992), and charge and degree of ionization (Maren and 
Jankowska, 1985) affect the route and rate of permeation in cornea.  
 
1.C.4.2. Ocular drug transport and pharmacokinetics 
Corneal route 
Drug absorption from the surface of the eye can be either corneal or non-corneal 
(Fig. I.3). For most ocular drugs, passive diffusion is the main transport process across 
the cornea. Passive diffusion is influenced by molecular weight, partition coefficient, and 
degree of ionization of the drug. The corneal epithelium is the main limiting barrier for 
hydrophilic drugs that penetrate through the paracellular pathway. The corneal surface 
epithelial intercellular pore size has been estimated to range between 20 Å (Hämäläinen 
et al., 1997b) and 30 Å (Tonjum 1974; Lee et al., 1986) and only very small ionic and 
hydrophilic molecules penetrate corneal epithelium paracellularly. The corneal 
epithelium is negatively charged and because the isoelectric point is 3.2, the paracellular 
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space is more permeable to cations than to anions at physiological pH (Rojanasakul and 
Robinson 1989; Liaw et al., 1992). Most drugs that are used clinically are sufficiently 
lipophilic to permeate across the cornea via transcellular route (Sasaki et al., 1999). Drug 
lipophilicity is one of the most important factors and it has been reported that the log 
(partition coefficient) of 2-3 is optimal for corneal penetration (Schoenwald and Ward 
1978; Huang et al., 1983; Schoenwald and Huang 1983). In general, adjusting pH so that 
drug is mostly in the unionized form increases its lipophilicity and, thus, its transcellular 
permeability and ocular absorption (Burstein and Anderson 1985; Mitra and Mikkelson 
1988). The hydrophilic stroma represents a limiting barrier for penetration by highly 
lipophilic compounds. The corneal endothelium is lipophilic in nature (Huang et al., 
1983). It is a 'leaky' barrier, which allows both paracellular and transcellular permeability 
of many drugs (Prausnitz and Noonan 1998). 
 
Non-corneal route 
The non-corneal route involves penetration across the conjunctiva and sclera into 
the intraocular tissues (Fig. I.3). The conjunctiva is a relative leaky membrane with rich 
blood flow and a large surface area (Watsky et al., 1988). Despite these properties, this 
pathway does not appear to be important in drug absorption for most ocular drugs, but the 
route has been shown to be particularly important for hydrophilic compounds with large 
molecular weights (Ahmed and Patton 1985 and 1987; Chien et al., 1990; Hämäläinen et 
al., 1997a and b). Drug absorption through conjunctiva is influenced less by the 
molecular size and lipophilicity than in the cornea. In general, sclera shows higher 
permeability than the cornea and conjunctiva. Conjunctival uptake via its blood vessels 
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and solution drainage via the nasolacrimal duct may lead to systemic absorption. In 
addition, drainage of tears and instilled solutions away from the front of the eye increase 
the precorneal loss of the drug (Patton and Robinson 1976). 
 
I.C.4.3. Challenges with conventional ophthalmic formulations  
 As reported in literature the primitive ophthalmic solutions, suspensions, and 
ointment dosage forms accounted for about 90% of available ophthalmic formulations in 
U.S, and a similar percentage is still presumably valid for the current global market. 
Solution dosage forms accounts for a majority (65%) of the commercially available 
dosage forms. The practical reasons for selecting solutions are the generally favorable 
cost advantage, the greater simplicity of formulation development and production, and 
the good acceptance by patients despite a little burning. But, the bioavailability of a drug 
introduced in this way is often very low, typically <5%, depending on its 
physicochemical properties (Figure I.4) (Nanjawade et al., 2007).
 
Such low 
bioavailability is attributed to extensive precorneal drug loss by nasolachrymal drainage. 
The rapid elimination of the instilled drug often results in a short duration of therapeutic 
effect and, consequently, the need for a frequent dosing regimen. Also, systemic 
absorption (i.e., ~50-100% of instilled dose) of drug drained through the nasolachrymal 
duct may increase the risk for undesirable side effects (Nanjawade et al., 2007; Martens-
Lobenhoffer and Banditt, 2002). For example, topical administration of beta-blockers for 
treatment of wide angle glaucoma causes systemic side effects on the heart (Meseguer et 
al., 1994; Qian et al., 2010). 
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An optimum ocular drug delivery system would be one which can be delivered in 
eye-drop solution form with no creation of blurred vision or irritancy and which would 
need no more than one to two instillations each day for it to sustain its therapeutic effect. 
The reportedly low ocular bioavailability (<5%) of many drugs as discussed earlier was 
due to poor contact time of the instilled dose with the ocular tissues and faster elimination 
due to tear drainage (Bourlais et al., 1998; Davies NM, 2000). Various ocular tear and 
solute balance mathematical models have been developed to relate the characteristics of 
the instilled preparations such as viscosity and surface tension to the factors that affect 
ocular bioavailability such as pre-corneal tear volume and drainage rate (Zignani et al., 
1995; Zhu and Chauhan, 2005).  
 
Figure I.4: Schematic diagram of ocular absorption (Nanjawade et al., 2007) 
 
Ocular drug absorption by corneal route is a much slower process than its 
elimination. A simplified ocular pharmacokinetic model describing the movement of a 
topically applied drug to the eye is shown in Figure I.5. For many drugs Kloss is 
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approximately 0.5–0.7/min and Kabs is about 0.001/min (Kaur and Kanwar, 2002). The 
sum of these two rate constants controls the fraction of the applied dose absorbed into the 
eye (Lee and Robinson, 1986). Thus, the ocular bioavailability can be increased 
significantly by decreasing Kloss or by increasing Kabs. The former can be achieved by 
modifying the ocular dosage forms and the latter by formulating ocular dosage forms 
containing lipophilic pro-drugs or by adding penetration enhancers. Studies carried out 
using viscous preparations resulted in a higher ocular bioavailability due to higher contact 
time with the ocular tissues and reduced systemic absorption due to relatively lower tear 
drainage rate (Guryny et al., 1981; Desai et al., 1998; Bonacucina et al., 2006). Hence, 
most of the current formulation efforts in ocular delivery have focused on maximizing 
ocular drug absorption through prolongation of the drug contact (residence) time in the 
cornea and conjunctival sac, as well as to slow drug release from the delivery system and 
minimize precorneal drug loss. 
 
Figure I.5: Ocular drug pharmacokinetics in the eye (Kaur and Kanwar, 2002). 
 
To overcome the challenges associated with conventional solution dosage forms, 
alternative dosage forms such as suspensions, ointments, inserts, and aqueous gels, have 
been investigated in attempts to extend the ocular residence time of the medications for 
topical application to the eye (Lee and Robinson, 1986; Bourlais et al., 1998; Kuno and 
Fujii, 2011). These alternative ocular drug delivery systems offer some improvement 
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over a conventional liquid dosage form, but are not devoid of problems of their own 
typically, blurred vision (e.g. ointments) or lack of patient compliance (e.g. inserts). Their 
problems have resulted in their poor acceptance. Therefore, good ocular bioavailability 
following topical delivery of a drug to the eye remains a challenge yet to be satisfactorily 
resolved.  
 
I.C.4.4. In situ gel-forming systems for ocular drug delivery 
From the point of view of patient acceptability, a liquid dosage form that can 
sustain drug release and remain in contact with the cornea of the eye for extended periods 
of time is ideal. If the precorneal residence time of a drug could be improved only 
modestly, then improved local bioavailability, reduced dose concentrations, less total 
drug dose, improved patient acceptability, and reduced dosing frequency may result. 
Therefore, delivery systems based on in situ gel-formation offer an attractive alternative. 
Such systems involve a phase transition in which the instilled liquid form gels upon 
reaching the cul-de-sac of the eye.
 
 Therefore, these systems offer the dual advantage of 
an easy to administer liquid formulation along with the increased residence time of a gel.  
Parameters that can change and trigger the phase transition of in situ gels include 
pH, temperature, and ionic strength (Shulin Ding, 1998; Mundada and Avari, 2009). 
Literature examples of some of the polymers used in in situ gel systems that employed 
one or more of these phase change mechanisms include the following: 
 Gelling triggered by a change in pH - CAP (cellulose acetate phthalate) latex, cross 
linked polycarbophil acid and its derivatives such as carbomers and polycarbophil 
(Desai and Blanchard, 1995; Le Bourlais et al., 1998). 
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 Gelling triggered by temperature change - poloxamers, methyl cellulose, and Smart 
Hydrogel
TM
 (Gurny R, et al. 1987; Rozier et al., 1989; Cohen et al., 1997). 
 Gelling triggered by change in ionic strength - Gelrite (gellan gum) and alginate 
(Rozier et al., 1997; Carlfors et al., 1998; Paulsson et al., 1999; Yuguchi et al., 2002)  
 Combination system with a thermally-induced gelling material (methyl cellulose) and 
pH-induced gelling material (carbomer) was also used to achieve in situ gelling 
property with less total polymer content (Bonacucina et al., 2006).
 
 
In all of the above systems, a polymer is used as the ―gelling‖ system. Many high 
molecular weight polymers (Figure I.6) with different functional groups (such as 
carboxyl, hydroxyl, amino, and sulfate) capable of forming hydrogen bonds, yet not 
crossing biological membranes, have been screened as possible excipients for in situ gel-
forming ocular delivery systems (Ludwig, 2005; Mundada and Avari, 2009). 
 
I.C.4.5. Polymers for in situ gel-forming drug delivery systems  
Cellulose derivatives 
A number of substituted cellulose-ethers have been employed for artificial tear 
solutions and as viscosity-enhancing ophthalmic vehicles (see Figure I.6) (Calonge, 2001; 
Lin and Boehnke, 1999). Methylcellulose also possesses wound-healing properties and is 
a suitable tear substitute for dry eyes, especially for those with punctate lesions (Toda et 
al., 1996). All cellulose-ethers impart viscosity to the solution and they have wetting 
properties and increase the contact time by virtue of their film forming properties. Some 
cellulose-ethers (e.g. hydroxypropylmethylcellulose and hydroxypropylcellulose) also 
exhibit surface active properties, interact with components of the tear film, and alter the 
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physicochemical parameters governing the tear film stability (Benedetto et al., 1975).
 
Surface active viscosifying agents can influence the blinking rate, which in turn 
influences the elimination of the drug instilled. They cause irritation and extensive 
lachrymation, provoking a rapid wash out of the ophthalmic solution and, consequently, a 
poor bioavailability. Generally, less surface active hydroxyethylcellulose is better 
tolerated, but the mucoadhesive properties of non-ionic cellulose-ethers are rather poor 
(Meseguer et al., 1993; Sechoy et al., 2000).
 
However, sodium carboxymethylcellulose 
(NaCMC) exhibits a mucoadhesive capacity comparable to that of poly (acrylic acid) 
(PAA) (Bourlais et al., 1995). 
 
Acrylates 
The mucoadhesive properties of poly (acrylic acid) are due mainly to hydrogen 
bonding, while hydrophobic interaction with mucin is not significant (Leung and 
Robinson, 1988). When anionic polymers interact with mucin, the maximum interactive 
adhesive force occurs at an acidic pH, suggesting that the mucoadhesive polymer in its 
protonated form is responsible for the mucoadhesion. The swollen polymer entangles 
with mucin on the eye surface, stabilizing a thick hydrogel structure (Degim and 
Kellaway, 1998). 
 
Polyanionic polymers, such as polyacrylates or carbomers, were 
proposed as long-lasting artificial tears for the relief of dry eye syndrome and traumatic 
injury. The use of these high molecular weight polymers is based on inherent mucus-like 
and lubricating properties, shear thinning behaviour, and good retention on the ocular 
surface (Oescher and Keipert, 1999; Bron et al., 1998). To enable the controlled release 
of drugs with low solubility, Setiawan and colleagues synthesized poly(acrylic acid)–
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cyclodextrin conjugates (Carbopol 934P:hydroxypropyl-beta-cyclodextrin) (Setiawan et 
al., 1998). When administrated to the eye, an increase in the bioavailability of the drug 
complexed with cyclodextrin can be obtained. Moreover, after instillation, the 
preparation forms a gel. In rabbits, the aqueous humor bioavailability (as determined by 
the area under the concentration time profile over the first 3 h) of hydrocortisone 0.3% 
(w/v) in the new delivery system was 6-fold higher than for the suspension. A similar 
increase was observed for the cornea and the iris/ciliary body bioavailability (Setiawan et 
al., 1998). 
 
Hyaluronan 
Besides synthetic polymers, natural macromolecules such as hyaluronan (HA), 
present in the vitreous body of the eye, were proposed as viscosifying agents. Sodium 
hyaluronate molecules have physical properties and a composition comparable to tear 
glycoproteins and easily coat the corneal epithelium. Polymers adsorbed at the 
mucin/aqueous interface extend into the adjacent aqueous phase, thereby stabilizing a 
thick layer of water. The non-Newtonian behaviour of sodium hyaluronate combines the 
advantage of high viscosity at rest between blinks with those of lower viscosity during 
blinking (Lauren, 1987; Wysenbeek et al., 1988).  
Diluted solutions of sodium hyaluronate have been employed successfully as tear 
substitutes in severe dry eye disorders. The beneficial effects are attributed to the 
viscoelasticity, biophysical properties similar to mucins, which provide a long-lasting 
hydration and retention. Moreover, good lubrication of the ocular surface is obtained 
(Simmura et al., 1995; Solomon and Merin, 1998). Hyaluronic acid is an important 
constituent of the extracellular matrix and may play a role in inflammation and wound 
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healing and may promote corneal epithelial cell proliferation (Aragona et al., 2002). 
Gurny and colleagues confirmed the positive influence of hyaluronate vehicles on the 
bioavailability of pilocarpine. High molecular weight of the polymer is an essential 
requirement for the prolonged precorneal residence time of the preparation (Gurny et al., 
1987). 
 
Chitosan 
The chitosan polymer is biodegradable, biocompatible and non-toxic. It possesses 
antimicrobial and wound-healing properties. Moreover, chitosan exhibits a pseudoplastic 
and viscoelastic behaviour (Hassan and Gallo, 1990; Greaves and Wilson, 1993; Felt et 
al., 1998)). The mucoadhesive properties of chitosan are determined by the formation of 
either secondary chemical bonds such as hydrogen bonds or ionic interactions between 
the positively charged amino groups of chitosan and the negatively charged sialic acid 
residues of mucins, depending on environmental pH (Alonso and Sanchez, 2003). The 
mucoadhesive performance of chitosan is significantly higher at neutral or slightly 
alkaline pH as in the tear film. Only in the presence of an excess of mucin, does a 
strengthening of the mucoadhesive interface occur (Rossi et al., 2001). A 3-fold increase 
of the precorneal residence time of tobramycin was achieved when adding chitosan to the 
formulations, compared to the commercial solution of the drug. Only a minimal influence 
was observed from the concentration and molecular weight of chitosans employed, 
indicating a saturable bioadhesive mechanism based on ionic interactions of the cationic 
polymer with the negative charges of the ocular mucus (Felt et al., 1999). 
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Thiomers 
Thiolated polymers, or so-called thiomers, are capable of forming covalent bonds 
with cysteine-rich sub-domains of mucins. The extensive cross-linking process of the 
thiomers with mucins resulted in a tremendous increase in viscosity and mucoadhesion 
independent of pH or ionic strength of the medium. The mucoadhesive properties of a 
chitosan thioglycolic acid conjugate and a poly (acrylic acid)–cysteine conjugate 
improved 10-fold and even 100-fold, respectively, compare to the native polymers (Kast 
and Bernkop-Schnuerch, 2001; Marschutz and Bernkop-Schnuerch, 2002). 
 
Polysaccharides 
Besides chitosan, numerous polysaccharides were evaluated as mucoadhesive 
ophthalmic vehicles: polygalacturonic acid, xyloglucan, xanthan gum, pullulan, 
scleroglucan, and carrageenan (Saettone et al., 1994; Albasini and Ludwig, 1995; Sintzel 
et al., 1996; Madsen et al., 1998). Also, in the case of polysaccharides, the formation of 
macromolecular ionic complexes with drugs improved the bioavailability and lengthened 
the therapeutic effect when compared to drug solutions. Toxicological studies indicate 
that xyloglucan is very well tolerated by conjunctival cells, has cell protective properties, 
and is able to reduce drug-related toxicity (e.g. fluoroquinolones, timolol, merthiolate) 
probably due to its mucin-like structure. Xyloglucan might promote wound healing 
depending on its influence on the integrin recognition system (Burgalassi et al., 2000; 
Raimondi et al., 2000). Timolol, in association with xyloglucan, has a prolonged duration 
of action and is suitable for ocular administration in cases of elevated intraocular 
pressure. In rabbits, high timolol concentrations in the ocular tissues were measured, but 
with low systemic absorption (Burgalassi et al., 2000).  
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Figure I.6: Polymers utilized in ocular drug delivery systems (Ludwig, 2005) 
(Reproduced with permission from Elsevier) 
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Gellan gum 
Among all in situ gel-forming systems, systems that function upon activation by 
change in ionic strength using gellan gum are most effective. These systems overcome 
the draw backs associated with other systems where phase transition is mediated by pH 
and temperature. In the former case, a highly acidic pH could result in ocular irritation 
and temperature fluctuations during storage could affect gelation and the inevitable need 
of high polymer contents.  
Gellan gum is an exocellular microbial hetero polysaccharide that is secreted by 
the strain Pseudomonas elodea and is of interest to the food and pharmaceutical 
industries. Chemically, it is an anionic polymer with a high molecular weight (approx. 
5105 daltons, deacetylated). The polymer is stable to both heat and pH (pH 3.5-10.0) 
(Singh et al., 2004). Native gellan gum (Figure I.7a) consists of a backbone of repeating 
unit of -1,3-D-glucose, -1,4-D-glucuronic acid, -1,3-D-glucose, -1,4-L-rhamnose, 
and the two acyl groups, acetate and glycerate, bound to a glucose residue adjacent to 
glucuronic acid. The acetyl groups in native gellan gum are removed by alkaline 
treatment to produce deacetylated gellan gum (Figure I.7b).  
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Figure I.7: Chemical structure of gellan gum; a) native grade, and b) deacetylated grade 
(Bajaj et al., 2007). 
 
Gellan gum has a characteristic property of temperature-dependent and cation-
induced gelation. Gellan gum in solutions forms a coaxial triangular 3-fold double helix 
from two left-handed chains coiled around each other with the acetate residues on the 
periphery and glyceryl groups stabilizing the inter-chain associations. Hydrogen-bonds 
are formed between the hydroxymethyl of 4-linked glucosyl units of one chain and the 
carboxylate group of other. There are ion-binding sites by carboxylate oxygen atoms and 
a hydroxyl group in one chain and two hydroxyl groups in the other, plus one strongly-
bound water molecule (Crescenzi et al., 1990). Hence, the mechanism of gelation 
involves formation of double-helical junction zones followed by aggregation of the 
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double-helical segments to form a three-dimensional network by complexation with 
cations and hydrogen bonding with water (Grasdalen H, et al 1987).
 
Acetyl content is the most important factor affecting the gel strength of the gellan 
gum based in situ gel formulations. There are two types of deacetylated gellan gum 
which are differentiated on the basis of degree of deacetylation: high acyl gellan gum 
(partially deacetylated) (e.g., Kelcogel
®
 CG-HA) and low acyl gellan gum (highly 
deacetylated) (e.g., Kelcogel
®
 CG-LA). Gellan gum with different acetyl content gives 
gels with different properties. Native gellan gum provides soft, elastic, thermoreversible 
gels, is very weak because of bulky acetyl and glyceryl groups that prevent close 
association between gellan polymer chains in bulk-helix formation, and hinders compact 
packing of the cross-linked double helix. Deacetylated gellan gum forms a firm, brittle, 
and thermoreversible gel because of the absence of acetyl and glyceryl groups (Bajaj et 
al., 2007). 
Gellan gum based systems are the only systems that offer clear gels with good in 
situ gelling characteristics in the presence of mono (Na
+
, K
+
) and divalent (Ca
2+
) cations 
present in physiological fluids even at as low as 0.1%(w/v) polymer concentrations. 
Reflex tearing upon ocular administration in eye further enhances the viscosity of the 
formulation by increasing the cation concentration in the tear fluid. The viscoelastic 
nature of the gellan gum preparations offers further advantages of low viscosity during 
blinking and stability of tear film during fixation.  Gelrite
®
 (gellan gum) has also been 
used in the formulation of a prescription ophthalmic product that has been approved by 
the US FDA. Timoptic-XE
®
, timolol in Gelrite
®
, was developed as an extension of the 
Timoptic
®
 ophthalmic solution product line. Through formulation into an in situ gel, the 
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dosing frequency of Timoptic
®
 was reduced from twice-a-day to once-a-day and without 
loss of ease of instillation (Schenker et al., 2000).
 
 
I.C.4.6. Kinetics of drug release from in situ gel-forming delivery systems 
As discussed in the earlier section (I.C.4.4), in situ gel-forming systems have a 
unique combination of characteristics that make them useful in drug delivery 
applications. Due to their hydrophilicity, hydrogels can imbibe large amounts of water 
(>90 wt.%). Therefore, the molecule release mechanisms from hydrogels are very 
different from hydrophobic polymers. Both simple and sophisticated models have been 
previously developed to predict the release of an active agent from a hydrogel device as a 
function of time (Boldhane SP, Kuchekar BS, 2009; Nagarwal et al., 2009; Singh et al., 
2010). These models are based on the rate limiting step for controlled release, and 
therefore are categorized as diffusion controlled and swelling controlled systems. Drug 
diffusion time and polymer chain relaxation time are two key parameters determining 
drug delivery from polymeric matrices. In diffusion-controlled delivery systems, the 
time-scale of drug diffusion, t, is the rate-limiting step; while in swelling-controlled 
delivery systems, the time-scale for polymer relaxation is the rate limiting step. 
 
Diffusion-controlled systems 
Diffusion-controlled is the most widely applicable mechanism for describing drug 
release from in situ gel-forming systems. Fick's law of diffusion with either constant or 
variable diffusion coefficients is commonly used in modeling diffusion-controlled 
release. Drug diffusivities are generally determined empirically or estimated a priori 
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using free volume, hydrodynamic, or obstruction-based theories (Amsden, 1998). In 
diffusion-controlled delivery systems, Fickian diffusion dominates the molecule release 
process and diffusion equation proposed by Peppas et al. (shown in Equation I.1) which 
assumes a time-dependent power law function and can be used to predict molecule 
release (Peppas et al., 2000; Siepmann and Peppas, 2001 ). 
nt tK
M
M


   Equation I.1 
Here, K is a structural/geometric constant for a particular system and n is designated as 
release exponent representing the geometry of the device as well as the physical 
mechanism for release. The n values for delivery matrices with different geometries and 
release mechanisms are summarized in Figure I.8 (Siepmann and Peppas, 2001). It is 
noteworthy that in a purely swelling-controlled, slab-based delivery system, the drug 
fractional release (Mt/M∞) appears to be zero-order as the release exponent equals unity. 
The power law is easy to use and can be applied to most diffusion-controlled release 
systems. However, it is too simple to offer a robust prediction for complicated release 
phenomena. For example, in diffusion-controlled systems, where n=0.5, the power law is 
only valid for the first 60% of the release profile. These empirical models can only 
predict the release profile after certain release experiments are conducted and have 
limited capability to predict how the release profiles will change as the chemical or 
network properties of the system are varied. 
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Figure I.8: Release exponent values (n) in the empirical power law model (Siepmann  
and Peppas, 2001). 
 
Swelling-controlled systems 
Another mechanism for drug delivery from in situ gel-forming systems is 
swelling controlled delivery. In situ forming hydrogels may undergo a swelling-driven 
phase transition from a glassy state where entrapped molecules remain immobile to a 
rubbery state where molecules rapidly diffuse. In these systems, the rate of molecule 
release depends on the swelling rate of polymer networks. Swelling-controlled release 
occurs when diffusion of drug is faster than hydrogel swelling. The modeling of this 
mechanism usually involves moving boundary conditions where molecules are released 
at the interface of rubbery and glassy phases of swollen hydrogels (Siepmann and Peppas, 
2001). The empirical power law (Eq. I.1) used to describe diffusion-controlled drug 
release from hydrogel matrices can also be used comprehensively in swelling controlled 
delivery systems. A modification of Eq.I.1 takes into account both the drug diffusion and 
polymer relaxation. 
m2
2
m
1
t tKtK
M
M


  Equation I.2 
where K1, K2, and m are constants characteristic of drug polymer system. This expression 
describes the release rates in terms of relaxation-controlled transport process, K2t
2m
, and 
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the diffusion-controlled process, K1t
m
 (Lin and Metters, 2006; Ganji and Vashegani-
Farahani, 2009). 
 
I.C.5. Estradiol (E2) Aqueous Solubility Enhancement 
I.C.5.1. Use of cyclodextrins (CD) 
One of the major limitations in ocular delivery of drugs is poor aqueous solubility 
and/or poor permeability. Estradiol is a BCS class-II drug with low aqueous solubility 
(0.03mg/L at RT) and high permeability (logp-3.94). Hence ocular absorption of estradiol 
from the formulation is solubility limited. Aqueous solubility enhancement of several 
steroidal drugs such as progesterone, cortisone, testosterone, hydrocortisone, 17-
estradiol, and other drugs for ophthalmic delivery, using cyclodextrins has been widely 
reported in the literature (Liu et al., 1990; Zia et al., 2000). CD complexation generally 
results in improved wettability, dissolution, solubility, and stability in solutions and with 
reduced side-effects (Bourlais et al., 1998).
 
 
 Cyclodextrins (CDs) are a family of cyclic ( -1,4)-linked oligosaccharides 
containing 6, 7 or 8 D-glucopyranosyl units and are referred to as alpha (), beta () and 
gamma () CD respectively (Figure 1.9) (Rajewski et al., 1995; Loftsson and Brewster, 
1996; Thompson, 1997).
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Figure I.9: Structure of -cyclodextrin (Loftsson and Brewster, 1996) 
 CDs are toroid-shaped due to lack of free rotation about the bonds connecting the 
glucopyranose units with all the secondary hydroxyl groups OH-2 and OH-3, located on 
the wider rim and all primary hydroxyl groups, OH-6, on the narrower rim. The glucose 
units are in the 
4
C1 chair conformation. The central cavity of the cyclodextrin molecule is 
lined with skeletal carbons and ethereal oxygens of the glucose residues making it 
lipophilic. The polarity of the cavity has been estimated to be similar to that of aqueous 
ethanolic solution (Coleman et al., 1995). The secondary -OH groups at the wider rim of 
the CD cavity form intra-molecular H-bonds in which OH-3 group of one glucose unit 
interacts with the OH-2 group of the neighboring glucose unit. This interaction leads to a 
belt of hydrogen bonds around the secondary CD cavity side that gives the whole 
molecule a rather rigid structure, especially in the case of -CD. This rigidity is probably 
why -CD has the lowest water solubility (1.85 g/100ml) of all the CDs. Moreover, 
aggregation of these rigid -CD molecules may also contribute to the low aqueous 
solubility (Coleman et al., 1995).
 
The H-bond belt is incomplete in -CD molecule 
(solubility of 14.5 g/100ml) because one glucopyranose unit is in a distorted position, 
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leading to only four H-bonds instead of six possible H-bonds. The -CD is a non-
coplanar, more flexible structure; therefore, it has better solubility (23.2 g/100ml) of the 
three CDs. The primary OH-6 groups placed at the smaller rim‘s torus are not 
participating in intramolecular hydrogen bonds and, therefore, can rotate so as to partially 
block the cavity of CDs (Schneider et al., 1998). Parent cyclodextrins are readily soluble 
in strongly polar aprotic solvents like dimethyl sulfoxide (DMSO), dimethyl formamide 
(DMF), N,N-dimethylacetamide, and pyridine and mixtures of these.  
The most critical draw back of the parent CDs is their relative insolubility and 
toxic effects on the kidneys, which is the main organ for the removal of CDs. Hence, 
modified β-cyclodextrins, like hydroxypropyl-β-cyclodextrin (HP-β-CD) and 
sulfobutylether-β-cyclodextrin (SBE- β-CD), are being used more extensively. 
 
I.C.5.1.1. Sulfobutylether 7-cyclodextrins (SBE 7) 
Stella and Rajewski described the preparation of sulfonate and sulfoalkylether 
derivatives with different degree of substitution (Rajeswski et al., 1992; Rajeswski et al., 
1995). The reaction of butane sulfone and -CD generates a mixture of sulfobutylether  
cyclodextrin derivative. These derivatives were isolated as sodium salts, and 
demonstrated solubilities independent of degree of substitution. Sulfobutylether -CD 
(Figure 1.10) has a different binding behavior compared to parent CDs because 
substitution at the 2, 3 or 6 hydroxy groups of the CD causes additional interactions. 
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R= [-CH2-CH2-CH2-CH2-SO3-Na+]7 
Figure I.10: Structure of Sulfobutylether 7-cyclodextrin 
 
The sulfobutylether -CDs do not show pH-dependent solubility behavior since 
they are expected to be ionized (pKa <1) between the pH of 3-10, that is typically 
employed in pharmaceutical preparations. The anionic charge at the end of the butyl 
chain in SBE -CD is expected to repel adjacent substituents, effectively maintaining an 
opening to the CD cavity. Although the substituents are long enough to bend into the 
cavity, they are not expected to do so because of the hydrophilic character of the ionic 
sulfate, which prefers to interact with the aqueous solvent. One major difference in the 
complexation performance of ionic (SBE--CD and CM--CD) versus neutral CDs such 
as -CD and HP -CD is the inability of the former to participate in 1:2 or 1:3 
complexations. The charged CDs do not effectively form higher order complexes 
probably because of electrostatic repulsions between the first CD that has sequestered the 
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drug and the incoming CD (Thompson, 1997). In addition to the charge on the CD torus, 
the ionic state of the guest molecule is important in determining complexation 
characteristics. The anionic SBEs often exhibit a 1:1 binding constant with neutral form 
of drug, such as indomethacin and naproxen, that are comparable to or higher than those 
observed for the neutral HP -CD (Okimoto et al., 1996).  This better binding may be due 
to the butyl micellar arms that extend the depth of the hydrophobic cavity of the CD.   
As the degree of substitution increases in the case of SBE--CD, the CD torus 
may be distorted in such a way as to result in decreased hydrophobic interaction between 
some guest molecule and the interior of the CD cavity, thereby decreasing the driving 
force for inclusion complexation. Additionally, steric interference may also play a role in 
observed decreased binding capacity of modified CDs. The cavity opening may be 
capped by substituents alone or by the formation of an aqueous solvation shell near the 
entrance of the cavity associated with charged substituents (SBE--CD and CM--CD). 
The presence of bulky highly charged and hydrated sulfonate groups near the cavity may 
also inhibit the approach of a hydrophobic molecule, thus reducing complex formation. 
On the other hand derivatization of the CD torus may provide additional sites of 
interaction for stabilization of some complexes. For example, the alkyl chains may 
provide additional hydrophobic binding sites or the sulfonate moieties may induce 
specific interactions with the guest molecule (Zia et al., 1997). 
 Sulfobutylether 7 -CD has an average of seven negative charges and seven 
sodium ions and, hence, it would be expected to also possess significant osmotic 
properties. Okimoto and colleagues
 
developed a controlled porosity osmotic pump system 
for poorly water-soluble drug (testosterone) in which SBE 7 -CD acts as a solubilizing 
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as well as an osmotic agent. The effect of anionic SBE 7 -CD was compared to a neutral 
cyclodextrin, HP -CD (i.e., solubilizing agent and osmotic agent), and a sugar mixture 
(i.e., osmotic agent). It was found that testosterone release was significantly faster with 
SBE 7 -CD compared to HP--CD and sugar mixture due to a great extent to osmotic 
pumping mechanism; whereas, for HP--CD, the major mechanism was by diffusion 
(Okimoto et al., 1996) .  
  
I.C.5.1.2. Mechanism of complexation 
For the association of guest molecules with cyclodextrins, several intermolecular 
interactions have been proposed such as the driving/binding forces for complexation. 
These comprise non-bonded attractive forces, such as van der Waals interaction, 
electrostatic attraction/repulsions and steric effects, and hydrogen bond interaction (a 
primarily electrostatic phenomenon). Hydrogen bond interaction that is especially 
significant to cyclodextrins because of many oxygen atoms that serve as Lewis base sites 
and hydroxyl groups acting as Lewis acid contributor. Complex formation comprises of 
the following steps: First, escape of water molecules from the CD cavity to an energy 
level corresponding to that of the 'gaseous state', a state in which the molecules are 
independent from each other with no intermolecular interaction. Second, conformation 
energy of the cyclodextrin ring decreases on relaxation due to the escape of water 
molecules from the cavity. Third, shedding of the hydrate shell by the guest molecule 
takes place that assumes a state of an ideal gas. Fourth, the entry of the guest molecule 
into the CD cavity results in stabilization of the complex by a non-bonded interaction, 
such as van der Waals interaction and hydrogen bonding. The guest molecule retains one-
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dimensional rotational freedom. The fifth step is the condensation of displaced water 
molecules, or transformation from the "gaseous state" to the liquid state. The last step 
involves the restoration of water structure around the exposed part of the guest molecule 
and integration with the cyclodextrin ring hydrate shell (Lipkowitz, 1998).
 
 
The complexation constant (K1:1, also known as stability or binding constant) and 
the free energy of interaction between the guest molecule and the -cyclodextrin are 
dependent on the enthalpy and entropy of complexation. Therefore, the evaluation of 
these thermodynamic parameters, i.e., the enthalpy and entropy of interaction may 
provide better insight into the various forces involved in complexation. In all 
complexation processes, the enthalpy of complexation is negative; indicating that 
complex formation is an exothermic process, i.e., there is release of high energy, 
enthalpy-rich water molecules from the CD cavity. Traditionally, hydrophobic 
interactions between two apolar molecules at room temperature have been known as an 
entropy-driven process, where the enthalpy of the process is small and entropy of 
interaction is large and positive. However, cyclodextrin inclusion complexation processes 
at room temperature are usually enthalpy driven processes with minor favorable or 
unfavorable entropies of interaction due to features specific to cyclodextrin cavity 
(Westphal, 1986; Inoue et al., 1993; Rekhsarky, 1998).
 
Several attempts have been made 
to separate the contributions of the hydrophobic effect and the hydrogen bond interaction 
from the other terms that contribute to the overall thermodynamics of complexation. The 
thermodynamic contribution from the hydrophobic effect may be estimated from 
increments in the measured values induced by the extension of the methylene chain, 
while the hydrogen bonding may be estimated by adding hydroxyl groups to the guest 
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molecule. Zia and colleagues found that complexation of substrates to sulfobutylether -
cyclodextrin to be more entropically favored as the number of sulfobutylether groups 
increased (Zia et al., 1997). This favorable entropy of interaction was compensated by a 
less favorable enthalpy of interaction. The systematic increase in the entropy of 
interaction was explained in terms of additional hydrophobic interactions with the alkyl 
chains. Moreover, derivatization of cyclodextrins may also distort the cavity interior 
inducing interaction with the alkyl chains around the torus.  
 
I.C.5.1.3. Characterization of inclusion complexation 
Drug-cyclodextrin interactions may be studied by a variety of techniques in both 
the solution and solid state, most of which examine the behavior of mixtures of the 
cyclodextrin (host) and drug species (guest) in solution. One such technique in frequent 
use is determination of the phase solubility diagram, which can be used to obtain 
approximate stability constant for the complex. Isothermal titration calorimetry (ITC) is a 
highly sensitive technique particularly useful for characterizing host-guest interactions 
involving low heats of binding or in which the energetic changes are quite small. It is 
used to establish the mechanism of interaction between the drug and cyclodextrin and to 
obtain information about the thermodynamic parameters, the binding constants, and the 
stoichiometry (Eli et al., 1999; Illapakurthy et al., 2005; Mic et al., 2009; Singh et al., 
2010). More direct evidence of complexation can also be obtained from proton nuclear 
magnetic resonance (
1
H NMR) spectra of the host-guest mixture in solution, which 
allows determination of the guest molecule orientation in the cyclodextrin cavity 
(Anguiano-Igea et al., 1997; De Paula et al., 2007).  
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Generally, the prepared CD inclusion complexes are used and stored mainly in 
solid state, so characterization of the inclusion complexes in the solid state is critical. For 
their analytical investigation, thermoanalytical technique, such as differential scanning 
calorimetry (DSC), is predominantly used (Badawy et al., 1996; Mura et al., 2003; Yap et 
al., 2005). Thermal analysis offers a simple, fast, and reliable approach of investigating 
these compounds, since inclusion complex formation remarkably changes the original 
thermal properties of the complexed guest(s), such as absence of melting or DSC peaks 
or shift in decomposition towards higher temperature, etc. Powder X-ray diffraction 
(PXRD) also provides useful evidence of complexation when the guest compound is a 
solid crystalline substance, such as E2, where formation of amorphous complexes with 
SBE 7 leads to the disappearance of certain peaks or the peaks become less sharp than 
those of the pure compounds or physical mixture (Variankaval, 2001; Jain and Adeyeye, 
2001). The application of FTIR is usually limited to the guests having some characteristic 
bands, such as carbonyl or sulfonyl groups. Although this technique is not generally 
suitable to detect the inclusion complexes and is less clarifying than the other methods, it 
can still provide information about the involvement of hydrogen in various functional 
groups (Koontz et al., 2009). The complexation generally shifts the absorbance bands to 
the lower or higher frequencies and/or increases their intensity, etc. Also, though the use 
of scanning electron microscopy (SEM) may not affirm inclusion complexation, it can 
indicate the differences in crystallization state of the raw materials and the resultant 
product obtained by co-precipitation/evaporation (Jun et al., 2007). 
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I.C.5.1.4. Cyclodextrins in ocular drug delivery 
Cyclodextrins may increase the ophthalmic delivery of drugs through multiple 
mechanisms, such as increased solubility of poorly soluble drugs and/or alteration in 
corneal permeability. If the corneal permeability is increased, the change may be 
reversible or irreversible (permanent corneal damage) (Rajewski and Stella, 1996; 
Okimoto et al., 1999). Hence, only non-damaging (i.e., safe) CDs have been used in 
ocular drug delivery. Both parent and modified cyclodextrins have been used for the 
ophthalmic delivery of a number of drugs, such as pilocarpine (Jarvinenet al., 1995; 
Suhonen et al., 1995; Jarho et al., 1996), hydrocortisone (Davies et al., 1997), 
dexamethasone acetate (Usayapant et al., 1991), anandamides (Pate et al., 1996; Pate et 
al., 1996), acetazolamide (Maren et al., 1986), dipivefrine (Jarho et al., 1007), etc. For 
example, co-administration of pilocarpine prodrug with either HP -CD or SBE 4 -CD 
or SBE 7 -CD significantly reduced the ocular irritation at low levels and the co-
administration of the CDs did not affect the mitotic response of the pilocarpine prodrug 
solution (Jarvinen et al., 1995).
 
At similar concentrations (9.2 mM), the negatively 
charged SBE -CD increased the aqueous stability of positively charged dipivefrine (pKa 
9.0) 15-30 times (at pH 5), and 20-300 times (at pH 7.4), while neutral HP -CD 
increased the stability only 4-5 times at either pH values. However, in vitro interfacial 
transfer and in vitro corneal uptake experiments suggested that the complexation of 
dipivefrine with CDs, especially SBE7-CD may adversely affect the ocular 
bioavailability of the drug due to the stronger complexation and greater intrinsic stability 
of dipivefrine in the SBE7-CD complex compared to HP--CD complex. 
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In general, only the free drug and not the drug/CD complex can penetrate 
lipophilic biological barriers, and therefore, for ophthalmic absorption, the drug must be 
released from the complex before absorption. In contrast to oral and parenteral 
administration, ophthalmic preparations do not exhibit significant increase in the fraction 
of available free drug after ocular administration due to the lack of drug/CD complex 
dilution by the small tear fluid volume (approximately 7 l). In addition, aqueous eye 
drops are removed from the pre-corneal area within a few minutes (Lipkowitz, 1998), so 
that drug/CD complex may not have enough time to release the drug before its clearance 
from the pre-corneal area. Thus, in ophthalmic preparation, complexation of a water-
soluble drugs or excess complexation of a poorly water-soluble drug may decrease 
bioavailability or control the release of the applied drug. 
 
I.C.5.2. Use of surfactants for E2 solubility enhancement: 
The ability of surfactants to enhance the solubility of poorly water-soluble 
compounds in an aqueous solution is widely known and used in many aspects of drug 
formulation development (Florence, 1981; Sweetana and Akers, 1996).
 
For example, 
surfactants are used as wetting agents to improve tablet dissolution (Chen and Zheng, 
1993; Ruddy et al., 1999) and are commonly used in the media for dissolution testing to 
maintain sink conditions for the drug (Rao et al., 1997).  
Enhancement of the aqueous solubility by surfactants occurs as a result of the 
dual nature of the surfactant molecule. Surfactants are amphiphilic molecules composed 
of a hydrophilic or polar moiety known as head and a hydrophobic or nonpolar moiety 
known as tail. The surfactant head can be charged (anionic or cationic), dipolar 
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(zwitterionic), or non-charged (nonionic). Sodium dodecyl sulfate (SDS), 
dodecyltrimethylammonium bromide (DTAB), polysorbate 80, and dioctanoyl 
phosphatidylcholine are typical examples of anionic, cationic, nonionic and zwitterionic 
surfactants, respectively. The surfactant tail is usually a long chain hydrocarbon residue 
and less often a halogenated or oxygenated hydrocarbon or siloxane chain (Rosen, 1989; 
Jones and Chapman, 1995). 
When surfactant molecules are dissolved in water at concentrations above the 
critical micelle concentration (cmc), they form aggregates known as micelles. In a 
micelle, the hydrophobic tails flock to the interior in order to minimize their contact with 
water, and the hydrophilic heads remain on the outer surface in order to maximize their 
contact with water (see Figure I.11) (Tanford, 1980; Chevalier and Zemb, 1990). This 
creates a discrete hydrophobic environment suitable for solubilization of many 
hydrophobic compounds like E2. The micellization process in water results from a 
delicate balance of intermolecular forces such as hydrophobic, steric, electrostatic, 
hydrogen bonding, and van der Waals interactions. The main attractive force results from 
the hydrophobic effect associated with the non-polar surfactant tails and the main 
opposing repulsive force results from steric interactions and electrostatic interactions 
between the surfactant polar heads (Israelachvili, 1991).  
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Figure I.11: Schematic illustration of the reversible monomer-micelle 
thermodynamic equilibrium (Rangel-Yagui et al., 2005). The black circles represent 
the surfactant heads (hydrophilic moieties) and the black curved lines represent the 
surfactant tails (hydrophobic moieties). 
 
I.C.5.3. Use of Surfactants in Ophthalmic Formulations 
The use of surfactants is greatly restricted in formulating ophthalmic solutions. 
Nonionic surfactants are most frequently used in pharmaceutical systems because of their 
compatibility with other formulation excipients, stability, and low toxicity.  The order of 
surfactant toxicity is anionic> cationic >> nonionic (Liu et al., 2007). The nonionic 
surfactants can be divided into those that are water soluble and those that are water 
insoluble. Among the most widely used water-soluble surfactants are sorbitan ether esters 
of oleic acid (Polysorbate or Tween 20 and 80), which are commonly used in oral, 
parenteral, and topical pharmaceutical formulations (Alvarez-Nunez et al., 2000). The 
head groups of these surfactant molecules contain no charged moieties, with their 
hydrophilic properties due to the presence of hydroxyl groups.  
Being a non-ionic surfactant, polysorbate 80, provides low toxicity and minimizes 
possible interactions with other ionic excipients in the formulation. Besides, its low 
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critical micellar concentration (CMC) (i.e., 0.012 mM) (Zhang et al., 2003; Chakraborty 
et al., 2009) allows achieving high aqueous solubility of sparingly water soluble drug 
such as E2, at much lower surfactant concentrations. Also, polysorbate 80 as a non-ionic 
drug solubilizing agent is widely used in ocular preparations to aid in dispersing drugs in 
suspensions [e.g., fluorometholone (Morshima and Shiotani, 2008; Cagle GD et al., 
1992), tobramycin (Cagle GD et al., 1992), prednisolone acetate (Akram et al., 2010)) 
and emulsions (e.g., cyclosporine (Napoli, 2001), difluprednate (Yamaguchi et al., 2005)] 
or to solubilize drugs to improve solution clarity and drug bioavailability [e.g., 
hydrocortisone (Zimmer et al., 1994), cyclosporine (Zhang, 2008), prostaglandin (Pilotaz, 
2010), diclofenac (Berganimi et al., 1997), ketotifen (Chapin et al., 2010), loratidine 
(Chang et al., 2003)]. Some of the commercial ophthalmic products that contain 
polysorbate 80 are Restasis
®
, Xibrom
TM
, Rohto
®
 V Ice, etc. 
 
Micellar solubilization can be defined as the spontaneous dissolving of a 
substance by reversible interaction with the micelles of a surfactant in water to form a 
thermodynamically stable isotropic solution with reduced thermodynamic activity of the 
solubilized material (Rosen, 1989). In the plot of drug solubility vs. surfactant 
concentration (Figure I.12) solubility is very low until the surfactant concentration 
reaches the cmc. At surfactant concentrations above the cmc the solubility increases 
linearly with the concentration of surfactant, indicating that solubilization is related to 
micellization. 
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Figure I.12: Schematic plot of the concentration of a poorly soluble compound as a 
function of the surfactant concentration in aqueous solution (Liu et al., 2007).  
 
There are a number of possible loci of solubilization for a drug in a micelle 
(Figure I.13). Accordingly, hydrophilic drugs are adsorbed on to the surface of the 
micelle,
 
drugs with intermediate solubility are located in intermediate positions within the 
micelle and completely insoluble hydrophobic drugs may be located in the inner core of 
the micelle (Torchilin, 2001). The existence of different sites of solubilization in the 
micelle results from the fact that the physical properties, such as microviscosity, polarity 
and hydration degree, are not uniform along the micelle (Dutt, 2003). The drug release 
characteristics and transport/ pharmacokinetics of ocular preparations are addressed in 
sections I.C.4.6 (pp. 32) and I.C.4.2 (pp.17), respectively. 
 
 
 50 
 
Figure I.13: Possible loci of solubilization of drugs in surfactant micelles, depending 
on the drug hydrophobicity (Rangel-Yagui et al., 2005). The black bold lines represent 
the drug at different sites in the micelle. The black circles represent the surfactant heads, 
the black bold curved lines represent surfactant heads and the light black curved lines 
represent the surfactant tails. 
 
I.C.6. Safety of Ocular Formulations and Preclinical Testing 
The success of a topical therapy intended for human administration is relied on its 
safety. Hence the test‘s that evaluate the potential of the developed ocular formulation to 
cause irritation or damaging effects to the eye forms a critical part of any ophthalmic 
drug product approval process by regulatory authorities. Traditionally, Draize test in 
rabbits has been used as a model for human drug exposure to test the ocular toxicity of 
ophthalmic formulations (Darize, 1944; Wilhelmus, 2001).  
Rabbits are used due to their availability, low cost, ease of handling and 
maintenance, large eyes with conjunctival and corneal tissues that are easily observed, 
and non-pigmented conjunctiva and iris facilitating observation of a response to irritation.  
However, it is important to note that the rabbit eyes differ from the human eye by having 
less tearing, a decreased blinking rate, looser eye lids, a nictitating membrane, a poorly 
defined corneal Bowman‘s membrane, a slower rate of corneal re-epithelialization, and a 
very labile blood-aqueous barrier (Nanjawade et al., 2007).  
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In vitro or ex vivo alternatives to Draize eye test in rabbits such as isolated 
chicken eye (ICE) test, the bovine corneal opacity and permeability (BCOP) assay, the 
hens egg chorioallantoic membrane (HET-CAM) assay are also available for testing the 
toxicity of the ocular formulations (Chan, 1985; Luepke and Kemper, 1986; Bruner et al., 
1991; Wilcox, 1992; Spielmann et al., 1993; Wilhelmus, 2001). But, these test tube 
methods do not represent the effect of preparation on tear film and other ocular tissues 
except corneal membrane.   
Toxicity studies performed using these methods found that none of the alternative 
tests, taken alone, proved to be a reliable replacement for the Draize animal test and 
combinations of two or more tests are required to achieve reliable data.  It is particularly 
important to test the irritation potential of the in situ gel-forming ophthalmic drug 
delivery systems in rabbits as the functionality of this novel formulation depends upon its 
ability to form an in situ gel in the presence of either pH, ionic strength of the tear fluid, 
or temperature of the eye. Potential for irritation upon ocular administration of a drug 
formulation is typically a function of the length of time it stays in the eye and its effect on 
tear film and other ocular tissues such as iris and conjunctiva. Further, blinking frequency 
of the eye will impact the residence time of the drug in the eye and its potential for any 
irritation. Hence, in this current research, rabbits will be used to evaluate the ocular 
irritation potential of the developed topical ophthalmic in situ gel-forming estradiol (E2) 
drug delivery system. 
Considering all the characteristics of the drug, potential excipients that could be 
used in the formulation of ophthalmic estradiol (E2) delivery system and formulation 
peculiarities including stability and ocular toxicity, the focus of the project is to develop a 
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statistically designed stable in situ gel-forming E2 ophthalmic solution that is safe and to 
evaluate the pharmacokinetic disposition and toxicity. The role of topically delivered 
estrogen and its ability to induce known estrogen-dependent responses in the eye will 
also be explored in order to understand the drug‘s treatment modality. These 
investigations will serve as a prelude to potential future use of the delivery system to 
prevent or delay cataract formation. 
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CHAPTER II 
MATERIALS AND EQUIPMENT 
Table II.1. List of Materials  
 
Material Manufacturer Lot number 
Sulfobutylether 7 -cyclodextrin 
(Captisol
TM
) 
Cydex Pharmaceuticals, Inc. 
Overland Park, KS 
CY-04A-05006.2F 
Deacetyalted gellan gum 
(Kelcogel
®
 CG-LA) 
CP Kelco, 
Atlanta, Georgia 
9G6158A 
Polysorbate 80, NF Spectrum Chemicals YG0196 
Mannitol powder, USP Spectrum Chemicals YS1139 
Potassium sorbate, NF Spectrum Chemicals ZQ1232 
Edetate disodium dihydrate, USP Spectrum Chemicals YM0468 
Estradiol, Micronized, USP Spectrum Chemicals XT3070 
Estriol, USP Sigma Aldrich 067K14851 
Estrone, USP Sigma Aldrich 080K1683 
Benzalkonium chloride Spectrum Chemicals XB1013 
Benzyldodecyl dimethyl 
ammonium bromide 
Sigma Aldrich 076K2632 
Sodium chloride, USP Fisher Scientific 034671 
Potassium chloride, USP Spectrum Chemicals ZQ3026 
Calcium choride, USP Spectrum Chemicals VU0231 
Sodium bicarbonate Spectrum Chemicals YX0581 
Trypticase soy agar BD & Company 9076809 
Tryptic soy broth EMD VM766059 
Reagent Alcohol, HLC grade Spectrum Chemicals ZP0825 
Acetonitrile, HPLC grade Spectrum Chemicals ZS0505 
Millex –HN 0.45 μm syringe 
filter 
Millipore R7BN30772 
CoTran
TM
 9711 microporous 
polyethylene membrane 
3M 125 
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Filtrare
TM
 0.22 μm sterile 
hydrophilic filter 
US Medical,, Inc. 
Hingham, MA 
A048 
Opti-Mole
TM
 
osmolality standards 
Wescor, Inc  
Blue-T
® 
buffer standards Spectrum Chemicals 9041-15 
DSC hermetic pans TA T092007 
DSC hermetic lids TA T111007 
Steri-Dropper
®
 The Medi-dose
®
 group T208100 
 
Table II.2. List of Equipment  
 
Equipment Manufacturer Model 
HPLC separation module Waters 2690 
Chromatography column 
(C18(2), 250 x 4.6 mm, 5 m) 
Phenomenex, 
Torrance, CA 
Luna 
HPLC PDA detector Waters 996 
HPLC Multi wavelength 
fluorescence detector 
Waters 2475 
Guard cartridge system Phenomenex, Torrance, CA 0575-56914 
X-Ray Diffractometer Phillips PW 3710 
DuPont DSC analyzer TA Instrument 2910 
Scanning electron microscopy Phillips XL 30 FEG 
FTIR Spectrometer Perkin Elmer, Norwalk, CT 1605 
NMR Spectrometer Bruker Instrument, Billerica, MA drx-500 
Dissolution Apparatus Vankel Industries Inc. VK6010 
UV-Vis Spectrometer Perkin-Elmer Lambda 35 
Vapor pressure osmometer Wescor, Inc VAPRO 5520 
Water purifier Millipore Milli-Q
®
 
Lab incubator Fisher Scientific Isotemp 
Freezer Fischer Scientific Isotemp 
Incubator shaker New Brunswick Scientific Co. Series 25 
Mechanical convection oven Thermo Scientific Precision 
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Stability chamber Associated environmental systems NA 
Stability chanber VMR 9000L 
Sonicator Branson 2510 
pH meter VWR Scientific products 9100 
Magnetic stirrer and heater Fisher Scientific Isotemp 
Autoclave TOMY ES-215 
Vortexer VWR Scientific Genie-2 
Precision microbalance Denver Instruments NA 
Microbalance Denver Instruments XE-400 
Micro centrifuge Fisher Scientific MicroV 
Centrifuge Fisher Scientific Marathon 16KM 
Isothermal titration 
calorimeter 
MicroCal, Inc. ITC-200 
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CHAPTER III 
 
AQUEOUS SOLUBILITY ENHANCEMENT AND DEVELOPMENT OF AN IN 
SITU GEL-FORMING OPHTHALMIC ESTRADIOL SOLUTION 
 
 
III. A. INTRODUCTION 
 
The aqueous solubility of E2 is around 2-3 μg/mL at 25C and its therapeutic dose 
by ocular delivery ranges between 10 to 25 μg (Johansson and Ohman, 1987). This dose 
results in a dose (D):solubility (S) ratio of 5-10. Due to the limitations associated with the 
maximum volume of a solution that a eye can hold upon administration (~20-30 μL), and 
the volume of tear fluid available for drug dissolution in the eye (~7-10 μL), E2 delivery 
by ocular route require the D:S ratio to be ≤0.01. Sulfobutylether 7β-cyclodextrin (SBE 
7), as discussed in Chapter I, is less toxic due to its anionic nature and provides greater 
solubility and stability constants for complexation with hydrophobic drugs compared to 
other cyclodextrin derivatives due to its high degree of substitution (i.e., seven).  Hence, 
aqueous solubility enhancement of E2 via inclusion complexation with SBE 7 was 
investigated. The development of an ophthalmic in situ gel forming system with desirable 
properties such as sterility, isotonicity, clarity, and viscoelasticity requires use of other 
functional excipients in the formulation; therefore, their compatibility with the SBE 7, 
and influence on product performance characteristics were further investigated.   
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III. B. EXPERIMENTAL AND METHODS 
III.B.1. Solution-state Characterization of E2 and SBE 7 Inclusion Complexation 
III.B.1.1. HPLC Assay Method Development & Validation  
HPLC based fluorescence method was developed to measure E2 concentrations in the 
binary mixtures with SBE 7 as it is relatively more sensitive and specific in E2 estimation. 
The developed method was further validated for specificity, linearity, accuracy and 
precision, limit of detection (LOD) and quantitation (LOQ) according to ICH Q2 (R1) 
guidelines as described below.  
 
Instrumentation 
The HPLC system consisted of a Waters Alliance (Waters Corporation, Milford, 
MA, USA) equipped with a Waters 2690 separation module and Waters 2475 
fluorescence detector. Data acquisition was performed by the Empower
TM
 2 Pro software. 
Analysis was carried out at excitation and emission wavelengths of 280 and 298 nm, 
respectively, with a Luna C18(2) reversed-phase column of 250 mm  4.6mm i.d., 5m 
dimensions (Phenomenex, Torrance, CA, USA) at ambient temperature. The mobile 
phase consisted of acetonitrile and water (50:50, v/v) set at a flow rate of 1 mL/min 
 
Preparation of Solutions 
Standard stock solution of 200μg/mL of 17β-estradiol (E2) was prepared by 
dissolving accurately weighed amount in reagent alcohol. Calibration standards were then 
prepared at concentrations of 60, 70, 80, 90, 100 and 120 ng/mL from the standard 
solution by appropriate dilution with ethanol. 
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Linearity and Range 
The calibration curves were constructed with 6 concentrations ranging from 60 to 
120 ng/ml. The fluorescence emission units of the drug solution were considered for 
plotting the linearity graph. The linearity was evaluated by linear regression analysis, 
which was calculated by least square regression method.  
Specificity  
Specificity of the developed method to accurately measure E2 in the presence of 
SBE 7 in the solution was evaluated by analyzing 6 replicates of a test sample containing 
E2-SBE 7 binary mixture that corresponds to theoretical E2 concentration of 90 ng/ml. 
Specificity was demonstrated by comparing the estradiol retention times in the test 
sample with the reference E2 standard chromatograms and reported as the mean peak 
retention times along with standard deviation.  
 
Accuracy and Precision  
Accuracy and precision of the assay method was evaluated for both intra-day and 
inter-day variations at three different concentrations (i.e., 60, 90 and 120 ng/mL) for three 
consecutive days. Accuracy and precision were expressed in terms of percent mean 
recovery and percent relative standard deviation (% RSD or %CV), respectively. 
Repeatability or intra-assay precision refers to the variations in the recovery values 
obtained upon analyzing the above samples within the laboratory over a short period of 
time during the same day. Whereas, intermediate precision represents inter-assay 
variations measured across different days (i.e., 3 days). Analysis of variance (ANOVA) 
was used to identify statistical differences in the intra- and inter-day recovery values.  
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Limit of Detection and Quantitation 
LOD and LOQ were calculated based on the standard deviation of the response 
(σ) and slope (S) of the calibration curve obtained from multiple calibration curves. LOD 
being given by the 3.3σ/S and LOQ given by 10σ/S: Where σ is the standard deviation of 
the intercept of the calibration curves and S is the mean slope of the calibration curves. 
 
III.B.1.2. Phase Solubility Analysis  
 Phase solubility studies of E2 in the presence of SBE 7 were performed at 22 ± 
1ºC and 37 ± 1ºC according to previously published method (Higuchi and Connors, 
1965). In these studies, excess of E2 was added to the glass vials containing aqueous 
solutions of SBE 7 in the concentration range of 0.46-2.31mM. The vials were agitated in 
an incubator shaker operated at 250 rpm and fixed temperature for 3 days until 
equilibrium was reached. The vials were then centrifuged and the supernatant was filtered 
through 0.45 µm nylon syringe filter and analyzed for E2 concentration using a validated 
reverse phase HPLC method described earlier.  
Using the phase solubility data obtained at two different temperatures, 
thermodynamic parameters, such as apparent stability constant of the complex (K1:1), 
change in enthalpy (∆H°), change in Gibbs free energy (∆F°), and change in entropy 
(∆S°) upon complexation were calculated using Eq(s). III.1 – III.4. In addition, the 
solubilizing efficiency of the SBE 7 in the aqueous vehicle was determined by either the 
slope of the phase solubility profile or the complex to free cyclodextrin ratio, which is 
referred to as the complexation efficiency (CE) according to Eq(s). III.5 and III.6. 
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So is the intrinsic aqueous solubility of the drug determined experimentally at a fixed 
temperature, [D/CD] is the concentration of the dissolved complex, [CD] is the 
concentration of the dissolved free SBE 7 and slope is obtained from the linear regression 
analysis of the phase solubility data.    
 
III.B.1.3. Isothermal Titration Calorimetry (ITC) 
  Isothermal calorimetric titration was performed using an isothermal titration 
calorimeter (ITC) (MicroCal, Inc., NJ, USA) in an attempt to relate the complexation or 
binding of E2 and SBE7 to the heat of reaction between the two entities.  The isothermal 
calorimetric unit consists of a reference cell and a sample cell enclosed in an adiabatic 
environment. The calorimetric titration reactions were performed at 25°C. The E2 
solution prepared in 90% (v/v) methanol/water was placed in the sample cell and the 
reference cell was filled with water. The solution in the sample cell was titrated with SBE 
7 solution using a Hamilton injection syringe placed over the sample cell. All the 
experiments were performed with constant stirring speed of 400 rpm, which produces 
complete mixing in the cell within few seconds after an injection. This baseline, with 
stirring, was used as the resting baseline so that no corrections for heat of stirring were 
necessary. The sample cell volume was fixed at 1.345 mL in all the experiments.  
Binding experiments were performed by injecting 3 L aliquots of SBE 7 solution into 
the sample cell containing E2 solution. In the control experiments, 3 L aliquots of E2 
)5.III(
)slope1(
slope
]CD[
]CD/D[
KSCE 1:1o 


 61 
solution were injected into the sample cell containing 90% (v/v) methanol/water without 
SBE 7.  The concentrations of the E2 and SBE 7 solutions were 0.5 mM and 40 mM, 
respectively. The concentrations were chosen such that saturation of all the binding sites 
could be obtained. The calorimetric data was analyzed using Origin 5 MicroCal 
software to obtain different thermodynamic parameters. 
 
III.B.1.4. 
1
H NMR Measurements 
1
H-NMR spectra of pure drug and the inclusion complex were recorded on a 
Bruker drx-500 spectrometer (Bruker AXS Inc., Madison, WI) operating at 500 MHz. 
Due to the limited solubility of E2 in D2O, the NMR spectra of E2 and their complexes 
were measured by dissolving in the mixture of CD3OD/D2O (3:1). Briefly, 1 mg (7.34 
mM) of E2 or the equivalent amount of the E2: SBE 7 complex was weighed and diluted 
with 0.5 mL of CD3OD:D2O (3:1) solvent mixture to determine proton chemical shifts 
using NMR. The chemical shifts were measured as parts per million (ppm) downfield 
with reference to the CD3OD signal at 3.31 ppm.  
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III.B.2. Solid-state Characterization of E2 and SBE 7 Inclusion Complexation 
III.B.2.1. Preparation of E2-SBE 7 Binary Mixtures 
The inclusion complexes of E2 and SBE 7 in different molar ratios of 1:1 and 1:2 
were prepared by solvent evaporation method. The solutions containing required amounts 
of E2 and SBE 7 were prepared separately in 90% (v/v) methanol/water. These solutions 
were then mixed, stirred at ambient temperature (20-25C) and evaporated to dryness 
under fume hood. The dry mass obtained was scraped from the beaker, screened through 
a sieve #60 and stored in a desiccator until analyzed. The corresponding physical 
mixtures were prepared by admixing E2 with SBE 7 in a jar mill for 15 min. Drug content 
uniformity in the physical mixtures was confirmed using the validated HPLC method 
prior to further characterization.  
 
III.B.2.2. Differential Scanning Calorimetry (DSC)  
 Differential scanning calorimetric measurements of pure components and their 
binary mixtures were performed on DuPont 2910 DSC (TA Instruments, New Castle, 
DE). 5-10 mg of the test samples were accurately weighed in aluminum pans and 
crimped. All samples were heated under nitrogen flow at a scanning rate of 10C/min 
from 25C to 195C. The upper limit was determined by the expected melting point of 
estradiol hemihydrate which is in the range of 176-182C. An empty aluminum pan was 
used as a reference. The thermodynamic data was obtained using Thermal Analyst data 
acquisition software. The relative degree of crystallinity of the drug (RDC %) in physical 
mixture and complexes was estimated according to the following equation (Mura et al., 
2003) : 
 63 
 
 
where ΔHsample and ΔHpure drug are the heats of fusion of the drug calculated in the physical 
mixtures or complexes and in the pure drug, respectively. Heat of fusion measurements 
were carried out in triplicate. 
 
III.B.2.3. Powder X-ray Diffraction (PXRD)  
 Powder XRD patterns of pure components and their binary mixtures were  
recorded using a Philips X-ray diffractometer (Philips, Almelo, Holland) with PW 3710 
scanner/PW 1830 generator and a Cu k anode operated at a voltage of 40 kV and a 
current of 30 mA. All the samples were analyzed in the 2  angle range of 10 to 40 
 
III.B.2.4. Fourier Transform Infrared (FTIR) Spectroscopy  
 The infra red spectra of pure components and their binary mixtures were recorded 
on a Nicolet 360 FT-IR Analyzer (Thermo Scientific, Madison, WI) in the scan region of 
4000-400 cm
-1
. The data were averaged over 16 scans at a sensitivity of 50 and resolution 
of 4 cm
-1
. 
 
III.B.2.5. Scanning Electron Microscopy (SEM)  
 The images of pure components and their binary mixtures were recorded using 
Phillips XL 30 FEG scanning electron microscope (Philips, Almelo, Holland) at an 
acceleration voltage of 2kV. The SBE 7 and E2 pure components were used ‗as received‘ 
from the company.  Prior to analysis, all the samples were palladium-coated using 
cresington sputter coater to neutralize any surface charge. 
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III.B.3. Development and Characterization of a Prototype In situ Gel-forming E2 
Ophthalmic Solution 
III.B.3.1. Formulation of in situ gel-forming E2 ophthalmic solution 
Having obtained considerable enhancement of E2 solubility in SBE 7, an in situ 
gel-forming ophthalmic solution was prepared as described next.  Fixed amounts of 
tonicity adjusting agent (mannitol-4.75%w/v) and preservative (benzalkonium chloride 
(0.015%w/v) or benzododecinium bromide (0.015%w/v)) were accurately weighed and 
transferred to pre-weighed amount of Millipore water (~ 90 ml), while stirring in a 300 
mL glass beaker. After the solution was clear, required amount (i.e., on dried basis) of 
gellan gum polymer (Kelcogel
® 
CG-LA) was added and allowed to hydrate in the beaker 
for 15 min. The preparation was then heated to 80°C and maintained for 1 min or until it 
turned clear. The clear solution obtained was then filtered through a Whatman

 filter 
No.1 (42.5mm Ø) and cooled to room temperature. After weight adjustment of the water 
loss due to evaporation, the preparation was sterilized by autoclave at 121°C and 15 psi 
pressure for 15 min. E2 stock solution containing aliquot of the drug in SBE 7 was 
prepared and added to the rest of the sterile preparation by filtering aseptically through 
0.22 μm sterilizing filter in a laminar flow hood. The resultant mixture was then stirred 
for 30 minutes to obtain a homogenous sterile in situ gel-forming estradiol ophthalmic 
solution. The composition of the formulations prepared with different preservatives is 
listed in Table III.1 shown below. 
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Table III.1: Composition of in situ gel-forming estradiol ophthalmic formulation 
Ingredients Functionality Concentration 
(%w/v) 
Estradiol (E2) Active ingredient 0.01 
SBE 7 cyclodextrin Drug solubilizing agent 0.5 
Kelcogel
®
 CG-LA In situ gel-forming polymer 0.1 – 0.5 
Mannitol Tonicity agent 4.75 
Benzalkonium Chloride (BKC) or 
Benzododecinium Bromide (BDDR) 
Preservative 0.015 
 
III.B.3.2. Characterization of in situ gel-forming E2 ophthalmic solution 
Pharmaceutical in situ gel-forming preparations intended for ocular administration 
should exhibit certain desirable characteristics to be suitable for human use and meet 
regulatory standards. These characteristics include clarity, pH, isotonicity, sterility 
(single-unit dosage form), or anti-microbial efficacy (multi-unit dosage form). In 
addition, the efficacy of an ophthalmic delivery system is dependent on prolonged drug 
contact time in the ocular tissues and its ability to resist elimination by the protective eye 
reflex mechanisms. Hence, the viscosity, shear thinning behavior, or viscoelasticity of the 
formulation become very critical for the obvious reason earlier stated and for ease in 
manufacturing, handling and administration and for improving overall patient 
compliance.  
In the subsequent sections, various methods used to test these characteristics are 
briefly addressed. Table III.2, shown below lists the acceptable values of the primary 
characteristics of the in situ gel-forming ophthalmic solutions considered in this study.  
The methodology of testing these characteristics was described in the subsequent 
sections. 
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Table III.2: List of desirable characteristics of an ophthalmic formulation 
Formulation Characteristic Acceptable Value 
pH 6-7 
Osmolality 275-325 mOsm/kg 
Clarity 
Visually clear (or) light transmittance 
>85% at 490 nm using water as reference 
E2 Potency 90-110% assay 
Anti-microbial efficacy 
Compliance with USP for Class-I 
products 
Rheology 
 Viscoelastic or shear thinning nature 
(i.e., G‘‘>G‘ and 0<δ<90°) 
 Gel formation in the presence of 
simulated tear fluid i.e. G‘>>G‖, 
δ<45°, and G‘α ωn where n<0.7 
 
Osmolality Testing 
Osmolality of the formulations was tested using Wescor Vapor Pressure 
Osmometer Model-5520. Prior to use, the instrument was calibrated using standard 
solutions of 290, 1000, and, 100 mOsm/kg and clean test was performed to check the 
level of contamination of the thermocouple sensor from previous measurements. 
According to the manufacturer instructions, if the level of contamination was less than 
10, test samples can be loaded and measured for osmolality. Measurements were done in 
triplicate and mean value for each formulation was calculated. 
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Clarity Measurement 
Qualitative measure of the formulation‘s clarity was first performed by visual 
observation against the light-dark background. Only those formulations that demonstrated 
clarity on visual observation were then quantified for their % light transmission. Using 
Perkin-Elmer UV-Vis spectrometer (Lambda 35 Model), formulations were initially 
scanned using water as a reference standard in the visible region of 400-700 nm to 
identify a wavelength where absorption due to drug (usually at 280 nm) was absent. 
Further, based on the observed scan, and, also the evidence from the literature, 490 nm 
was chosen as the wavelength for measurement of clarity. All formulations were scanned 
for % light transmission at 490 nm against water reference as a measure of their clarity. 
 
Formulation pH  
The pH of the formulations was tested using VWR-9100 pH meter. Prior to 
testing, the pH meter was calibrated using pH standards of 4, 7, and 10 ± 0.01 at 25°C. 
All formulations were tested for pH in triplicate and the mean value was calculated. 
 
E2 Potency 
Drug (E2) content in the formulations was measured using the validated 
fluorescence based HPLC method described earlier. Reagent alcohol was used as a 
solvent for E2 and non-solvent for the polymer. For the extraction process, 50 μL of the 
formulation was sampled and diluted to 1 mL with the solvent in a 1.2 mL centrifuge 
tube. This mixture was then vortexed for a minute and sonicated for 15 min in a water 
bath maintained at 35°C. Further, the tubes were vortexed for another minute and 
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centrifuged in a MicroV micro centrifuge for 5 min at 8000 rpm. The supernatant was 
then diluted and analyzed for E2 concentration. 
 
Preservative Content in the Formulation and Assay Conditions 
 Antimicrobial effectiveness of any preservative is dependent on its concentration 
in the formulation. Since, the procedure for formulation preparation as indicated earlier, 
involves filtration, loss in preservative upon adsorption to the filter membrane was 
probable. Hence, an HPLC assay method specific for the estimation of preservatives in 
the presence of drug & other excipients in the formulation was developed. The 
chromatographic conditions used for the estimation of preservative benzododecinium 
bromide (BDDR) in the presence of drug (E2) were as follows: a mobile phase of 
acetonitrile (ACN) and pH 3.0 phosphate buffer (62: 38), flow rate of 1mL/min, and, UV 
wavelength of estimation at 210 nm. Similarly, the chromatographic conditions for 
estimation of another preservative, benzalkonium Chloride (BKC), in the presence of 
drug were: a mobile phase of acetonitrile (ACN) and pH 3.0 phosphate buffer gradient of 
85% ACN to 75% ACN in 4 min and continue further for 6 minutes, flow rate of 1 
mL/min and UV wavelength of estimation at 210 nm. 
 
USP Anti-microbial Efficacy 
 Formulations containing preservative (BDDR or BKC) along with their 
appropriate positive (i.e., preservative solution) and negative controls (i.e., formulation 
without preservative) were prepared and tested according to USP 31 <51> Antimicrobial 
effectiveness testing procedure for USP Class-I products (i.e., ophthalmic and otic 
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preparations). In this test, aliquots of each formulation were inoculated with 10
5
-10
6
 
cfu/mL concentration of Pseudomonas aeruginosa, Escherichia coli, and, Staphylococcus 
aureus and incubated for 28 days at 22.5 ± 2.5°C. The efficacy of preservatives in 
inhibiting the growth of microorganisms was tested during storage at 7, 14, and 28 days. 
According to USP 31 <51>, the preservative in the formulations are considered to be 
anti-microbially effective only if there was a ―1log‖ decrease in the concentration of the 
microorganisms at day 7, ―3log‖ decrease in the concentration of the microorganisms at 
day 14 and no significant change in the concentration of microorganisms from day 14 to 
day 28.  
 
Rheological Characterization 
To establish in situ gel formation, simulation of in situ gelling upon contact with 
tear fluid and subsequent stability of the formulation upon storage, viscoelastic 
characterization of the developed formulations was conducted with AR 1000 rheometer 
(TA Instruments, New Castle, Delaware, USA) using double-concentric cylinder 
geometry and dynamic small amplitude oscillatory rheometry (SAOR). The instrument 
was operated according to the standard operating procedure. To evaluate viscoelasticity 
or shear thinning behavior of the formulations alone, 6.5 mL of the formulation was 
poured into the double-concentric cylinder geometry and measurements were taken. 
Whereas, to characterize for in situ gel formation and viscoelastic behavior and also to 
simulate the in vivo situation wherein the administered in situ gel-forming eye drops 
interact with the tear fluid in the conjunctiva, formulation and the simulated tear fluid 
(STF) are pre-mixed in 30:7 (v/v) ratios and 6.5 mL of the resulting mixture was 
 70 
transferred to the double-concentric cylinder geometry and analyzed for viscoelastic 
parameters.. The STF was composed of 6.8 g NaCl, 2.2 g NaHCO3, 0.084 g 
CaCL2.2H2O, 1.4 g KCL in 1l of ultra pure water. These amounts results in the mono and 
divalent ion concentrations of 142 mM of Na
+
, 19 mM of K
+
, and 0.6 mM of Ca2
+
 that 
are comparable with ionic contents of the tears. The pH of the STF was then adjusted to 
7.4 using 1N HCl. Prior to testing; the double-concentric cylinder geometry was 
preheated to 35C, to make measurements at the physiological eye temperature.  
 In SAOR, the oscillatory ―stress sweep‖ and ―frequency sweep‖ examines the 
micro structural properties of the material such as elastic modulus (G‘), viscous modulus 
(G‖), and phase angle (δ) under increasing stress and frequency, respectively. These 
properties are used to define the rheological characteristics of samples and to verify if 
their structure corresponds to the rheological definition of gel. A gel state is defined in 
rheological terms as where G‘ >> G‘‘ with low to moderate dependency on the angular 
frequency and phase angle () is low, preferably <45°. In this study, the oscillatory 
stress sweep measurements are carried out first to determine the linear viscoelastic (LVE) 
region of the sample and, therefore, the consequent choice of the stress value to use in the 
oscillatory frequency sweep test.  
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III. C. RESULTS AND DISCUSSION 
III.C.1. Solution-state Characterization of E2 and SBE 7 Complexation 
III.C.1.1. HPLC Assay Method Development & Validation 
The fluorescence based HPLC assay method was found to be suitable for the 
estimation of drug in the binary mixtures with SBE 7. The least squared regression 
analysis of the calibration curve data of E2 in the range of 60-120 ng/mL was shown in 
Figure III.1. The observed high correlation coefficient of 0.9989 indicated good 
agreement and linearity between increasing drug levels and the observed fluorescence 
emission units.  The developed analytical method was further validated in compliance 
with ICH Q2 (R1) guidelines as explained in Section III.B.1.1. The results of validation 
studies are shown in Table III.3. It was observed that the developed method was accurate 
(% mean recovery: 100.3 ± 3.1), precise (CV-3.1%) and highly reproducible with low 
intra-day (CV<2%) and inter-day variation (CV<3%). Two-way ANOVA analysis 
indicated no significant differences between the intra- and inter-day recoveries at 
different E2 concentrations (p>0.05). The limit of detection and quantitation calculated 
using the slope and intercept of the calibration curves were 10 and 33 ng/mL, 
respectively. 
 72 
                  
Figure III.1. Regression plot of E2 calibration standards 
Table III.3. Validation parameters of fluorescence based E2 HPLC assay method. 
Validation 
Parameters 
Values 
Linearity and range 60 – 120 ng/mL (r2= 0.99) 
Specificity  90 ng/mL solution of E2  has retention time (RT) of 7.72 ± 0.02 min 
Accuracy and 
Precision 
E2 Conc. 
(ng/mL) 
Intra-day Inter-day 
% Recovery 
± SD 
Precision 
(% RSD) 
% Recovery 
± SD 
Precision 
(% RSD) 
60  97.45 ± 1.93 1.98 97.92 ± 2.99 3.05 
90 100.30 ± 2.01 2.00 99.10 ± 1.90 1.92 
120 99.29 ± 1.21 1.22 100.78 ± 2.40 2.38 
Limit of Detection 
(LOD) 
10 ng/mL 
Limit of 
Quantification 
(LOQ)  
33 ng/mL 
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III.C.1.2. Phase Solubility Analysis 
There was linearity in the phase solubility diagrams plotted as aqueous solubility 
of E2 as a function of SBE 7 concentration at two different temperatures, 22C and 37C 
(Fig. III.2). The observed linearity in the plots (r
2
 >0.98) indicates formation of soluble 
complexes of E2 and SBE 7 in the concentration range studied and also represents AL-
type of behavior according to the classification proposed by Higuchi and Connors (1965). 
The slope values obtained upon linear regression of the solubility data at 22C and 37C 
were 0.427 and 0.434, respectively. The slope values of <1 reflect existence of 1:1 
stoichiometry between E2 and SBE 7 in the complex. The 1:1 stability constants (K1:1) 
and other thermodynamic parameters calculated using the solubility data are listed in 
Table III.4. The observed differences in the thermodynamic parameters at two different 
temperatures were a result of changes in non-bonded interactions, such as hydrogen 
bonding, van der Waals, and hydrophobic forces between E2 and cyclodextrin due to 
complexation. The observed negative change in enthalpy of association of E2 and SBE 7 
indicated that the complexation was an exothermic process, where E2 inclusion into the 
SBE 7 cavity displaced the enthalpy-rich water causing the release of energy that favored 
the formation of inclusion complex. The apparent stability constant (K1:1), indicative of 
the stability of the complex, decreased with increase in temperature from 25 to 37C due 
to decrease in the non-bonded interactions, such as hydrogen bonding, van der Waals and 
hydrophobic forces. At both investigated temperatures, the entropy change was negative, 
indicating that the complexation was thermodynamically favored and caused an increase 
in the order of the system.  Further, using Eq(s). III.5 and III.6, CE values of 0.75 (22C) 
and 0.77 (37C) along with the [D]/[CD] ratio of 1:2.3 were obtained. From these values 
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it can be inferred that, on average, only about three out of every seven SBE 7 molecules 
in solution are forming a water-soluble complex with E2, assuming 1:1 molar E2-SBE 7 
complex formation. Furthermore, the similarity in the CE values at the two different 
experimental temperatures is indicative of little or no effect of temperature on the 
complexation efficiency of E2 with SBE 7. 
 
Table III.4. Thermodynamic parameters of E2 complexation with SBE 7  
Temperature 
 
K1:1 
(M
-1
) 
ΔHo 
(KJ/mole) 
ΔFo 
(KJ/mole) 
ΔSo 
(J/mole/
o
K) 
CE [D]/[CD] 
22°C (295°K) 93.26 × 10
3
 
-54.3 
-28.07 -88.9 0.75 1:2.3 
37°C (310°K) 31.97 × 10
3
 -26.73 -88.9 0.77 1:2.3 
 
 
Figure III.2. Phase solubility diagram of E2 with SBE 7 in water at 22 and 37°C 
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III.C.1.3. Isothermal Titration Calorimetry (ITC) 
The binding isotherm and the corresponding thermodynamic parameters obtained 
at 25°C were K (1660  258 M-1), N (0.96  0.17), H (-63.84  13.48 KJ/mole) and S 
(-6.67 J/mole/K) as shown in Fig(s). III.3a and 3b. The complexation process was 
exothermic and enthalpy driven, as change in enthalpy obtained was negative. This 
negative change in enthalpy was a result of partitioning of the hydrophobic E2 molecule 
into the SBE 7 cavity and release of enthalpy-rich water from cyclodextrin cavity.  The 
negative change in entropy also suggests that the binding was thermodynamically favored 
and caused an increase in the order of the system.  The ―N‖ values close to 1 (i.e., 0.96  
0.17) suggest that the stoichiometry of binding between E2 and SBE 7 is mainly 1:1. 
Based on the assumption of 1:1 molecular complexation,  the close agreement of the heat 
of enthalpy value obtained in this experiment (H = -63.84  13.48 KJ/mole) to the 
enthalpy value (-54.3 KJ/mole) calculated from the phase solubility data using the 
empirical equation (Eq. III.2)  further confirmed the validity of the equation.  
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Figure III.3. a) Representative ITC plot of SBE 7 titration into E2 solution at 25C, b) 
binding isotherm of SBE 7 titration into E2 solution at 25C 
 
III.C.1.4. 
1
H NMR Measurements 
Proton nuclear magnetic resonance (
1
H NMR) spectra of the host-guest mixture in 
solution was used to confirm possible interaction (within the cavity or at the surface) 
between estradiol and SBE 7 as implied from the DSC and PXRD measurements. In 
addition, 
1
H-NMR experiments were performed to confirm that the increase in the 
estradiol (E2) aqueous solubility occurred due to inclusion complexation with SBE 7   
(Fig. III.4). The chemical shifts of the protons of E2 were assigned according to the 
published report (Variankaval et al., 2000). The induced shift, Δδ, is defined as the 
difference in chemical shifts of E2 protons in the presence and absence of SBE 7. In the 
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present study, the induced shifts were calculated by the following equation: Δδ = Δδ 
(complex) – Δδ (free). In this convention, positive and negative signs show a downfield and 
upfield shifts, respectively. The 
1
H chemical shifts of E2 in the absence and presence of 
SBE 7 are shown in Table III.5. Aromatic protons of the phenyl group of E2 showed 
considerable 
1
H-chemical shifts compared to E2 available freely in the solution, 
indicating that the environment of the aromatic or phenyl group of E2 is considerably 
different due to complexation with SBE 7. Also, all the aromatic hydrogens were 
deshielded due to decrease in the electron density around E2 molecules, probably due to 
van der Waals forces, dipole-dipole interactions, and/or hydrogen bonds between the 
drug and SBE 7 molecules. These results suggested that the possible orientation in which 
E2 binds to the SBE 7 is with its A-ring into the cyclodextrin cavity (Fig. III.5). However, 
the effect of E2 binding on the 
1
H chemical shifts of SBE 7 could not be measured as they 
were overlapped by those of E2 in the NMR graphs.  
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Figure III.4. One-dimensional 
1
H-NMR of  a) SBE 7, b) E2, and c) complex of E2 with 
SBE 7 in CD3OD:D2O (3:1) solvent mixture. 
 
Table III.5. Chemical shifts (ppm) for the protons of E2 due to complexation with SBE 7. 
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Figure III.5. The model structure complex of E2 and SBE 7 in 1:1 stoichiometry. 
 
III.C.2. Solid-state Characterization of E2 and SBE 7 Complexation 
III.C.2.1. Differential Scanning Calorimetry (DSC)  
 Thermal analysis using DSC offers a simple, fast, and reliable approach of 
investigating these binary systems. Inclusion complex formation remarkably changes the 
original thermal properties of the complexed guest(s), such as absence of melting peak or 
shift in decomposition towards higher temperature, etc. The DSC curve of E2 (Fig. III.6) 
indicated the crystalline hemihydrate state of E2 with the dehydration endotherm around 
110C and the melting endotherm at a Tonset= 177.49C, Tpeak= 179.22C, and enthalpy of 
melting (Hf) of 102.7 J/g. SBE 7 did not exhibit a melting point, indicative of an 
amorphous material. The DSC thermogram of SBE 7 (shown in Fig. III.6)  showed a 
broad endotherm in the range of 40 - 150C, consistent with dehydration of the sample. 
In both the 1:1 equimolar physical mixtures (178.45C) and complexes (178.29C) of 
drug with SBE 7, the characteristic, well identifiable peak of the drug appeared at the 
temperature corresponding to its melting point. But, the intensity (i.e., change in 
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enthalpy) was strongly reduced along with the relative degree of crystallinity (shown in 
Table III.6) in the complex (∆Hf =1.45 J/g and RDC (%) = 16) compared to the physical 
mixture (∆Hf =8.01 J/g and RDC (%) = 3). However, complete amorphization was only 
obtained in the case of the 1:2 complexes of E2 and SBE 7, where the characteristic E2 
melt peak completely disappeared while, it still remained distinct in the corresponding 
physical mixture (Tmelt = 178.42C, ∆Hf =7.26 J/g and RDC (%) = 22). This observation 
may be attributed to amorphization of the drug and/or the formation of an inclusion 
complex between E2 and SBE 7. 
 
 
Figure III.6. Differential scanning thermograms of E2, SBE 7, and their corresponding 
1:1 and 1:2 molar physical mixtures and complexes. 
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Table III.6. DSC thermodynamic data and relative degree of crystallinity (RDC %) of E2 
in physical mixtures and inclusion complexes with SBE 7 
Sample Tpeak/°C 
Wt. adjusted  
ΔHf (J/g)  
RDC (%) 
E2 Pure 179.22 100.5 100 
E2-SBE 7 (1:1) physical mix 171.25 16.0 16 
E2-SBE 7 (1:1) complex 178.29 2.9 3 
E2-SBE 7 (1:2) physical mix 178.42 21.8 22 
E2-SBE 7 (1:2) complex 
no melt 
peak 
NA 
complete  
amorphization 
 
III.C.2.2. Powder X-ray Diffraction (PXRD)  
The diffractograms of E2 and its corresponding physical mixtures and complexes 
with SBE 7 in different molar ratios are shown in Fig. III.7a and 7b.  In the PXRD of E2, 
the observed sharp characteristic peaks at diffracting angles (2θ) of  13.96°, 16.87°, 
18.39°, 21.98°, and 26.01° indicate crystalline nature of the drug. PXRD of SBE 7 
showed a single broad peak indicating its amorphous nature. Peaks due to E2 crystallinity 
were still detectable in the respective physical mixtures and complexes with SBE 7 in 1:1 
molar ratio (Fig. III.7a). But, the complexes showed considerable reduction in the 
diffraction peak intensities, suggesting that it was less crystalline than the physical 
mixture (Fig. III.7a). The observed decrease in drug crystallinity or drug amorphization 
was attributed to its complexation with SBE 7. However, a total drug amorphization was 
observed in the diffractograms of E2-SBE 7 complexes of 1:2 molar ratios (Fig. III.7b) as 
the characteristic peaks of the drug were not observed. These results are in complete 
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agreement with the DSC results that showed complete drug inclusion at 1:2 molar ratios 
in the solid state. 
 
 
Figure III.7. Powder X-ray diffraction patterns of E2, SBE 7 and their binary systems. a) 
E2 and SBE 7 (1:1 molar) physical mixture and complex, b) E2 and SBE 7 (1:2 molar) 
physical mixture and complex. 
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III.C.2.3. Fourier Transform Infrared (FTIR) Spectroscopy  
 FTIR is typically used to characterize compounds containing functional groups 
that show distinguishing IR bands, such as carbonyl or sulfonyl groups. In this study, 
although E2 and SBE 7 lack such characteristic functional groups, FTIR was still used to 
gather valuable information about the participation of hydrogen in the inclusion 
complexation. Such an involvement generally shifts the absorbance bands to the lower or 
higher frequencies and/or increases their intensity, etc. Infrared spectra of E2, as well as 
those of its solid binary mixtures with SBE 7 in the 2500-4000 cm
-1
 range are presented 
in Fig. III. 8a and 8b. IR spectral overlay shown in Fig. III.8a revealed that there were no 
variations in the spectrum of the physical mixture with respect to the spectra of the pure 
components, but that there were variations in the IR spectrum of the complex. Namely, 
the aromatic and aliphatic –CH, aliphatic –CH2 stretching vibrations of E2 in the range of 
2600-3100 cm
-1
 were absent in the complex as they were masked due to inclusion of E2 
into the cavity of SBE 7. This proof is indicative of breakdown of the intermolecular 
hydrogen bonds of the crystals associated with the inclusion of the drug into the 
hydrophobic cavity of the carrier (SBE 7). Further, E2 inclusion into the SBE 7 cavity in 
their 1:1 molar complex caused the aliphatic -CH/-CH2 stretching vibration. In contrast, it 
remained unaffected at 2929.2 cm
-1
 in the 1:2 molar complexes of E2 and SBE 7 (Fig. 
III.8b), indicating the diminishing influence of drug on its interaction with SBE 7 at 
higher SBE 7 ratios in their binary mixtures. In addition, the IR spectra of the complexes 
(Fig. III.8a and III.8b) demonstrated close resemblance with the SBE 7, indicating drug 
amorphization in the solid-state due to its inclusion into the hydrophobic cavity of SBE 7. 
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Figure III.8. FT-IR spectra of E2, SBE 7 and their binary systems in 2500-4000cm
-1
 
region. a) E2 and SBE 7 (1: 1 molar) physical mixture and complex, b) E2 and SBE 7 (1:2 
molar) physical mixture and complex. 
 85 
III.C.2.4. Scanning Electron Microscopy 
Scanning electron microscopy (SEM) photographs (in Fig. III. 9a and III. 9b) 
show the particle morphology of pure components E2 and SBE 7 as plate-like and hollow 
spherical particles, respectively. The physical mixtures in Fig. III.9c showed particles of 
SBE 7 embedded with E2 particles. In contrast, the inclusion complexes of E2 and SBE 7 
(in Fig. III.9d) showed a completely different morphology with columnar particles 
formed as a result of molecular inclusion complexation. 
 
 
Figure III.9. Scanning electron microscopy images of a) SBE 7, b) E2, c) Physical 
mixture, and d) Inclusion complex 
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III.C.3. Characterization of in situ gel-forming E2 ophthalmic solution 
III.C.3.1. Osmolality Testing 
Solutions intended for administration in the eye should be isotonic with the 
physiological fluids. Instillation of hypo or hypertonic solutions could elicit reflex tears 
and reflex blinks in the eye due to discomfort and irritation. Hence, osmolality testing is 
one of the key quality attributes to be tested for ophthalmic preparations. Based on the 
preliminary osmolality measurements using vapor pressure osmometer, addition of 4.75 
%w/v of mannitol along with the fixed amounts of other excipients resulted in 
formulations that possessed osmolality in the desired or acceptable range. The osmolality 
of different formulations is listed in Table III.7 below. Preservative type and content or 
polymer amount in the formulations didn‘t show any significant influence on the resultant 
osmolality. 
Table III.7. In vitro characteristics of the developed in situ gel-forming E2 formulations 
Preservative 
(%w/v) 
Kelcogel 
(%w/v) 
pH 
Osmolality 
(mOsm/Kg) 
Clarity 
(% transmittance) 
BKC 
(0.015) 
0.1 6.09 ± 0.03 277 ± 4 94.51 ± 0.18 
0.3 6.06 ± 0.01 285 ± 2 90.13 ± 1.10 
0.5 6.01 ± 0.02 279 ± 6 86.66 ± 0.92 
BDDR 
(0.015) 
0.1 6.18 ± 0.03 277 ± 4 99.89 ± 1.02 
0.3 6.15 ± 0.02 277 ± 4 99.22 ± 0.09 
0.5 6.09 ± 0.03 277 ± 4 98.76 ± 2.01 
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III.C.3.2. Clarity Measurement   
Turbidity or clarity of the formulations was quantitatively estimated by 
transmittance measurements. Clarity measurement is critical because quaternary 
ammonium class of preservatives tends to cause turbidity in the formulations as a result 
of columbic interaction with the anionic gellan gum polymer. Evaluation of percent 
transmittance as a measure of clarity of the formulations indicated varying degree of 
interaction, i.e. clarity of formulation with benzododecinium bromide > benzalkonium 
chloride. As shown in Table III.7, polymer concentration showed no effect on the clarity 
of the formulations containing BDDR as the preservative, but caused decrease in the 
clarity of the formulations containing BKC as the preservative. Such decrease in clarity 
with BKC is because at the same preservative concentration (i.e., 0.015%w/v) the number 
of molecules of BKC available in the solution to interact with anionic gellan gum 
polymer relative to BDDR was higher due to its relatively lower molecular weight (i.e., 
354.08 g/mol for BKC and 384.51 g/mol for BDDR).  
 
III.C.3.3. Formulation pH 
Increasing the concentration of gellan gum in the formulation resulted in lower 
pH values due to its anionic nature. All the developed formulations had pH in the 
acceptable range of 6-7 units (Table III.7). However, formulations containing BDDR 
preservative showed substantially different and higher pH values than the formulations 
containing BKC because of the differences in the number of molecules present in the 
formulations at the same preservative concentration based on the different molecular 
weights.  
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III.C.3.4. Potency of E2 
Ethanol was found to be a suitable extraction solvent for E2 and the extraction   
resulted in an acceptable assay values (i.e. 90-110% recovery). From the E2 assay values 
shown in Table III.8, it was evident that increasing the polymer, especially in case of 
formulations containing BKC as the preservative resulted in lower assay values. Lower 
E2 potency values suggest that drug was strongly bound within the polymer matrix 
formed due to greater propensity of BKC for columbic interactions with anionic gellan 
gum polymer and SBE 7 relative to BDDR at same concentration.  
Table III.8. E2 and preservative content in the ophthalmic formulations 
Preservative 
(%w/v) 
Kelcogel 
(%w/v) 
E2 Assay 
(% recovery) 
Preservative 
(% recovery) 
BKC 
(0.015) 
0.1 96.87 ± 1.65 98.91 ± 0.87 
0.3 93.79 ± 2.98 100.05 ± 1.98 
0.5 92.62 ± 3.36 98.23 ± 1.16 
BDDR 
(0.015) 
0.1 98.72 ± 0.66 101.10 ± 2.13 
0.3 96.07 ± 1.95 99.66 ± 2.15 
0.5 97.11 ± 1.01 99.04 ± 0..88 
 
III.C.3.5. Preservative Content 
The quaternary ammonium preservatives (BKC or BDDR) used in the 
formulations was a mixture of different homologs of C12 & C14. Hence, one or more 
peaks corresponding to the preservative were observed in the overlay of chromatograms 
of BBDR and BKC calibration standards in Fig.III.10 and III.11.  High r
2
 (>0.99) 
obtained upon the least-square linear regression of the calibration data indicated good 
correlation between the concentration of the preservative and its absorbance (Table III.9). 
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Also, the high recovery values (>95%) obtained for preservatives in the formulations (as 
shown in Table III.8) indicated suitability of the developed method for their estimation. 
 
Figure III.10. Overlay of chromatograms of calibration curve of BDDR & E2 at 210 nm. 
 
 
Figure III.11. Overlay of chromatograms of calibration curve of BDDR & E2 at 210 nm. 
 
Table III.9. Regression equation and calibration range of E2, BKC and BDDR. 
 
Sl. 
No 
Preservative Peaks 
Regression 
Equation 
Calibration 
range 
Linearity 
(r
2
) 
1 
Benzalkonium 
Chloride (BKC) 
BKC_1 Y= -2868+86521X 1 - 4 μg/ml 0.9999 
E2 Y= -9.8e
5
+1.76 e
8
X 1.5 - 6 μg/ml 0.9999 
BKC_2 Y= -4175+41955X 1 - 4 μg/ml 0.9998 
2 
Benzododecinium 
Bromide (BDDR) 
BDDR_1 Y= -1282+56996X 0.5 - 3 μg/ml 0.9994 
E2 Y= -2327+282017X 0.75 – 4.5 μg/ml 0.9999 
BDDR_2 Y=-2531+116385X 0.5 - 3 μg/ml 0.9999 
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III.C.3.6. USP Anti-microbial Efficacy 
Anti-microbial efficacy through the use of preservatives was done to establish that 
the formulation will not support bacterial growth during administration and storage since 
Kelcogel CG-LA being a polysaccharide can sustain microbial growth. BDDR or BKC 
were chosen as the preservatives of choice in this study due to their established evidence 
of efficacy against both gram positive and negative microorganisms. These quaternary 
ammonium preservatives (i.e., BDDR and BKC) being cationic in nature, prevent 
microbial proliferation by emulsifying and disrupting the bacterial external membrane. 
The preservative concentration in the formulations was fixed at 0.015% w/v based on 
their maximum allowable concentration for use in pharmaceutical products for 
administration in humans. However, addition of any of the two preservatives to the 
formulations did not provide USP anti-microbial efficacy (shown in Table III.10).   
Such loss in preservative efficacy could not be attributed to any loss in 
preservative during manufacturing and handling, as the recovery values were well with-in 
the acceptable limit of 95-105% recovery (Table III.8). However, such loss in the 
efficacy could be a result of low amounts of free preservative available in the formulation 
due to columbic interaction between the cationic preservative and anionic polymer and 
solubilizing agent that possibly led to reduced accessibility of the preservative to the 
microorganisms. 
In order to test this hypothesis and to investigate role of excipients in causing 
preservative inefficacy caused by binding, appropriate positive and negative formulation 
controls were prepared and tested for antimicrobial effectiveness.  All the formulations 
were found to be sterile indicating that the method of preparation was aseptic.  
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Table III.10. USP anti-microbial efficacy of the E2 ophthalmic formulations 
Preservative 
(%w/v) 
Kelcogel 
(%w/v) 
Test Product Sterility 
USP Anti-microbial Efficacy 
Gram +ve Gram -ve 
S.aureus E.coli P.aureus 
BKC 
(0.015) 
0.3 Formulation Yes Yes No No 
0.3 
Positive 
Control-I
#
 
Yes Yes Yes Yes 
0.3 
Positive 
Control-II
*
 
Yes Yes Yes Yes 
0.3 
Negative 
Control
†
 
Yes No No No 
BDDR 
(0.015) 
0.3 Formulation Yes Yes No No 
0.3 
Positive 
Control-I
#
 
Yes Yes Yes Yes 
0.3 
Positive 
Control-II
*
 
Yes Yes Yes Yes 
0.3 
Negative 
Control
†
 
Yes No No No 
#
 Positive control –I: Preservative (0.015%w/v) solution 
*
 Positive control –II: Formulation without E2 and SBE 7 
† 
Negative control: Formulation without preservative 
 
The results shown in Table III.10 indicate that the preservative solutions as alone 
(Positive control–I) and in the presence of anionic gellan gum polymer in the formulation 
(Positive control-II) demonstrated required USP anti-microbial efficacy. These findings 
suggest, that despite their tendency for excipient-excipient ionic interaction, there was 
still a required amount of free preservative available in the formulation (i.e., Positive 
control-II) to provide anti-microbial efficacy. However, when preservatives are present in 
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the formulation together with the anionic gellan gum polymer and anionic SBE 7 
complexing agent, its efficacy in inhibiting the growth of microorganisms was lost due to 
increased excipient-excipient ionic interactions. Hence, in the next chapter use of a non-
ionic drug solubilizing agent and a new preservative system will be studied in an effort to 
minimize excipient- excipient interactions that could influence product performance 
characteristics.  
 
III.C.3.7. Rheological Characterization 
 
Small amplitude oscillatory rheometry (SAOR) was used for rheological 
characterization of the formulations as it allows measuring the viscoelastic properties of 
materials at low amplitudes without destroying the structure. The ―double concentric 
cylinder‖ geometry was used in this study as its design maximizes the available surface 
area over which the measurements can be obtained and improves sensitivity. Besides, it is 
also the most sought after geometry to use with low-viscous preparations where sample 
slip effects could be significant.  
The ―oscillatory stress sweep‖ test was performed at a fixed angular frequency (5 
rad/s) on all the formulations as alone and in a pre-defined mixture with STF, to identify 
the linear viscoelastic region (LVE) within which the material under applied stress retains 
structural integrity. The LVE for formulations containing different concentrations of 
polymer or preservative type are listed in Table III.11 and III.12.  
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Figure III.12. Oscillatory stress sweep of E2 ophthalmic formulation containing 0.5%w/v 
Kelcogel CG-LA and 0.015%w/v BDDR performed at 5 rad/s angular frequency. 
 
Figure III.13. Oscillatory frequency sweep of E2 ophthalmic formulation containing 
0.5%w/v Kelcogel CG-LA and 0.015%w/v BDDR performed at 0.5 Pa oscillatory stress.  
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Figure III.14. Oscillatory stress sweep of the mixture of E2 formulation containing 
0.5%w/v Kelcogel CG-LA and 0.015%w/v BDDR and STF in 30:7 (v/v) ratios 
performed at 5 rad/s angular frequency. 
 
Figure III.15. Oscillatory frequency sweep of the mixture of E2 formulation containing 
0.5%w/v Kelcogel CG-LA and 0.015%w/v BDDR and STF in 30:7 (v/v) ratios 
performed at 0.5 Pa oscillatory stress 
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The representative oscillatory stress sweep and frequency sweep plots for the 
formulation containing 0.5%w/v Kelcogel CG-LA and 0.015%w/v of BDDR along with 
other excipients listed in Table III.1 are shown in Fig. III.12 and III.13, respectively. 
Similarly, Fig. III.14 and III.15 represent oscillatory stress sweep and frequency sweep 
plots for the mixture of formulation containing 0.5%w/v Kelcogel CG-LA and 
0.015%w/v of BDDR and STF in 30:7 v/v ratios. 
In Fig. III.12, the loss modulus (G‖), which is a measure of liquid-like nature of 
the material, was higher than (G‘), a measure of solid-like nature of the material, 
throughout the entire stress range studied. However, the modulus values started to 
decrease at the oscillatory stress >1 Pa, indicating a threshold stress value beyond which 
the structural integrity of the material was lost. Thus, the LVE in this case was identified 
as oscillatory stress <1 Pa and angular frequency of 5 rad/s. The oscillatory frequency 
sweep generated in this LVE region (shown in Fig. III. 13) provides a way of probing the 
morphology of the material without disturbing it and gives the dynamic moduli of G‘ and 
G‖. From the Fig. III.13 and the summary of viscoelastic parameters listed in Table III.10 
and III.11, it was clearly evident that all the formulations when tested alone indicated 
viscoelastic or shear thinning behavior, where G‖>G‘ and phase angle (δ) was between 0 
and 90°.  
Increasing the polymer concentration in the formulations had significantly 
increased the dynamic moduli values (Table III.11 and III.12) suggesting formation of a 
stronger polymer network with higher strength. Also, formulations containing BKC as 
the preservative produced higher moduli values compared to formulations containing 
BDDR as the preservative, due to their higher propensity for columbic interaction with 
 96 
other excipients in the formulation.  Relatively lower δ values observed in case of BKC 
formulations further confirms that BKC interaction with the gellan gum polymer has 
resulted in overall improvement in the morphology and structure of the formulations. 
 
Table III.11. Linear viscoelastic region (LVE) and the corresponding viscoelastic 
properties of E2 ophthalmic formulations containing BDDR preservative as alone, and in 
the mixture with STF in 30:7 (v/v) ratios. 
Preservative 
(%w/v) 
Kelcogel 
(%w/v) 
Linear viscoelastic region  
(LVE) (formulations alone) 
Viscoelastic properties of the 
formulations 
Stress 
(Pa) 
Frequency 
(rad/s) 
G‘(Pa) G‘‘(Pa)  (delta) 
BDDR 
(0.015) 
0.1 0.1 5 0.02 0.04 64 
0.3 0.5 5 0.12 0.19 58 
0.5 0.5 5 0.22 0.38 60 
Preservative 
(%w/v) 
Kelcogel 
(%w/v) 
Linear viscoelastic region  
(formulations + STF (30:7)) 
Viscoelastic properties in the 
presence of STF (30:7) 
Stress 
(Pa) 
Frequency 
(rad/s) 
G‘(Pa) G‘‘(Pa)  (delta) 
BDDR 
(0.015) 
0.1 0.1 5 0.11 0.06 29 
0.3 0.5 5 0.39 0.22 29 
0.5 1.0 5 1.02 0.35 19 
 
  However, when formulations were tested in the presence of STF, drastic change 
in the morphology was observed. In both the oscillatory stress and frequency sweep plots 
shown in Fig. III.14 and III.15, G‘>>G‖, δ<45° and there was a moderate to weak 
dependency of dynamic moduli, especially G‘, on the angular frequency. These 
viscoelastic characteristics reflected in situ gel structure formation due to gellan gum 
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interaction with the cations in the STF. Increasing the polymer concentration in the 
formulations resulted in the gels with stronger gel network and higher gel strengths (i.e. 
higher G‘ and lower δ). Since, the volume and, hence, the ionic strength of the STF was 
kept constant with all the formulations, such increase in viscoelastic behavior is simply a 
result of increased interactions between the anionic gellan gum polymer and mono and 
divalent cations in STF due to higher polymer in the formulation. The final preservative 
and surfactant used will be discussed in the next chapter.   
 
Table III.12. Linear viscoelastic region (LVE) and the corresponding viscoelastic 
properties of E2 ophthalmic formulations containing BKC preservative as alone, and in 
the mixture with STF in 30:7 (v/v) ratios. 
Preservative 
(%w/v) 
 
Kelcogel 
(%w/v) 
Linear Viscoelastic Region  
(LVE) (formulations alone) 
Viscoelastic Properties of 
the formulations 
Stress 
(Pa) 
Frequency 
(rad/s) 
G‘(Pa) G‘‘(Pa) 
 
(delta) 
BKC 
(0.015) 
0.1 0.1 5 0.05 0.09 61 
0.3 0.5 5 0.16 0.20 51 
0.5 0.5 5 0.29 0.36 51 
Preservative 
(%w/v) 
 
Kelcogel 
(%w/v) 
Linear Viscoelastic Region  
(formulations + STF (30:7)) 
Viscoelastic Properties in 
the presence of STF (30:7) 
Stress 
(Pa) 
Frequency 
(rad/s) 
G‘(Pa) G‘‘(Pa) 
 
(delta) 
BKC 
(0.015) 
0.1 0.1 5 0.24 0.09 21 
0.3 0.5 5 0.46 0.25 29 
0.5 0.5 5 1.21 0.41 19 
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In accordance with the earlier observation, formulations that contained BKC as 
the preservative produced gels with stronger strengths and higher elastic modulus (Table 
III.12) compared to formulations containing BDDR as the preservative due to their higher 
propensity for columbic interaction with other anionic excipients in the formulation. 
Similar observations were also reported by Carlfors et al., 1998 and Magny et al., 1994, 
where they ascribed increase in the elasticity of the gel network to formation of micellar 
aggregates of cationic surfactant at the oppositely charged carboxylic groups of the gellan 
gum polymer which participates in the intermolecular gel network.  
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III. D. CONCLUSIONS 
Sulfobutylether 7β-cyclodextrin (SBE 7) was found to be a suitable solubility 
enhancing agent for improving aqueous solubility of estradiol (E2). An inclusion complex 
of the E2 and SBE 7 was formed and it resulted in an increased aqueous solubility of the 
drug. The fluorescence based HPLC method developed for estimation of E2 was found to 
be precise, accurate, and reproducible.  
Characterization in the solution state using phase solubility study and ITC 
revealed 1:1 stoichiometry between E2 and SBE 7 in the complex. The complexation 
process was thermodynamically favored and resulted in increased order of the system. 
The decrease in the apparent stability complex of the complex with increasing 
temperature indicated the exothermic nature of the inclusion complexation.  
Considerable chemical shifts in the aromatic protons of E2 in the presence of SBE 
7 indicated that the interaction was favored with A-ring entering the SBE 7 hydrophobic 
cavity. Also, both DSC and XRPD results indicated the formation of amorphous systems 
of E2 in the solid state due to inclusion complexation with SBE 7. The E2 stock solution 
in SBE 7 was then used to develop an in situ gel-forming ophthalmic solution.  
 Addition of mannitol (4.75%w/v) resulted in isotonic formulations. 
Benzalkonium chloride (BKC) and benzododecinium bromide (BDDR) were chosen as 
suitable preservatives based on their established evidence of efficacy against 
microorganisms.  But, being cationic in nature, they showed tendency to interact with the 
polymer and affect clarity of the preparations. The formulations containing BKC as the 
preservative caused significant decrease in the clarity at higher polymer concentrations.  
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USP anti-microbial efficacy study results indicated that the preservative solutions 
alone and in the presence of gellan gum in the formulation demonstrated antimicrobial 
efficacy. But, when preservative was present together with anionic gellan gum polymer 
and anionic SBE 7 in the formulation, its efficacy in inhibiting the growth of 
microorganisms was lost. This loss could be due to low amounts of free preservative 
available as a result of excipient-excipient columbic interactions in the formulations. 
Rheological characterization by small amplitude oscillatory amplitude showed 
that Kelcogel CG-LA offers great potential as a vehicle for in situ gel-forming 
ophthalmic system. All formulations exhibited viscoelastic behavior when tested as 
alone, but when mixed with STF, in situ gel formation along with a drastic change in 
morphology and viscoelastic behavior was observed. Polymer concentration was found to 
have positive influence on the resulting dynamic moduli; where, increasing the polymer 
concentration resulted in stronger polymer or gel networks with higher elastic modulus. 
Also, formulations containing BKC as the preservative produced stronger gel structures 
by interacting with the carboxylic acid groups of the gellan gum polymer and minimizing 
electrostatic repulsion between the two successive polymer strands.  
Although the developed formulation provided some desirable characteristics of an 
ophthalmic formulation, it still failed to demonstrate the most important and critical 
characteristic of anti-microbial efficacy due to excipient-excipient ionic interactions in 
the formulation. Hence, in the next chapter, a new preservative system and drug 
solubilizing agent are investigated and an optimized in situ gel-forming E2 ophthalmic 
formulation were identified using statistically designed experiments.  
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CHAPTER IV 
 
DEVELOPMENT AND OPTIMIZATION OF THE IN SITU GEL-FORMING 
OPHTHALMIC ESTRADIOL SOLUTION 
 
IV. A. INTRODUCTION 
 
The prototype in situ gel-forming estradiol solution described in Chapter III failed 
to demonstrate antimicrobial efficacy due to potential excipient-excipient ionic 
interactions between the preservative and other excipients in the formulation. Gellan gum 
and SBE 7 being anionic in nature showed tendency to interact with cationic quaternary 
ammonium preservatives. As a result, low amounts of free preservative were available in 
the formulation to act against microbial growth and achieve required efficacy. In order to 
overcome this challenge, the present work focused on identifying suitable excipients that 
could minimize excipient-excipient interactions in the formulation and developing an 
ophthalmic estradiol formulation with acceptable product performance characteristics.  
Firstly, suitability of polysorbate 80 to enhance E2 aqueous solubility as well as 
minimize potential interactions with other excipients in the formulation will be 
investigated. Secondly, use of potassium sorbate as alone or in combination with EDTA 
as a preservative system will be studied for their compatibility with other excipients in 
the formulation and also for their capacity to overcome challenges related to anti-
microbial efficacy. In addition, using a pre-optimization study design, optimum levels of 
each of these preservatives that will demonstrate desired anti-microbial efficacy at all 
polymer levels in the formulation will be identified. The successful formulation will then 
be characterized using statistical design of experiments (DOE) to understand the 
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influence of polymer and drug concentrations on the product performance characteristics 
and identify an optimized in situ gel-forming E2 ophthalmic formulation.   
 
IV. B. EXPERIMENTAL AND METHODS 
IV.B.1. Solubilization of E2 by Polysorbate 80 
Having observed the potential of the anionic drug solubilizing agent SBE 7 for 
excipient-excipient ionic interaction with other excipients in the prototype formulation in 
Chapter III, aqueous solubility enhancement of E2 was investigated using nonionic 
polysorbate 80-water mixtures at concentrations between 0 and 114.5 mM (i.e. 0 to 
15%w/v). Excess E2 was added directly into the surfactant-water mixture and agitated in 
an incubator shaker operated at 250 rpm and fixed temperature (23 ± 2°C or 35 ± 2°C) 
for 3 days until equilibrium was reached. After equilibration, the solutions were 
centrifuged and the supernatant filtered through 0.45 µm nylon syringe filter and 
analyzed for E2 concentration using a validated reverse phase HPLC method discussed 
earlier. All the solubility experiments were carried out in triplicate. 
 
IV.B.2. Anti-microbial Efficacy of New Preservative System 
Formulation Preparation 
Potassium sorbate as alone or in combination with EDTA were investigated for 
their ability to provide satisfactory USP anti-microbial efficacy of the formulation. 
Except for anti-microbial efficacy, the prototype in situ gel-forming E2 formulation 
discussed in Chapter III provided acceptable characteristics of clarity, pH, osmolaity, and 
viscoelasticity. Hence, the polymer, Kelcogel
®
 CG-LA and the osmotic agent, mannitol 
 103 
were retained as the suitable excipients. Formulations containing these excipients along 
with potassium sorbate, alone or in combination with EDTA, were prepared according to 
the composition shown in Table IV.1. The amount of potassium sorbate in the 
formulation was fixed at 0.3%w/v based on its maximum allowable use; whereas, the 
amount of EDTA (0.03%w/v) was chosen in the allowable range of 0.005-0.1%w/v. 
These formulations, along with their negative controls (i.e., with out preservatives), were 
prepared using the method described in section III.B.1, except that the E2 stock solution 
used was made in polysorbate 80. The positive controls of these formulations containing 
potassium sorbate alone or in combination with EDTA in water were prepared aseptically 
and tested along with other formulations for USP anti-microbial efficacy. 
 
Table IV.1: Composition of E2 ophthalmic formulations containing new preservative and 
solubilizing agents along with their positive and negative controls. 
Ingredients 
Concentrations (%w/v) 
Formulations Positive Controls Negative 
Control (A) (B) (A) (B) 
Estradiol (E2) 0.01 0.01 --- --- 0.01 
Polysorbate 80 1.6 1.6 --- --- 1.6 
Kelcogel
®
 CG-LA 0.3 0.3 --- --- 0.3 
Mannitol 4.75 4.75 --- --- 4.75 
Potassium Sorbate 0.3 0.3 0.3 0.3 --- 
Edetate disodium  
dihydrate (EDTA) 
--- 0.03 --- 0.03 --- 
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Preservative Efficacy Testing  
The E2 ophthalmic formulations and their positive and negative controls shown in Table 
IV.1 were tested for USP anti-microbial efficacy. The testing procedure used was similar 
to the method described in III.B.3.2. 
 
IV.B.3. Pre-optimization: Selection of Optimum Preservative Concentration  
In situ gel-forming ocular formulations being part of USP class-I products, have 
to demonstrate USP anti-microbial efficacy of the formulation in addition to the fact that 
gellan gum is a polysaccharide which has the potential to support microbial growth in the 
formulation. The higher the level of gellan gum, the susceptibility towards microbial 
contamination is increased. Therefore, the optimization of preservative level in 
conjunction with the polymer level was considered extremely important. Moreover, 
potassium sorbate and EDTA are salts of potassium and sodium and high amounts of 
these preservatives in the formulation can interact with gellan gum, by a similar gelation 
mechanism described previously, to result in formulations that can be too viscous to flow. 
In order to accommodate the role of the excipients, a 3
2
 full factorial screening study was 
designed to investigate the influence of polymer and preservative levels on some critical 
product performance attributes, such as antimicrobial efficacy, clarity, osmolality, and 
drug potency.  
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Pre-Optimization Design of Experiment (DOE): Selection of Preservative (EDTA) and 
Polymer Levels  
A simple 3
2 
full factorial design was employed and nine formulations (shown in 
Table IV.2) containing three levels of Kelcogel
®
 CG-LA (0.1, 0.3 and 0.5%w/v) and 
three levels of EDTA (0.01, 0.03 and 0.05%w/v) were prepared using the method 
described in section III.B.1. In these experiments the concentrations of the other 
excipients in the formulation, i.e., mannitol (4.75%w/v), potassium sorbate (0.3%w/v), 
polysorbate 80 (1.6%w/v), and E2 (0.01%w/v) were fixed.  
 
Characterization of the DOE formulations 
Since the primary aim was to identify an optimum level of preservative which 
would provide anti-microbial efficacy across different polymer levels, all nine 
formulations of the experimental design were  characterized for anti-microbial efficacy 
using the USP method. However, other critical attributes such as pH, clarity, osmolaity 
and drug content of the formulations were monitored as well. All the above mentioned 
formulations characteristics were measured in triplicate using their respective methods 
described in III.B.3.2. 
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Table IV.2. 3
2
 factorial design E2 formulations prepared for pre-optimization studies  
Sl. No 
Kelcogel CG –LA 
(%w/v) 
EDTA 
(%w/v) 
Formulation 
Label 
1 
0.1 
0.02 K0.1_E0.02 
2 0.03 K0.1_E0.03 
3 0.05 K0.1_E0.05 
4 
0.3 
0.02 K0.1_E0.02 
5 0.03 K0.3_E0.03 
6 0.05 K0.3_E0.05 
7 
0.5 
0.02 K0.5_E0.02 
8 0.03 K0.5_E0.03 
9 0.05 K0.5_E0.05 
 
 
IV.B.4. Effect of Polymer and Drug Concentrations on Performance Characteristics 
of E2 Ophthalmic Solution  
The objective of this study was to investigate the influence of E2 and Kelcogel
® 
CG-LA concentrations on the critical product performance attributes, especially drug 
release and viscoelasticity using statistical design of experiments.  The utility of in situ 
gel-forming system lies in its ability to form a gel upon administration and provide 
viscoelastic behavior that prolongs the drug release and ocular contact times. Polymer 
and drug concentrations in the in situ gel-forming formulations had been shown 
previously to influence the ocular drug contact times, and hence, its bioavailability 
(Sultana et al., 2006; Kalam et al., 2008; Gupta et al., 2007). Such functionality largely 
depends on the level of polymer in the system. Also, drug release from these in situ gels 
is the function of both the polymer and drug concentration in the formulation. Besides, 
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investigation of estrogens potential in cataracts treatment requires understanding the 
effect of E2 dose on their onset and severity.   
 
IV.B.4.1. Design of Experiments:  Selection of Drug and Polymer Levels 
Having identified the levels of preservatives and polymer levels in the pre-
optimization experiments above, a 3
2 
full factorial design for two factors at three levels 
each was selected to investigate varied response variables. The goal is to identify 
optimum drug and polymer levels that will provide desirable product performance 
characteristics. The two factors, Kelcogel
®
 CG-LA (X1) and E2 (X2) were varied in the 
formulations, as required by the experimental design, and the factor levels suitably coded 
(Table IV.3). In these experiments, the concentrations of the other excipients in the 
formulation were fixed at mannitol (4.75%w/v), potassium sorbate (0.3%w/v), and 
EDTA (0.03%w/v) based on their satisfactory results in pre-formulation and pre-
optimization studies. Different concentrations of E2 in the formulations were achieved by 
adding different volumes of E2 stock solution (1000 μg/mL) prepared in polysorbate-80 
(16%w/v). Hence, along with E2, the concentration of the surfactant remains different 
across the formulations. All these formulations were prepared using the method described 
in section III.B.3.1 and analyzed in replicates.  
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Table IV.3. A 3
2 
full factorial design showing runs in standard order 
Run 
Coded variables Actual Values 
Formulation 
Label X1 X2 
Kelcogel 
CG-LA 
E2 
1 1 0 0.5 0.010 K0.5_MedE2 
2 -1 1 0.1 0.025 K0.1_HighE2 
3 0 -1 0.3 0.001 K0.5_LowE2 
4 -1 0 0.1 0.010 K0.1_MedE2 
5 1 -1 0.5 0.001 K0.5_LowE2 
6 -1 -1 0.1 0.001 K0.1_LowE2 
7 1 1 0.5 0.025 K0.5_HighE2 
8 0 0 0.3 0.010 K0.3_MedE2 
9 0 1 0.3 0.025 K0.3_HighE2 
 
The desirable product performance characteristics considered in this study and 
their acceptable range are listed in Table IV.4. Time taken to release 20% (t20%) and 80% 
(t20%) of E2, apparent viscosity (μ), elastic modulus (G‘), and phase angle(δ) were chosen 
as the response variables. A second-order polynomial equation with added interaction 
terms to correlate the studied responses with the examined variables model was initially 
generated. Thereafter, second order quadratic model was assessed. The response (Yi) in 
each run shown in Table IV.3 was measured by carrying out a multiple factorial 
regression analysis using the quadratic model, Eq. IV.1, shown below. 
2
25
2
1421322110 XbXbXXbXbXbbi
Y    Eq. IV.1 
Where, Yi is the dependent variable; bo is the arithmetic mean response of all the 
runs; and bi is the estimated coefficient for factor Xi. The main effects, X1, X2, represent 
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the average values of changing factor one at a time; X1X2 represent the interaction term 
and the polynomial terms (X1
2
 and X2
2
) are used to assess nonlinearity. 
 
Table IV.4. Acceptable characteristics of an ophthalmic in situ gel-forming E2 solution 
Formulation Characteristic Acceptable Value 
A. pH 6-7 
B. Osmolality 275-325 mOsm/kg 
C. Clarity 
Visually clear (or) light transmittance >85% at 
490 nm using water as reference 
D. E2 Potency 90-110% assay 
E. Anti-microbial efficacy Compliance with USP for Class-I products 
F. Rheology  
a) Flow behavior 
Shear thinning with apparent viscosity, 
μ<50cps at shear rate of 100 s-1 
b) Viscoelasticity 
Gel formation in the presence of simulated tear 
fluid i.e. G‘>>G‖, δ<45°, and G‘α ωn where 
n<0.7 
G. Drug Release t20% ≤ 0.5 hr  and t80% in 6-12 hr  
 
IV.B.4.2. In vitro Characterization of the DOE Formulations 
The formulations developed were characterized in the order shown in Table IV.3 
for their critical attributes (i.e., pH, osmolaity, clarity, E2 assay, and USP anti-microbial 
efficacy) as well as design attributes (i.e., drug release and rheology) of the in situ gel-
forming E2 ophthalmic formulations. The methods used for testing critical attributes were 
described previously in III.B.3.2. However, the methods developed to test for flow 
behavior (i.e., apparent viscosity) of the formulation, viscoelasticity, and drug release are 
discussed briefly in the following sections. 
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IV.B.4.2.1. Rheological Characterization  
A). Flow Behavior 
 Apparent viscosity of the DOE formulations was measured as a quality control 
parameter to monitor the effects of formulations variables on the functionality of 
ophthalmic E2 in situ gel-forming solutions. The precorneal tear film in the eye exhibits 
pseudoplastic or shear thinning behavior. Any pharmaceutical preparation intended for 
ocular administration should influence this ocular tear film as little as possible. Hence, to 
minimize any discomfort in the eye, the developed formulations should also be shear 
thinning in nature. Besides, shear thinning nature will allow for easy processing, 
handling, and administration of the in situ gel-forming ophthalmic solutions (Zignani et 
al., 1995; Dikstein, 1992). The formulation is considered shear thinning if its apparent 
viscosity decreased with increase in the applied shear rate.  
 Rheological flow characterization of the developed formulations was conducted 
with AR 2000 rheometer (TA Instruments, New Castle, Delaware, USA) using double-
concentric cylinder geometry and steady state peak-flow method. The instrument was 
operated as per the standard operating procedure. 6.5 mL of the formulation was 
transferred to the geometry and apparent viscosity (ηapp) at 25°C was determined using 
peak hold step, in which a constant shear stress was applied and the corresponding shear 
rate was recorded for 45 seconds period. This peak-hold step was further repeated at 
various constant shear stress and the corresponding apparent viscosities and shear rates 
were recorded. The ranges of shear stress investigated were those that would result in 
shear rates range of 10-1000 s
-1
 that a formulation typically experiences in the eye at rest 
and during blinking (Dikstein et al, 1992). The flow behavior of the formulation was then 
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characterized by fitting the data obtained to the Ostwald Power-law rheology model. The 
magnitude of the flow index (n) will then be used to categorize the flow behavior of the 
formulation as Newtonian (n=1) and Non-newtonian (i.e., shear-thinning (n<1) or shear-
thickening (n>1)).  
        Eq. IV.2   
Where μapp is apparent viscosity, τ is shear stress, γ is shear rate, K is consistency 
coefficient, and n is flow index.  
 
B). Viscoelasticity 
Ocular residence times of the gels are dependent on their viscoelastic properties 
(Carlfors et al., 1998; Edsman et al., 1997). Successful design of an optimal in situ gel 
system with reproducible in vivo performance requires thorough understanding of the 
influence of various formulation variables on the rheological properties. Viscoelastic 
characterization of the DOE formulations was conducted with AR 2000 Rheometer (TA 
Instruments, New Castle, Delaware, USA) using double-concentric cylinder geometry 
and dynamic small amplitude oscillatory rheometry (SAOR). The instrument was 
operated according to the standard operating procedure. To evaluate in situ gel formation 
and viscoelastic behavior, the formulation and the STF were pre-mixed in 30:7 v/v ratios 
and 6.5 mL of the resulting mixture was transferred to the geometry and analyzed for 
viscoelastic parameters. The geometry was preheated to 35C, to make measurements at 
the physiological eye temperature. In this study, the oscillatory stress sweep 
measurements were carried out first to determine the linear viscoelastic (LVE) region of 
the sample and, therefore, the consequent choice of the stress or strain value to use in the 
1nγ
γ
τ  

Kμapp
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oscillatory frequency sweep test. In situ gel structure formation and viscoelastic behavior 
were then confirmed by analyzing the frequency dependency of the viscoelastic indices 
obtained from the frequency sweep test by fitting to the power-law rheology model 
shown below. 
      Eq. IV.3 
Where, G‘ is elastic modulus, ω is angular frequency, and n is power law coefficient. 
 
IV.B.4.2.2. Drug Release Characterization 
Drug release from the in situ gel-forming E2 ophthalmic solutions was studied 
using modified USP-XXXII Type-II dissolution apparatus and Enhancer Cells™. The 
test was performed at 100 rpm paddle speed and 35°C temperature. Simulated tear fluid 
(200 mL, pH 7.4, and 30%v/v ethanol) maintained at 35 ± 0.2°C was used as dissolution 
medium. 1mL of the test formulation was transferred to the Enhancer Cell™ reservoir 
using a micropipette. The formulation was then covered by a thin CoTran™9711 
polyethylene membrane (3M, St Paul, MN) previously soaked overnight in the 
dissolution medium. The membrane was then secured in place using sealing ring and 
patch retainer. The Enhancer Cell™ was then carefully transferred to the dissolution 
vessel and drug release was measured at different time points of 0.5, 1, 2, 3, 4, 6, 8, 10 
and 24 hr. At each time point, a fixed volume (i.e., 2 mL) of the dissolution medium was 
sampled and replaced by the fresh dissolution medium. The drug (E2) concentration in the 
dissolution media at each time point was measured using a validated fluorescence-HPLC 
assay method discussed earlier. Using the drug (E2) release data obtained at different time 
n)('G 
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points, release kinetics were characterized by treating the data to various drug release 
kinetic models.  
Firstly, the drug release data were fitted to a power-law model proposed by 
Korsemeyer-Peppas, and Higuchi square-root kinetics, shown in Eq. IV.4 and Eq. IV.5. 
The Korsemeyer-Peppas model is often used to describe drug release from polymeric 
drug delivery systems when the mechanism is not well known or when more than one 
type of release mechanism is involved (Boldhane SP, Kuchekar BS, 2009; Nagarwal et 
al., 2009; Singh et al., 2010). Whereas, Higuchi square-root kinetics is used when 
diffusion is considered the predominant mechanism of drug release. 
  nt tK
M
M


       Eq. IV. 4 
  tK
M
M t 

     Eq. IV.5  
Where, Mt/M∞ is the fraction of drug released in time t, K is drug release rate constant, 
which incorporates structural and geometrical characteristics of the controlled release 
system, and n represents the release exponent indicative of mechanism of drug release. 
When n=0.5, the drug diffuses through and is released by a quasi-Fickian diffusion 
mechanism. For 0.5>n<1.0, non-Fickian solute diffusion is observed and when n=1, the 
diffusion is swelling controlled and is termed pseudo-Case II solute transport.  
In cases when n>0.5, drug release data was further treated to Peppas-Sahlin model 
shown in Eq. IV.6. Using this model, Fickian (F) and non-Fickian or relaxation (R) 
contribution to the overall drug release from the in situ gel-forming formulations can be 
quantitatively estimated (Siepmann and Peppas, 2001). The F/R ratios obtained using Eq. 
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IV.7 can then be used for better understanding of the influence of various formulation 
variables on the overall drug release mechanism from the formulations. 
RFtKtK
M
M m2
2
m
1
t 

   Eq. IV.6 
m
1
2 t
K
K
F
R
       Eq. IV.7 
Where, k1 and k2 are constants of Fickian and non-Fickian diffusional contribution, m is 
purely Fickian diffusional exponent, F is Fickian contribution and R is case-II 
relaxational contribution. 
 
IV.B.4.3. Statistical Analyses 
Statistical analyses were conducted on the results of the DOE using standard-least 
squares regression to determine the factors that had a significant effect on the product 
performance estimates especially, drug release and rheology. The polynomial regression 
results were demonstrated for the studied responses. The significance level (α) for all 
analyses was ≤0.05. All statistical analyses were conducted in JMP (version 8.0.1, SAS 
Institute, Inc., Cary, NC). 
 
IV.C. RESULTS AND DISCUSSION 
IV.C.1. Solubilization of E2 by Polysorbate 80 
Phase solubility curves for E2 and polysorbate 80 at 23°C and 35°C are shown in 
Figure IV.1.  Since the surfactant concentrations used were above CMC, E2 solubility 
increased linearly (r
2
>0.99) with increasing surfactant concentration, indicating that the 
solubilization was related to micellization. E2 solubilization was higher at 35°C than at 
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23°C. Such increase in the solubilizing capacity at higher temperature could be due to a) 
an increased thermal agitation that caused an increase in the space available for drug 
solubilization in the micelle (i.e., micellar growth), b) asymmetrical shaped micelle 
formed at higher temperature caused the volume of inner micelle core to increase relative 
to that of outer core, and c) an increase in E2 intrinsic solubility in water at higher 
temperatures (Atwood, Florence, 1983; Rangel-Yagui et al., 2005).   
Phase solubility of E2 in the aqueous solutions of polysorbate 80 can be evaluated 
using the common descriptors of the micellar solubilization, molar solubilization 
capacity, χ, and molar micelle-water partition coefficient, PM. (Alvarez-Nunez et al., 
2000). The χ value is defined as the number of moles of the solute (drug) that can be 
solubilized by one mole of micellar surfactant, and it illustrates the ability of the 
surfactant to solubilize the drug. It can be calculated based on the general equation for 
micellar solubilization (Eq. IV.8 or IV.9). 
E2 Phase Solubility Study
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Figure IV.1. Aqueous solubility of E2 as a function of polysorbate 80 at 23 and 35°C 
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Solubilization of E2 by polysorbate 80 is given by the following equation: 
)CMCC(SS ttanSurfacoTotal        Eq. IV.8 
Rearranging Eq.IV.1 for χ results in Eq. IV.2, shown below. 
 
 CMCC
SS
ttanSurfac
oTotal


        Eq. IV.9 
Where STotal is the total concentration of E2 solubilized, So is the solubility of E2 in the 
absence of surfactant, CSurfactant is the concentration of surfactant, CMC is the critical 
micellar concentration of the surfactant.  
On the other hand, the micelle-water partition coefficient is the ratio of drug 
concentration in the micelle to the drug concentration in water for a particular surfactant 
concentration, as follows: 
o
oTotal
S
)SS(
P

         Eq. IV.10 
Combining Eq. IV.9 and IV.10 the two solubility descriptors can be related as shown 
below. Where, for a given surfactant concentration: 
o
ttansurfac
S
)CMCC(
P

        Eq. IV.11 
Further, to eliminate the dependence of P on the surfactant concentration, a molar 
micelle-water partition coefficient, PM, can be defined as follows: 
o
M
S
)CMC1(
P

         Eq. IV.12 
Since the CMC of polysorbate 80 (0.012 mM) is significantly lower than the range of 
surfactant concentrations studied, the solubility relationship in Eq. IV.8 simplifies to: 
)C(SS ttanSurfacoTotal         Eq. IV.13 
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Using the phase solubility data above, the values of ‗χ‘ and ‗PM‘ were then 
calculated from the solubility curves for E2 and polysorbate 80 (STotal vs. CSurfactant) and 
Eq. IV.12 and IV.13. Molar solubilization capacity, χ, is equal to the slope of the linear 
regression plot of STotal vs. CSurfactant shown in Figure IV.1. Using this value of χ, and 
CMC of surfactant the molar micelle-water partition coefficient (PM) values were 
calculated. Table IV.5 lists the estimated values of solubilization descriptors at 23°C and 
35°C. The higher value of χ obtained at 35°C further reiterates the fact that increasing the 
temperature increased the solubilizing capacity of the surfactant due to micellar growth. 
On the contrary, ‗PM‘ values decreased with increase in the temperature. Higher PM value 
at lower temperature suggests that the tendency of E2 to partition preferentially with the 
polysorbate 80 micelle was higher at 23°C compared to 35°C. Since ‗PM‘ is related to the 
water solubility of E2 (So) according to Eq. IV.11 and IV.12, such increase is presumably 
due to the increase in the aqueous solubility of E2 (i.e., 0.008 mM at 23°C and 0.024 mM 
at 35°C) relative to its partitioning into micelles.  
From thermodynamic point of view, micellar solubilization process can be 
considered as a normal partitioning of the drug between micelle and aqueous phases, and 
the standard free energy of solubilization (ΔGs°) can be represented by the equation 
shown below. 
MPRT lnGS 
        Eq. IV.14 
Where R is the universal gas constant, T is the absolute temperature, and PM is the molar 
micelle-water partition coefficient. 
S
0
 values for E2 solubilization process at different temperatures are listed 
S
0
 was negative, indicating spontaneous 
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solubilization. The lowest value was observed at 23°C, confirming that E2 solubilization 
by polysorbate 80 was energetically more favorable at low temperature.  
 
Table IV.5. Micellar solubilization descriptors for the solubilization of E2 in polysorbate 
80 aqueous solutions 
Temperature χ PM ΔGs°(KJ/mol*K) 
23°C (296°K) 0.028 3500 -20.08 
35°C (308°K) 0.047 2000 -19.46 
 
IV.C.2. Anti-microbial Efficacy of New Preservative System 
Selection of preservative type and amount remains a critical task especially when 
non-ionic surfactant, polysorbate 80, was used as E2 solubility enhancing agent in the 
formulation due to its ability to take up the preservative into micelles and reduce 
antimicrobial activity. Potassium sorbate was chosen based on the literature evidence that 
it was hardly taken up by the micelles of polysorbate 80 surfactant and also provided 
satisfactory preservative effect of ophthalmic solutions (Kawashima et al., 1996). 
Addition of EDTA to the formulations containing potassium sorbate had shown to 
increase preservative effect (Kawashima et al., 1996; Tsuji et al., 2004; Morishima et al., 
2007). Presumably, EDTA binds to the essential minerals in the microbial cytoskeleton 
and disorganizes its assembly, thereby, enhancing the permeability of potassium sorbate 
resulting in a synergistic anti-microbial effect. 
USP anti-microbial efficacy test results of the E2 ophthalmic formulations shown 
in Table IV.1 are listed in Table IV.6. All the formulations and their appropriate controls 
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were found to be sterile indicating that the method of preparation was aseptic. Lack of 
efficacy shown by the negative control supports the need for a preservative in the 
formulation and highlights the fact that, in the absence of a suitable preservative, the 
polysaccharide polymer (i.e. Kelcogel CG-LA) in the formulations supports microbial 
growth.  In contrast, the efficacy shown by both the positive controls (i.e., with or without 
EDTA) suggest the suitability of new preservative system in preventing microbial 
proliferation. 
 
Table IV.6. USP 31 <51> anti-microbial efficacy of the E2 ophthalmic formulations 
containing new preservative and solubilizing agent 
Test Product Sterility 
USP Anti-microbial Efficacy 
Gram +ve Gram -ve 
S.aureus E.coli P.aeruginosa 
Formulation A Yes Yes No No 
Positive Control-A Yes Yes Yes Yes 
Formulation-B Yes Yes Yes Yes 
Positive Control-B Yes Yes Yes Yes 
Negative Control Yes Yes No No 
 
Although potassium sorbate (0.3%w/v) solution in water (Positive control-A) 
demonstrated antimicrobial efficacy, when present at the same concentration in the 
formulation, it failed to demonstrate required anti-microbial efficacy, especially against 
gram negative bacteria.  These results highlight the need for titration of the preservative 
depending on the contents of the formulation. Because the amount of potassium sorbate 
used was already at the maximum allowed dose for safe use in humans, EDTA 
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(0.03%w/v) was added to the formulation to enhance preservative efficacy. Accordingly, 
the Formulation-B which contained the mixture of potassium sorbate and EDTA 
demonstrated the desired anti-microbial efficacy.  
 
IV.C.3. Pre-optimization: Selection of Optimum Preservative Concentration  
pH, Clarity and Osmolality:  All the factorial design formulations exhibited acceptable 
characteristics of pH, clarity, and osmolality (shown in Table IV.7). With the 
preservatives used in the formulation being salts of sodium and potassium, increasing 
their amounts may in turn increased the probability of interaction with the anionic gellan 
gum polymer and affect the clarity of the formulation. As a result, the clarity of the 
formulations decreased with an increase in the polymer as well as EDTA concentrations 
(as shown in Table IV.7,). Further, Formulation K0.5_E0.05, containing highest amounts 
of polymer (0.5%w/v) and EDTA (0.05%w/v) formed a gel that was too viscous to flow. 
Hence, this formulation was discontinued and not tested for any other characteristics. The 
pH of the formulations decreased with increasing concentrations of EDTA or polymer in 
the formulations (shown in Table IV.7). 
The osmolaity of the formulations was found to be with in the acceptable range of 
275-325 mOsm/Kg (shown in Table IV.7). These values were noticeably higher than 
those listed in Table III.6, due to difference in the type of preservative used in the 
formulations. Potassium sorbate and EDTA being the salt forms contribute to the 
osmolality of the formulation as opposed to benzalkonium chloride or benzododecinium 
bromide.  
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Potency of E2:  The potency of E2 in the formulations was in the range of 97.3-99.7% 
assay (as shown in Table IV.7). The potencies within the acceptable range of 90-110% 
indicated that the recovery method and the HPLC assay used were suitable for extraction 
and estimation of E2 from the formulation.  
 
Anti-microbial Efficacy:  The anti-microbial efficacy of the factorial design 
formulations in Table IV.7 was found to be the function of polymer and preservative 
concentrations. At the lowest polymer level (0.1%w/v) studied, the formulations 
demonstrated anti-microbial efficacy even at the lowest preservative concentration (i.e., 
0.02%w/v). However, as the polymer level was increased to 0.3% and 0.5% w/v, 
Formulation K0.3_E0.02 and Formulation K0.5_E0.02, which contained the lowest 
EDTA concentration (0.02%w/v) failed anti-microbial efficacy test. Lack of efficacy 
could be due to greater susceptibility to microbial growth at higher gellan gum 
concentrations. The observed loss in preservative efficacy stresses the need to adjust the 
preservative concentration with the gellan gum polymer in the formulation.  In 
accordance with the aim of this study, the preservative system containing 0.3%w/v 
potassium sorbate and 0.03%w/v EDTA was identified as an optimum composition that 
provides required anti-microbial efficacy to the formulations at all polymer levels.  
 
 122 
Table IV.7. In vitro characteristics of the factorial design ophthalmic formulations 
Formulation pH 
Clarity 
(% trans.) 
E2 Assay 
(%) 
Osmolality 
(mOsm/Kg) 
Anti-microbial 
Efficacy 
K0.1_E0.02 6.43 ± 0. 02 99 ± 2 98.7 ± 1.2 299 ± 2 Yes 
K0.1_E0.03 6.38 ± 0.01 98 ± 1 98.0 ± 1.7 298 ± 5 Yes 
K0.1_E0.05 6.19 ± 0.01 98 ± 2 98.3 ± 0.6 289 ± 1 Yes 
K0.3_E0.02 6.19 ± 0.01 97 ± 2 97.8 ± 1.9 296 ± 3 No 
K0.3_E0.03 6.08 ± 0.01 96 ± 1 98.6 ± 1.3 289 ± 2 Yes 
K0.3_E0.05 6.00 ± 0.01 95 ± 1 99.7 ± 2.4 288 ± 8 Yes 
K0.5_E0.02 6.05 ± 0.01 94 ± 2 98.1 ± 1.8 284 ± 0 No 
K0.5_E0.03 6.02 ± 0.01 92 ± 1 97.3 ± 2.9 298 ± 2 Yes 
K0.5_E0.05 Formulation was too viscous to flow 
 
IV.C.4. Formulation Optimization:  Effect of Polymer and Drug Concentrations on 
Performance Characteristics of E2 Ophthalmic Solution 
pH, clarity, and osmolality:  All the factorial design formulations exhibited acceptable 
characteristics of pH, clarity, and osmolality, as shown in Table IV.8. Both polymer and 
E2 concentrations were found to have significant influence on the pH of the formulations 
(p<0.05). Increasing the concentration of the anionic polymer (i.e., Kelcogel CG-LA) in 
the formulation decreased its pH, whereas increasing the E2 concentration increased the 
resultant pH.  Polysorbate 80 being a non-ionic E2 solubilizing agent, increasing the drug 
concentration did not cause any interactions with the ion-sensitive polymer in the 
formulation and affect its clarity. Hence, all formulations in Table IV.8 were found to be 
clear with percent UV transmittance (>92%) values well with in the acceptable range. 
Similarly, the osmolaity of the formulations was found to be with in the acceptable range 
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of 275-325 mOsm/Kg. Kelcogel CG-LA or E2 concentrations had no significant influence 
on the resulting osmolality of the formulations.  
Potency of E2:  The potency of E2 in the formulations was >97% (as shown in Table 
IV.8) and well within the acceptable range of 90-110% assay. Such high recovery values 
indicate; drug content uniformity in the formulation, and suitability of the recovery 
method and the HPLC assay for extraction and estimation of E2 from the formulations.  
 
Table IV.8. Summary of critical characteristics of E2 ophthalmic formulations prepared 
according to 3×3 full-factorial statistical design  
Formulation pH 
Clarity 
(%trans) 
E2 Assay 
(%) 
Osmolality 
(mOsm/Kg) 
Antimicrobial 
Efficacy 
K0.1-Low E2 6.49 ± 0.03 97 ± 2 99.1 ± 2.1 292 ± 1 Yes 
K0.1-Med E2 6.54 ± 0.02 97 ± 1 98.3 ± 1.1 296 ± 2 Yes 
K0.1-High E2 6.61± 0.02 98 ± 2 98.6 ± 1.5 300 ± 4 Yes 
K0.3-Low E2 6.21 ± 0.01 95 ± 1 97.7 ± 2.4 287 ± 2 Yes 
K0.3-Med E2 6.30 ± 0.02 95 ± 1 96.6 ± 1.3 288 ± 3 Yes 
K0.3-High E2 6.38 ± 0.01 96 ± 2  97.8 ± 1.9 291 ± 2 Yes 
K0.5-Low E2 5.99 ± 0.03 92 ± 2 98.7 ± 3.2 281 ± 5 Yes 
K0.5-Med E2 6.03 ± 0.03 92 ± 1 97.9 ± 2.9 285 ± 5 Yes 
K0.5-High E2 6.11 ± 0.02 93 ± 2 98.6 ± 1.8 285 ± 2 No 
 
Although, the preservative amounts (i.e., 0.3%w/v potassium sorbate and 
0.03%w/v EDTA) in the formulation were pre-optimized for the studied polymer levels 
(i.e., 0.1-0.5%w/v), the Formulation K0.5-High E2, containing 0.5%w/v Kelcogel CG-LA 
and 0.025%w/v E2, did not demonstrate USP anti-microbial efficacy. As mentioned 
earlier, the required concentration of E2 in the formulation was achieved by addition of 
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fixed volume of 1mg/ml stock solution prepared in 16%w/v polysorbate 80. To achieve 
0.025%w/v E2 concentration, 25 mL of the stock solution was added to the formulation, 
which resulted in 4%w/v polysorbate 80 compared to 1.6%w/v polysorbate 80 with the 
mid E2 (0.01%w/v) concentration, in the formulation.  Loss in anti-microbial efficacy of 
the Formulation K0.5-High E2 could be due to greater potential for microbial growth at 
higher polymer and non-ionic surfactant concentrations. But, the Formulation K0.3-High 
E2, containing 0.3%w/v polymer and 0.025%w/v E2 dose was antimicrobially effective 
and did not show this loss in efficacy due to relatively lower polymer concentration. 
 
IV.C.4.1. Flow Behavior of DOE Formulations 
The apparent viscosity of the DOE formulations decreased with increasing 
applied shear rate (as shown in Figures IV.2 –IV.4). The high r2 (i.e., >0.96) values in 
Table IV.9 further confirms the goodness of fit to the model and shear thinning behavior 
of all 9 of the formulations. The power-law model exponent, n, is a flow index whose 
magnitude classifies the material into Newtonian or non-Newtonian (i.e., shear thinning 
or shear-thickening). The observed values of n<1 (shown in Table IV.9) in case of all the 
formulations suggest shear thinning behavior (Balaji et al., 2007). Such shear-thinning 
behavior was observed due to the presence of gellan gum polymer network in the 
formulation that provided low-resistance to flow upon shear. The consistency coefficient, 
K, is the slope of the flow curve and is a measure of the viscosity of the formulation at 
shear rate of 1s
-1
. Kelcogel CG-LA and E2 concentrations in the formulation had 
significant influence (p<0.05) on the observed K values (shown in Table IV.9). Change of 
5-fold increase in the polymer concentration from 0.1 to 0.5%w/v caused ~ 40-fold 
increase in observed K values for each E2 concentration of the formulation. Also, the 
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apparent viscosity (μ) values estimated for the formulations at 100s-1 shear rate increased 
with increasing polymer as well as E2 concentrations (shown in Table IV.9). 
 
Figure IV.2. Flow curve for 0.1%w/v Kelcogel CG-LA formulations  
 
Figure IV.3. Flow curve for 0.3%w/v Kelcogel CG-LA formulations 
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Figure IV.4. Flow curve for 0.5%w/v Kelcogel CG-LA formulations 
 
Table IV.9. Power-law rheology model fitting parameters and apparent viscosity of E2 
ophthalmic formulations prepared according to 3
2
 full-factorial statistical design  
Formulation 
Power law rheology model coefficients Apparent viscosity 
(mPa.S) at 100s
-1
 n K (mPa.S) r
2
 
K0.1-Low E2 0.82 14 0.98 6.1 
K0.1-Med E2 0.79 15 0.96 5.7 
K0.1-High E2 0.78 20 0.97 7.3 
K0.3-Low E2 0.75 45 0.99 14.2 
K0.3-Med E2 0.73 55 0.99 15.9 
K0.3-High E2 0.63 134 0.99 24.4 
K0.5-Low E2 0.49 505 0.99 48.2 
K0.5-Med E2 0.46 619 0.99 51.5 
K0.5-High E2 0.42 889 0.99 61.5 
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To gain better understanding of the influence of polymer and drug levels on the 
apparent viscosity of the formulations, the data was treated to a second-order quadratic 
model in Eq. IV.1 (page 108).  The observed linearity (r
2
 = 1) in the correlation plots 
between the observed and predicted values of μ shown in Figure IV.5 suggest that the 
chosen model was a good-fit to the data. The model was found to be significant (p<0.05) 
and accounts for 99% (Adj-R
2
 =0.99) of the error in the observed data. The quantitative 
factor effects on the observed μ values are summarized in Table IV.13 (page 146). The 
influence of the parameter effects of X1(Kelcogel CG-LA), X2 (E2), X1X2 and X1
2
,
 
on the 
apparent viscosities of the formulations was found to be significant (p<0.05). Also, the 
positive magnitude of their regression coefficients suggests that increasing their 
concentrations increased the apparent viscosities of formulations. Polysorbate 80 being a 
highly viscous (~300-500 mPa.s) solution, increasing its amount in the formulation along 
with E2 increases formulations viscosity. Hence, the interaction term (X1X2) in Table 
IV.13 was found to have significant influence on the apparent viscosity of the 
formulations. 
Response surface plots with contour lines were further generated for easy visual 
interpretation of the influence of model factors on the apparent viscosity of the 
formulations in Figure IV.6. Contour lines represent the pair of X1 and X2 values that 
have the same response value of Y. The observed curvilinearity of the surface plot (in 
Figure IV.6) in the direction of polymer was in accordance with earlier observation that 
the quadratic term (X1
2
) of the polymer had significant influence on the apparent 
viscosity of the formulations. 
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Figure IV.5. Correlation plots between observed and predicted values of  a) K, b) t20%, c) 
t80%, d) viscosity, e)  G‘, and f) phase angle (δ) 
a) b) 
c) d) 
e) f) 
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Figure IV.6. Response surface and contour plot showing the influence of polymer and 
drug concentration on the apparent viscosity of the formulations. 
 
IV.C.4.2.Viscoelasticity of DOE Formulations 
Oscillatory measurements:  These measurements were carried out to identify linear 
viscoelastic region (LVE) for the characterization of in situ gels. For this study, the 
conditions for LVE were identified as 3% strain and 5 rad/s angular frequency. At these 
conditions, the DOE formulations in Table IV.3 were pre-mixed with STF in 30:7 v/v 
ratios and tested for in situ gel formation using frequency sweep measurements.  
Frequency Sweep Plots:  The corresponding frequency sweep plots for different 
formulations in the presence of STF are shown in Figures IV.7-IV.9. A gel state, as 
defined earlier in Table IV.4 is confirmed when G‘>G‘‘, δ<45° and G‘ shows moderate 
to weak dependency on angular frequency according to power-law relation shown in 
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Eq.IV.3, where n<0.7. The viscoelastic parameters along with power-law model fitting 
parameters for factorial design formulations are summarized in Table IV.10.  
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Figure IV.7. Frequency dependency of formulations containing 0.1%w/v Kelcogel CG-
LA and different E2 levels in the presence of STF in 30:7v/v ratios. 
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Figure IV.8. Frequency dependency of formulations containing 0.3%w/v Kelcogel CG-
LA and different E2 levels in the presence of STF in 30:7v/v ratios. 
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Figure IV.9. Frequency dependency of formulations containing 0.5%w/v Kelcogel CG-
LA and different E2 levels in the presence of STF in 30:7v/v ratios. 
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Table IV.10. Power-law rheology model fitting parameters and viscoelastic parameters 
of E2 ophthalmic formulations prepared according to 3
2
 full-factorial statistical design 
Formulation 
Model fitting parameters and viscoelastic indices  
measured in LVE of 5 rad/s and 3% strain 
G'(Pa) G''(Pa) δ (°) n r2 
K0.1-Low E2 0.12 0.09 37 0.55 0.93 
K0.1-Med E2 0.25 0.13 27 0.38 0.97 
K0.1-High E2 0.36 0.19 28 0.34 0.91 
K0.3-Low E2 0.37 0.28 38 0.34 0.93 
K0.3-Med E2 0.55 0.31 29 0.22 0.92 
K0.3-High E2 0.96 0.45 25 0.16 0.93 
K0.5-Low E2 1.38 0.84 31 0.30 0.99 
K0.5-Med E2 1.95 0.92 25 0.26 0.99 
K0.5-High E2 2.68 1.18 24 0.18 0.99 
 
All formulations showed evidence of phase transition and in situ gel structure 
formation in the presence of STF as G‘>G‘‘ and δ<45° (shown in Table IV.10). The 
mechanism of gelation as mentioned previously, involves formation of double helical 
junction zones followed by aggregation of double helical segments to form three 
dimensional networks by complexation with cations in the tear fluid and hydrogen 
bonding with water (Nagarwal et al., 2009; Paulsson et al., 1999; Hagerstrom et al., 
2000). The values of the exponent ―n‖ obtained upon treating the data to the power law 
rheology model were in the range of 0.16-0.55. The n value in this range further confirms 
the nature of the material formed to be viscoelastic and that it corresponds to a gel state. 
Lower the value of n, stronger will be the resulting gel structure. Increasing the polymer 
or drug concentration increased the elastic contribution (i.e., higher G‘ and lower δ 
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values) to the overall viscoelastic behavior. But, at higher polymer concentrations the 
influence of E2 on the G‘ appeared minimal, and the width between the G‘ lines in 
Figures IV.7-IV.9 corresponding to different drug loads at each polymer concentration in 
the formulations also decreased. 
 
Figure IV.10. Response surface and contour plots showing the influence of polymer and 
drug concentrations on (a) elastic modulus, G‘; (b) Phase angle, δ of the formulations.  
 
Second-order Quadratic Modeling:  Influence of formulation variables on the observed 
viscoelasticity was analyzed by treating the data to second-order quadratic model in 
Eq.IV.1 (Page 108). The linearity (r
2
 = 1) in the correlation plots between the observed 
and predicted values of G‘ and δ shown in Figure IV.10 suggest that the chosen model 
was a good-fit to the data. The model was found to be significant (p<0.05) and accounts 
for 100% (Adj-R
2
 =0.99) and 94% (Adj-R
2
 =0.94) of the error in the observed data of G‘ 
and δ, respectively.  
The influence of the parameter effects of X1(Kelcogel CG-LA), X2 (E2), X1X2 and 
X1
2
,
 on the elastic modulus (G‘) of the formulations was found to be significant (p<0.05). 
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But, in case of phase angle (δ), only X2 and X2
2
 were found to be significant (P<0.05).  In 
addition, the positive and negative magnitude of the regression coefficients observed for 
parameter effects on G‘ and δ respectively, in Table IV.13 indicated that higher levels of 
polymer and drug level in the formulation result in overall improvement of the gel 
network formed. Since the quadratic terms for polymer and drug levels were significant 
in G‘ and δ, the response surface plot of G‘ and δ in Figure IV.10a and IV.10b, appeared 
curvilinear in the direction of polymer and drug concentrations, respectively.  
 
IV.C.4.3. Drug Release Characterization 
Drug release from the gel systems has been previously studied using Enhancer 
Cell
®
. In this study, Enhancer Cell
®
 is used to characterize drug release kinetics from E2 
in situ gel-forming ophthalmic solutions. To separate the ophthalmic E2 solution from the 
dissolution medium, a thin (0.22 μm) PET membrane (3M, St.Paul, MN) was used. 
Potential for E2 binding to the polymer membrane was evaluated by soaking the 
membrane in the E2 stock solutions in ethanol containing different concentrations of E2 
and evaluating any decrease in its concentration due to adsorption to the polymer 
membrane. Results indicated that the E2 binding to the PET membrane was negligible.  
Simulated tear fluid (STF) containing 30 %v/v ethanol was chosen as the 
dissolution medium based on E2 solubility to maintain sink conditions through out the 
duration of the study. The paddle rotation speed of 100 rpm was chosen based on 
preliminary studies that indicated that the dissolution method was discriminating at 
higher paddle speeds (i.e., 100 rpm compared to 50 rpm).  
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Drug release characterization from each of the formulations listed in Table IV.3 
was performed at least in triplicate. The drug (E2) concentration in the dissolution media 
at each time point was measured using a validated fluorescence-HPLC assay method 
discussed earlier.  
Using the cumulative drug (E2) released vs. time data, release kinetics from the in 
situ gels were characterized by treating the data to Korsemeyer-Peppas, and Higuchi 
square-root kinetic models shown in Eq. IV.4 and Eq. IV.5 (Page 113). The 
corresponding drug release plots up to 60% of the drug release from the factorial design 
formulations are shown in Figures IV.11-IV.16. The summary of model fitting 
parameters, such as release rate constant (K), and release exponent, n, and drug release 
parameter estimates calculated using these parameters, such as time to release 20% (t20%) 
and 80% (t80%) of the drug from the formulation, are listed in Table IV.11.  
Table IV.11. Summary of model fitting parameters and drug release estimates obtained 
upon treating the E2 drug release data of the formulations prepared according to 3
2
 full-
factorial statistical design to Peppas and Higuchi drug release kinetic models.  
Formulation 
Korsmeyer and Peppas Model Higuchi Model 
K  
(%h-n) 
n r2 
t
80% 
(hr) 
t
20% 
(hr) 
K  
(%h-0.5) 
r2 
K0.1-Low E2 23.4 ± 0.9 0.54 ± 0.01 0.99 9.6 ± 0.8 0.75 ± 0.05 24.5 ± 0.8 0.99 
K0.1-Med E2 28.1 ± 0.7 0.51 ± 0.01 0.99 7.8 ± 0.6 0.51 ± 0.02 28.9 ± 0.5 0.99 
K0.1-High E2 31.6 ± 0.6 0.50 ± 0.01 0.99 6.4 ± 0.4 0.40 ± 0.01 33.2 ± 0.9 0.99 
K0.3-Low E2 22.2 ± 0.9 0.55 ± 0.01 0.99 10.4 ± 1.2 0.83 ± 0.06 20.8 ± 0.4 0.99 
K0.3-Med E2 25.3 ± 0.7 0.52 ± 0.01 0.99 9.0 ± 0.6 0.64 ± 0.03 25.4 ± 0.4 0.99 
K0.3-High E2 27.7 ± 0.2 0.51 ± 0.01 0.99 7.9 ± 0.1 0.53 ± 0.01 27.4 ± 0.3 0.99 
K0.5-Low E2 20.4 ± 0.9 0.48 ± 0.01 0.99 17.7 ± 2.1 0.96 ± 0.09 20.6 ± 0.5 0.99 
K0.5-Med E2 21.8 ± 0.6 0.44 ± 0.02 0.99 19.8 ± 2.8 0.82 ± 0.05 20.3 ± 0.8 0.99 
K0.5-High E2 24.8 ± 1.1 0.42 ± 0.01 0.99 16.4 ± 2.3 0.60 ± 0.06 22.2 ± 1.0 0.99 
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Figure IV.11. Cumulative percent E2 released vs. time plots of formulations containing 
0.1%w/v Kelcogel
®
 CG-LA and different E2 levels 
 
Figure IV.12. Cumulative percent E2 released vs. time plots of formulations containing 
0.3%w/v Kelcogel
®
 CG-LA and different E2 levels 
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Figure IV.13. Cumulative percent E2 released vs. time plots of formulations containing 
0.5%w/v Kelcogel
®
 CG-LA and different E2 levels 
Kel 0.1_Highchi Plots
yHigh = 33.213x - 0.9491
R2 = 0.9972
yMed = 28.974x - 1.0639
R2 = 0.9898
ylow = 24.483x - 1.2801
R2 = 0.9945
0
10
20
30
40
50
60
70
0 0.5 1 1.5 2 2.5 3
Sqrt(hrs)
%
C
u
m
 D
ru
g
 R
e
le
a
s
e
d
High_Kel0.1 Med_Kel0.1 Low_Kel0.1
 
Figure IV.14. Cumulative percent E2 released vs. t
0.5 
plots of formulations containing 
0.1%w/v Kelcogel
®
 CG-LA and different E2 levels 
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Figure IV.15. Cumulative percent E2 released vs. t
0.5 
plots of formulations containing 
0.3%w/v Kelcogel
®
 CG-LA and different E2 levels 
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Figure IV.16. Cumulative percent E2 released vs. t
0.5 
plots of formulations containing 
0.5%w/v Kelcogel
®
 CG-LA and different E2 levels 
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An ideal sustained release ophthalmic delivery system is one which provides a 
burst release of drug to achieve required therapeutic concentrations at the site of action 
followed by sustained drug release for prolonged durations of time. E2 release from in 
situ gels-formed in the presence of STF was sustained (Table IV.11) as the estimated 
time for 80% drug release (i.e. t80%) was in the range of 6-19 hr. Burst release of the drug 
from in situ gel-forming solutions was also observed with 20% of the drug released (i.e. 
t20%) in 0.4-1 hr.  Such burst release was expected in the presence of STF due to lag time 
in the formation of complete gel structure due to interaction with the ions of the tear 
fluid.  
Increasing the gellan gum concentration in the formulation decreased the release 
rate constants and increased the time taken for 20% and 80% of drug release from the 
gels formed in the presence of STF (Table IV.11). The observed decrease in the drug 
release rate could be explained by the fact that increasing the gellan gum concentration in 
the formulation caused concomitant increase in the gel strength as shown in Table IV.10. 
This effect was expected as at higher gel strengths the gel network formed would be 
stronger and it would take longer time for the drug molecules to diffuse out of the gel 
matrix into the dissolution medium.  
In contrast, increasing the drug load increased the release rate constants and 
decreased the time taken for 20% and 80% of drug release from the gels. Such a result 
can be explained based on the fact that with increasing drug loading, the gel-matrix 
formed would become more relaxed to allow easy solvent penetration and enhance drug 
diffusion. However, at higher gellan gum concentrations (i.e., 0.5%w/v), the effect of 
drug loading on the E2 release was found to be minimal, with only small differences in 
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the observed E2 release rate constants in Table IV.11 for different drug loadings (i.e., 
Low, Med and High E2).  
The magnitude of the release exponent n obtained upon treating the drug release 
data to Kormeyer-Peppas model was in the range of 0.42-0.55. The closeness of these n 
values to 0.5, justifies treating the drug release data to Higuchi square-root kinetic model, 
which assumes the value of n to be 0.5.  The observed linearity (r
2
>0.99) in the Higuchi-
plots in Figures IV.14.-IV.16 and closeness of the K values for different formulation in 
Table IV.11 further confirms it.  
The cut-off value of n, the release exponent in Eq. IV.4, for a purely Fickian 
diffusion mechanism in case of gel systems with aspect ratio of 3.6 (i.e., 2a = 21.34mm 
and l = 5.96mm), according to Figure IV.17, was 0.45. The n values >0.45 obtained using 
Korsmeyer-Peppas model in case of some formulations in Table IV.11 suggest that E2 
release from the gels followed non-Fickian mechanism or anomalous diffusion. The 
observed deviation from the Fickian mechanism could be attributed to the reason that the 
formulations during gelation imbibe large amount of dissolution media leading to a 
swollen state of the gel. In such case, E2 release would be function of its diffusion from 
the polymer gel matrix as well as polymer relaxation. Hence, the data was further treated 
using Peppas-Sahlin model to estimate the Fickian (F) and relaxation (R) contribution to 
the overall drug release.  
The summary of model fitting parameters obtained upon treating the E2 drug 
release data to Peppas and Sahlin drug release kinetic model are listed in Table IV.12. 
Also, the drug release plots in Figures IV.18-IV.20 display Fickian and relaxational 
contribution to the overall E2 release from the factorial design formulations. In Table 
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IV.12, the magnitude of the Fickian diffusion constant (k1) decreased with increasing 
polymer concentration for each E2 concentration due to concomitant increase in the 
strength of the gel network formed. Whereas, the magnitude of relaxation constant (k2) 
increased with increasing drug concentration. As reasoned earlier, this could be due to 
formation of more void space or pores in the gel network due to dissolution of more 
amount of drug at high drug loads. Thus, the greater void space allows for greater solvent 
penetration and polymer relaxation. Hence, the ratio of relaxation to diffusion 
contribution (k2/k1) values in Table IV.12 increased with increasing drug concentration in 
the in situ gel-forming E2 formulations.   
 
Table IV.12. Summary of model fitting parameters obtained upon treating the E2 drug 
release data of the formulations prepared according to 3
2
 full-factorial statistical design to 
Peppas and Sahlin drug release kinetic model. 
Formulation 
Peppas and Sahlin Model Parameters 
k
1
(%h
-0.45
) k
2
(%h
-0.9
) r
2
 k2/k1 
K0.1-Low E2 21.86 1.57 0.93 0.06 
K0.1-Med E2 26.23 1.89 0.92 0.07 
K0.1-High E2 27.96 3.59 0.99 0.13 
K0.3-Low E2 21.44 0.73 0.94 0.03 
K0.3-Med E2 23.42 1.92 0.96 0.08 
K0.3-High E2 25.08 2.61 0.90 0.10 
K0.5-Low E2 19.61 0.75 0.99 0.04 
K0.5-Med E2 --- --- --- --- 
K0.5-High E2 --- --- --- --- 
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Figure IV.17. Variation of the Fickian diffusional exponent, m, with the aspect ratio, 2a/l, 
where 2a is the diameter and l is the thickness (height) of the device (Peppas et al., 1989) 
 
Figure IV.18. Fickian diffusional and relaxational contribution to the overall E2 release 
from the formulations containing 0.1%w/v Kelcogel
®
 CG-LA and different E2 levels 
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Figure IV.19. Fickian diffusional and relaxational contribution to the overall E2 release 
from the formulations containing 0.3%w/v Kelcogel
®
 CG-LA and different E2 levels 
 
Figure IV.20. Fickian diffusional and relaxational contribution to the overall E2 release 
from the formulations containing 0.5%w/v Kelcogel
®
 CG-LA 
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The results of the drug release kinetics summarized in Tables IV.11 and IV.12 
indicated that E2 release from the in situ gel formulations was function of polymer and 
drug concentrations. To further understand the influence of these formulation variables, 
drug release data was analyzed by treating the data to second-order quadratic model in 
Eq.IV.1 (page 108). The linearity (r
2
 = 1) in the correlation plots between the observed 
and predicted values of K, t20% and t80% in Figure IV.5 (page 128) suggests that the 
chosen model was a good-fit to the data. The model was found to be significant (p<0.05) 
and accounts for >98% of the error in the observed data of different drug release 
parameter estimates.  
The quantitative factor effects and their associated p-values for drug release 
parameter estimates are summarized in Table IV.14. The positive and negative 
magnitudes of the regression coefficients observed for polymer and drug factors in Table 
IV.14 reflects their positive and negative influence on the drug release parameter 
estimates, respectively. Positive coefficient for the polymer indicates that increasing its 
concentration increased the t20% and t80% values. Similarly, negative coefficient for the 
drug indicates that increasing its concentration decreased the t20% and t80% values. The 
influence of the parameter effects of X1(Kelcogel CG-LA), X2 (E2), and their quadratic 
term X1
2
 or X2
2
,
 
on the drug release parameter estimates, t20% and t80% was found to be 
significant (p<0.05). The response surface plots showing the influence of formulation 
parameters on the product characteristics are shown in Figure IV.21. Since the quadratic 
terms of drug and polymer concentrations in the formulation were significant in case of 
t20% and t80%, respectively, their response surface plots in Fig. IV. 21a and IV. 21b 
appeared curvilinear in the direction of polymer and drug concentrations, respectively.  
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Figure IV.21. Response surface and contour plots showing the influence of polymer and 
drug concentrations on (a) time taken for 20% E2 release, t20%; and (b) time taken for 
80% E2 release, t80%, and (c) E2 release rate constant, K, from the formulations. 
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Table IV.13. The quantitative factor effects and associated p-values for flow and 
viscoelasticity parameter estimates 
 
Flow Parameter 
Estimates 
Viscoelastic Parameter Estimates 
Viscosity at 100s
-1
 
(Y1) 
G’ 
(Y2) 
Phase angle (δ) 
(Y3) 
Factor Effect p-value Effect p-value Effect p-value 
Intercept -22.33 0.0003* -1.03 0.0006* 35.92 0.0004* 
X
1
(polymer) 118.42 <.0001* 4.40 <.0001* -10.00 0.0982 
X
2
(E2) 320.03 0.0046* 29.98 0.0013* -472.53 0.0085* 
X
1
X
2
 1274.66 0.0119* 109.69 0.0045* 153.06 0.7430 
X1
2
 297.08 0.0007* 12.42 0.0020* -50.00 0.2641 
X2
2
 11512.35 0.1486 -200.62 0.6204 34876.50 0.0496* 
 
Table IV.14. The quantitative factor effects and associated p-values for drug release 
parameter estimates 
 
Drug Release Parameter Estimates 
K 
(Y4) 
t20% 
(Y5) 
t80% 
(Y6) 
Factor Effect p-value Effect p-value Effect p-value 
Intercept 26.515802 <.0001* 0.56 0.0001* 3.31 0.0525 
X
1
(polymer) -13.41667 0.0025* 0.67 0.0007* 24.00 0.0016* 
X
2
(E2) 263.30247 0.0020* -15.00 0.0004* -83.18 0.1270 
X
1
X
2
 -363.9456 0.0849 -11.05 0.1009 198.98 0.4340 
X1
2
 -1.25 0.9254 0.83 0.1314 90.00 0.0177* 
X2
2
 -5956.79 0.2040 555.56 0.0194* -3549.38 0.5756 
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IV.D. CONCLUSIONS 
 
Polysorbate-80 was found to be a suitable non-ionic solubility enhancing agent 
for improving the aqueous solubility of estradiol (E2).  Pre-optimization studies identified 
the need for titration of the preservative concentrations with the gellan gum 
concentrations in the formulations. Preservative system composed of potassium sorbate 
(0.3%w/v) and EDTA (0.03%w/v) provided USP antimicrobial efficacy to the in situ gel 
formulations containing Kelcogel CG-LA in the range of 0.1-0.5%w/v. The preservatives 
being the salts of potassium and sodium showed some degree of interaction with the 
gellan gum polymer and influenced the clarity of the formulations. Also, it was observed 
that increasing the level of potassium sorbate (>0.3%w/v) or disodium EDTA 
(>0.03%w/v) in the in situ gel formulations containing ≥0.5%w/v gellan gum polymer 
resulted in the gel formation and the preparations were too viscous to flow.   
Statistical design of experiments performed to investigate the influence of 
formulation variables on the product performance characteristics of the in situ gel E2 
formulations indicated polymer and drug concentrations to be significant.  The measured 
values of the performance characteristics such as pH, clarity, osmolality, E2 potency, and 
viscoelasticity of all the formulations were within the pre-defined acceptable range. 
However, in case of formulations containing 0.5%w/v Kelcogel CG-LA, the apparent 
viscosities were outside the acceptable range and, at high drug loading of 0.025%w/v, the 
anti-microbial efficacy was not observed. Besides, the drug release from the formulations 
containing 0.5%w/v Kelcogel CG-LA was slow, sustained and not within the acceptable 
criteria. In contrast, formulations containing 0.1-0.3%w/v Kelcogel CG-LA and 0.001-
0.025%w/v E2 concentrations demonstrated acceptable characteristics of in situ gel –
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forming ophthalmic solutions. Hence, these formulations were further used for in vivo 
evaluation of product safety and efficacy in animal models.  
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CHAPTER V 
 
ESTABLISHING ESTROGEN ROLE IN CATARACTS: INVESTIGATION OF 
IN SITU GEL-FORMING E2 OPHTHALMIC FORMULATIONS IN ERΔ3 
TRANSGENIC MOUSE MODEL 
 
 
V. A. INTRODUCTION 
 
ER3 mice are a transgenic mouse model which expresses a dominant negative 
estrogen receptor that results in cataract formation in the presence of high doses of 
estradiol (i.e., endogenous levels in intact females and exogenously administered 
estrogen in males, ovariectomized females, and immature mice). Kirker and Davis 
previously demonstrated that estrogen activation of the ER3 repressor in ER3 mouse 
model would inhibit the activity of wild-type ER in lens and results in lens opacity and 
induction of genes important to lens transparency only in the presence of estrogen. 
However, in these studies high doses (~1000 μg/kg) of estradiol (E2) was required by 
systemic administration to provide sufficient estrogen levels in the avascular lens tissue 
to activate ER3 repressor and block estrogen action. Hence, in this study, the benefits of 
topical estradiol delivery using in situ gel-forming eye drops over systemic delivery in 
terms of ocular safety, enhancing ocular drug absorption with limited systemic 
bioavailability, systemic side effects, and onset and severity of cataracts in ERΔ3 mouse 
model was investigated. The main goals of this study were to a) verify if topical estrogen 
delivery can induce known estrogen responses in lens by examining cataract induction 
and lenticular gene expression in the ER3 mice; b) to verify if estrogen responses in the 
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lens are increased at the same estrogen dose via ocular delivery over systemic delivery; c) 
to identify topical estrogen doses that provide low to no systemic effects using 
uterotrophic assay while providing E2 action in lens; d) to improve estrogen 
responsiveness in the lens with in situ gel-forming E2 eye drop formulations containing 
higher polymer concentrations. 
 
V. B. EXPERIMENTAL AND METHODS 
V.B.1. Animals 
All animal procedures were performed in accordance with the Animal Welfare 
Act and were approved by the Institutional Animal Care and Use Committee at Duquesne 
University. All study mice (FVB/n strain) were produced from breeding colonies 
established in our facility. The ERΔ3 mice used in this study were generated on the 
FVB/n background strain. All mice were housed in a well-ventilated, controlled 
environment; temperatures ranging from 22-25 °C and humidity between 50-75% with a 
standard 12hr:12hr light:dark cycle. The breeding colonies were maintained on standard 
rodent chow and water was available ad libitum. A semi-purified, isoflavone-free diet 
(Harlan Teklad, Indianapolis, IN) was used to generate and maintain all study mice in 
order to eliminate the exposure to estrogenic soy isoflavones that are present in standard 
rodent chow (Thigpen et al., 1999; Degen et al., 2002). Ear punches were used to 
designate animal numbers. All mice were euthanized by carbon dioxide asphyxiation 
followed by cervical dislocation to assure death. 
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V.B.2. Cataract Induction Study 
In this study, male and female mice with ERΔ3 transgene in the FVB/n strain 
were used. At day19 after the birth (i.e., prepubescent age), mice were randomly divided 
into different groups (n ~ 8 mice/group) containing both males and females.  Female 
mice in each group were ovariectimized (i.e., ovaries were surgically removed) to 
eliminate production of endogenous estrogens at puberty (around 25 days) which would 
result in cataracts developing spontaneously (Davis et al., 2002) and confound the 
induction study. The procedure for ovariectomy is described below. Mice in each group 
were given one of the treatments listed in Table V.1 followed by visual examination 
every week for onset and severity of cataracts up to 2 months. All mice were weaned at 
the age of 19 days. In the case of ophthalmic treatments, 2 μL of the vehicle or E2 in situ 
gel-forming solution was administered in both the eyes once a day for 6 days. In the case 
of injection treatments, 0.1 mL of the vehicle (i.e., 95% ethanol in corn oil) or E2 
preparation was administered subcutaneously once a day for 6 days. Mice in each 
treatment group were visually examined every week for ocular irritation and onset and 
severity of cataracts up to 2 months after treatment. At the end of 2 months or 8 weeks, 
eyes from each mouse were collected at necropsy and fixed in 4% paraformaldehyde for 
6 hr at 4°C and processed for histological analysis. The procedure used for mouse lens 
collection and histology was briefly described below. 
 
Treatment Preparation 
Ophthalmic in situ gel-forming E2 formulations that were prepared according to 
the procedure listed in III.B.3.1 and identified in the previous chapter to provide 
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acceptable product performance characteristics were used in this study. Ophthalmic 
vehicle formulation containing 0.3%w/v polymer and 4%w/v polysorbate-80 without the 
drug was similarly prepared and used. For injection study, a primary stock solution of 
17β-estradiol was prepared by dissolving 5 mg/mL of 17β-estradiol (Sigma-Aldrich, St. 
Louis, MO) in 95% ethanol. Secondary stock solutions of different E2 concentrations 
were then prepared by making dilutions in corn oil. These concentrations were chosen 
based on 0.1mL per 10 g mouse to match the E2 dose administered by in situ gel-forming 
ophthalmic solution treatments. As a vehicle for injection treatments, 95% ethanol was 
dissolved in corn oil at the same ratio of ethanol to corn oil as with the appropriate E2 
dose.  
Table V.1. Treatment groups for cataract induction study in ERΔ3 mouse. 
Treatment 
Kelcogel 
CG LA (%w/v) 
E2 Conc. 
(μg/ml) 
Volume 
 
Dose 
(μg/ 
Mouse) 
Dose/day 
(μg/kg) 
 
 
Ophthalmic 
eye drops 
0.1 10 2 μL /eye 0.04 4 
0.1 100 2 μL /eye 0.4 40 
0.1 250 2 μL /eye 1 100 
0.3 10 2 μL /eye 0.04 4 
0.3 100 2 μL /eye 0.4 40 
0.3 250 2 μL /eye 1 100 
0.3 0 (control) 2 μL /eye 0 0 
 
Subcutaneous 
injection 
----NA---- 0.4 0.1 mL/mouse 0.04 4 
----NA---- 4 0.1 mL/mouse 0.4 40 
----NA---- 40 0.1 mL/mouse 4 400 
----NA---- 0 (control) 0.1 mL/mouse 0 0 
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Ovariectomy Surgery 
Female mice were placed in an induction chamber under the nose cone of the 
isoflurane vaporizer and anesthetized with 3% isoflurane in oxygen by inhalation. The 
hair over the mid-back of the mouse was shaved and the skin was treated with betadine 
solution. A single incision was made in the skin followed by bilateral incisions in the 
abdominal wall to expose ovaries on each side. The fat pad containing the ovary was 
pulled through each opening and the ovarian pedicle was isolated and the ovary was 
excised. The fat was then pushed back through the opening and the skin incision was 
closed with wound clips. Mice were then placed under a heat lamp to warm, given 
subcutaneous warmed saline (0.1 mL/10g body weight) to rehydrate and watched for 
recovery from anesthesia. After the mice were moving around and trying to stand, they 
were administered an analgesic, buprenorphine hydrochloride, at a dose of 0.1 mg/kg (2 
μg/20g mouse given as 0.1 mL) to ease pain and returned to cages. After the animals 
appeared fully recovered, they were returned to the room where they were housed. 
Wound clips were removed within 7-10 days post surgery. 
 
Mouse Lens Collection 
At necropsy, each animal was euthanized by CO2 inhalation. Enucleated eyes 
were microdissected. To harvest the whole lens, a stab incision using a 27-gauge needle 
was made along the cornea. Using fine scissors, the cornea and iris were removed leaving 
the posterior cup. The whole lens was scooped out using curved forceps. All tissues 
collected were flash-frozen with liquid nitrogen and stored at -80° C. 
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Histology 
At necropsy, each animal was euthanized by CO2 inhalation. Eyes were 
enucleated and fixed in 4% ice-cold paraformaldehyde fixative prepared no more than 2 
weeks in advance and stored at 4°C until use. Eyes were fixed in 4% paraformaldhyde for 
6 hr at 4° C, rinsed with 70% ethanol and then immediately processed and embedded. 
The fixed eyes from cataract induction studies were processed using the Pathcentre 
(Shandon, ThermoFisher Scientific, Waltham, MA) under the following conditions 
(Table V.2) and then embedded in paraffin (Tissue Infiltration Medium, Surgipath®, 
Richmond, IL) using the Histocentre-2 (Shandon, ThermoFisher Scientific, Waltham, 
MA) the following morning. The paraffin-embedded eyes were then shipped to Mass 
Histology Service, Inc. (Worcester, MA), where they were cut into 5 μm sections, placed 
onto a glass slide and stained with hematoxylin and eosin. The slides and blocks were 
then shipped back to the laboratory and the ocular sections were observed for 
morphological changes associated with cataracts in the lens of all study animals. 
 
Table V.2. Processing conditions for lens samples (hr) 
 
Reagent Time (hr) 
70% Ethanol 1:00 
80% Ethanol 0:30 
90% Ethanol 0:30 
95% Ethanol 0:30 
100% Ethanol 0:30 
100% Ethanol 0:30 
Xylene 0:30 
Xylene 1:00 
Xylene 0:30 
Paraffin 0:30 
Paraffin 0:45 
Paraffin 0:45 
 
 
 155 
V.B.3. Gene Expression Study 
To evaluate if the E2 dose and delivery route influenced the upregulation of 
estradiol-regulated genes in the ERΔ3 mice (i.e., pax6, six3, six2), gene expression study 
was conducted. In this study, pre-pubertal ERΔ3 mice of pre-pubescent age (i.e., age 19 
days) were randomly divided into different treatment groups (n = 3-4/gender/group) 
according to Table V.3. These groups contained both male and female mouse. In this 
study, the female mice were not ovariectimized considering they were of pre-pubescent 
age and expected to be euthanized at the end of study which was less than 1 day duration. 
Prior to puberty, mice in the ophthalmic treatment groups in Table V.2 received 2 μL of 
the topical eye drops containing vehicle or one of the E2 doses of 0.002, 0.02 or 0.2 
μg/eye (~ 0.004, 0.04 or 0.4μg/mouse). Similarly, mice in the injection treatment groups 
received a single sc injection (0.1 mL) of vehicle, or one of the E2 doses (0.004, 0.04 or 
0.4 μg/mouse). At 5.5-6 hr post-treatment, these mice were euthanized by CO2 inhalation 
and their eyes were enucleated. Immediately post-enucleation, the lenses were dissected, 
flash frozen with liquid nitrogen, and stored at -80° C prior to RNA isolation. RNA 
expression in the lens was examined by real-time, reverse transcriptase-polymerase chain 
reaction (RT –PCR).  
Table V.3. Treatment groups for gene expression study 
Treatment 
Kelcogel 
CG LA (%w/v) 
E2 Conc. 
(μg/ml) 
Volume 
 
Dose (μg/ 
mouse) 
Dose/day 
(μg/kg) 
 
Ophthalmic 
eye drops 
0.1 1 2μL/eye 0.004 0.4 
0.1 10 2μL/eye 0.04 4 
0.1 100 2μL/eye 0.4 40 
0.1 0 (vehicle) 2μL/eye 0 0 
sc 
injection 
----NA---- 0.04 0.1mL/mouse 0.004 0.4 
----NA---- 0.4 0.1mL/mouse 0.04 4 
----NA---- 4 0.1mL/mouse 0.4 40 
----NA---- 0 (vehicle) 0.1mL/mouse 0 0 
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RNA Isolation from Ocular Tissue 
 
RNA was isolated from the ocular tissues from individual animals (i.e., both 
whole lenses) using the Absolutely RNA
®
 Miniprep Kit (Stratagene, La Jolla, CA) 
according to the manufacturer‘s protocol. Briefly, 5-20 mg of frozen lens tissue was 
homogenized in a ratio of 7μL:1mL β-mercaptoethanol:lysis buffer. Tissue homogenates 
were centrifuged for 60 seconds at 13,200 rpm using a microcentrifuge filter spin-cup 
provided in the kit. Additional lysis buffer was added to the spin cup and spun again for 2 
min at 13200 rpm. The filtrate was combined with equal parts 70% ethanol and 
transferred to the RNA spin-cup to bind RNA. Samples were then treated with RNase-
free DNase and incubated for 20 min in a 37°C air incubator to remove DNA 
contamination that may interfere with amplification. 
 Following incubation, samples were washed with a high-salt wash buffer (60 
seconds at 13,200 rpm) and two subsequent low-salt wash buffer applications (60 
seconds at 13,200 rpm; 120 seconds at 13,200 rpm) to prepare them for downstream PCR 
applications. RNA spin columns were transferred to nuclease-free 1.5 mL 
microcentrifuge tubes. To elute total RNA, two-50 μL aliquots of 60°C elution buffer 
was added to the spin column and centrifuged at 13,200 rpm for 60 seconds. RNA 
concentrations were determined spectrophotometrically and RNA integrity was 
calculated using the 260:280 nm ratios. High quality-RNA possessing a ratio between 1.8 
and 2.1 was used for the subsequent real-time RT-PCR analysis.   
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cDNA Reverse Transcriptase (RT) Reaction 
First-strand cDNA was synthesized from total RNA using qScript
TM
 cDNA 
Synthesis Kit (Quanta Biosciences, In., Gaithersburgh, MD) under the manufacturer‘s 
suggested protocol. Briefly, 250 ng of the RNA template was mixed with 4 μL of 
qScript
TM
 reaction mix (5X), 1 μL of qScriptTM RT, and the volume was made up to 20 
μL with sterile nuclease-free water in a PCR tube sitting on ice. The reaction mixture in 
the tube was gently vortexed and centrifuged for 10 seconds prior to incubation. The 
reaction mixture was incubated at 22°C for 5 min, and 42°C for 30 min to synthesize the 
cDNA strand followed by 85°C for 5 min to inactivate the reverse transcriptase. In 
addition to the RT reaction, a ―No RT‖ reaction consisting of RNA and all other reagents 
except the qScript
TM
 RT (substituted with equal volume of sterile nuclease-free water) 
was prepared to serve as a control to identify if the RNA sample had DNA 
contamination. 
  
Real-Time RT-PCR 
Real-time detection of relative RNA levels was performed using the iCycler iQ
TM
 
Real-Time PCR detection system (Bio-Rad Laboratories, Hercules, CA) using SYBR
®
 
green detection. cDNA samples, from the RT reactions described above, were used for 
real-time PCR analysis. Lens tissue from immature ERΔ3 male and female mice were 
analyzed for expression of pax6, six3, and sox2 gene transcripts. Primers were designed 
to span at least one intron/exon boundary to ensure the amplification of cDNA versus 
potential contaminating genomic DNA. All reaction mixes (25 μL total volume) included 
the following: 2x SYBR green master mix, forward primer (200 nM), reverse primer (200 
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nM), cDNA template (1/20 dilution of the RT reaction) and nuclease-free water. Primer 
sequences are found in Table V.4.  
Real-time RT-PCR amplification of the cDNA from immature ERΔ3 mice was 
performed to quantify the expression of the above mentioned estrogen-regulated genes in 
the lens using B-R SYBR
®
 Green SuperMix for iQ
TM
 (Quanta BioSciences, 
Gaithersburg, MD) with the following PCR conditions: enzymatic activation at 95°C for 
1.5 min followed by 50 cycles of denaturation (95°C for 15 seconds) and 
annealing/extension (60°C for 45 seconds).  
All samples were run in duplicate and additional wells consisting of ―no RT‖ for 
each sample and no template (water in the place of the RT enzyme) for each gene tested 
to identify amplification of genomic DNA or other contaminants. In addition to the 
experimental genes, a housekeeping gene, ppia (cyclophilin A), was examined as an 
internal control for each set of genes in each run. The use of a control gene allows 
normalization for data analysis by the ΔΔCt method of relative expression addressed 
below. The ppia gene has been validated as an endogenous control gene for RT-PCR in 
studies previously performed in cell lines and tissues such as in primary breast tissue 
(McNeill RE et al., 2007), mouse liver (Tatsumi et al., 2008), and tissues from brain, 
breast, colon, kidney, ovary, pancreas, prostate, skin, and vascular origin (Feroze-
Merzoug et al., 2002). A melting curve was performed following all real-time RT-PCR 
runs to confirm the presence of a single product in each cDNA sample. Additionally, gel 
electrophoresis was completed on a subset of the samples to visualize amplification of the 
correct product based on base pair size for each gene. 
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Table V.4. Oligonucleotide primers and anticipated sizes of amplified cDNA products 
using real-time RT-PCR 
Mouse 
Gene 
Accession 
No. 
Orientation Nucleotide Sequence 
Amplified 
Product Size 
(bp) 
ppia NM_008907 
Forward TAT CTG CAC TGC CAA GAC TG 
145 
Reverse ACA GTC GGA AAT GGT GAT CT 
pax6 NM_013627 
Forward TCT AAT CGA AGG GCC AAA TG 
151 
Reverse AGG AGG AGA CAG GTG TGG TG 
six3 NM_011381 
Forward GTT TAA GAA CCG GCG ACA G 
219 
Reverse CTG GAG GTT ACC GAG AGG AT 
sox2 NM_011443 
Forward ACT AGG GCT GGG AGA AAG AA 
281 
Reverse AGT GCA ATT GGG ATG AAA AA 
 
Relative Gene Expression using the 2
-ΔΔCt
 method 
Relative expression was calculated using the 2
-ΔΔCt
 method with ppia (mouse) as 
the housekeeping or normalizing gene. First, the ΔCt value was calculated by subtracting 
the threshold value (Ct) for the housekeeping gene from the Ct value for the gene of 
interest for each sample. The Ct value is defined as the number of cycles required for the 
fluorescent signal to cross the designated threshold value; therefore, the fewer cycles 
needed to cross the threshold would indicate higher levels of mRNA for that gene. The 
ΔCt value for each individual sample/group/gene of interest was averaged to obtain the 
average ΔCt ± standard error of the mean (SEM). Relative gene expression between 
treatment groups and the control group was determined by the equation 2
-ΔΔCt; ΔΔCt 
values were calculated by subtracting the average ΔCt value for the control group from 
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the average ΔCt value for the treatment group. Values were expressed as a relative fold 
change; 2
-ΔΔCt. Statistical analyses were performed on the ΔCt values using GraphPad
®
 
Prism Version 5. 
 
V.B.4. Uterotrophic Assay in Mice and Rats 
An uterotrophic assay in immature mice was performed to determine if E2 
delivery resulted in stimulation of the estrogen-responsive uterus. In this study, the 
influence of E2 dose as well as its delivery route was investigated.  Female mice of pre-
pubescent age (19 day-old) were weighed and randomly divided into different treatment 
groups according to Table V.5.  All mice were treated with either control (i.e., vehicle 
formulation containing 0.1%w/v polymer and 4%w/v polysorbate 80) or E2 by injection 
(sc) or ophthalmic drops, once daily for 3 days. The polymer (Kelcogel
®
 CG-LA) 
concentration in these ophthalmic in situ gel-forming E2 eye drops was fixed at 0.1%w/v. 
On the 4
th
 day, all mice were weighed and euthanized by carbon dioxide inhalation and 
pneumothorax. The uterus was excised, trimmed, and weighed. The uterine stimulation or 
change in uterine wet weight in response to systemic E2 concentration was recorded and 
normalized with the body weight.  
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Table V.5. Treatment groups for uterotropic assay in mouse species 
Treatment 
Kelcogel
®
 
CG LA (%w/v) 
E2 Conc. 
(μg/ml) 
Volume 
 
Dose (μg)/ 
mouse 
Dose/day 
(μg/kg) 
 
 
Ophthalmic 
eye drops 
0.1 0 (vehicle) 2 μL /eye 0 0 
0.1 1 2 μL /eye 0.004 0.4 
0.1 2.5 2 μL /eye 0.01 1 
0.1 10 2 μL /eye 0.04 4 
0.1 25 2 μL /eye 0.1 10 
0.1 100 2 μL /eye 0.4 40 
0.1 250 2 μL /eye 1.0 100 
sc injection 
--- 0 (vehicle) 0.1mL/mouse 0 0 
--- 0.04 0.1mL/mouse 0.004 0.4 
--- 0.4 0.1mL/mouse 0.04 4 
--- 4 0.1mL/mouse 0.4 40 
--- 40 0.1mL/mouse 4 400 
 
Similarly, uterotropic study was also performed in Sprague-Dawley rats to 
understand the influence of E2 dose, E2 delivery route, as well as the concentrations of 
Kelcogel
®
 CG-LA in the eye drop on the uterine stimulation due to the bioavailable E2 
systemic concentration. Ophthalmic in situ gel-forming formulations containing 0.1%w/v 
or 0.3%w/v Kelcogel
® 
CG-LA and injectable solutions containing different 
concentrations of E2 along with their appropriate controls were prepared in a similar 
manner as discussed in previous sections. Female Sprague-Dawley rats were weighed and 
randomly divided into different treatment groups (n=4/group) as shown in Table V.6. All 
rats were treated with either control (vehicle) or E2, by injection (sc) or ophthalmic drops, 
once daily for 3 days. On the 4
th
 day, all rats were weighed and euthanized by carbon 
dioxide inhalation and cervical pneumothorax. The uterus was excised, trimmed, and 
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weighed. The uterine stimulation or change in uterine wet weight in response to systemic 
E2 concentration was recorded and normalized with the body weight. 
 
Table V.6. Treatment groups for uterotropic assay in rat species 
Treatment 
Kelcogel
®
 
CG LA (%w/v) 
E2 Conc. 
(μg/ml) 
Volume 
Dose  
(μg)/rat 
Dose/day 
(μg/kg) 
Ophthalmic 
eye drops 
0.1 20 5 μL/eye 0.2 4 
0.1 50 5 μL/eye 0.5 10 
0.1 200 5 μL/eye 2 40 
0.3 0 5 μL/eye 0 0 
0.3 20 5 μL/eye 0.2 4 
0.3 50 5 μL/eye 0.5 10 
0.3 200 5 μL/eye 2 40 
sc  
injection 
--- 0 0.1 mL/rat 0 0 
--- 2 0.1 mL/rat 0.2 4 
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V.C. RESULTS AND DISCUSSION 
V.C.1. Cataract Induction Study 
Previous studies by Kirker and Davis established that spontaneous cataracts 
develop in female ERΔ3 mice exposed to endogenous estrogen and high doses (i.e., 1000 
μg/kg) of exogenously administered estrogen in males, ovariectomized females, and 
immature mice. They demonstrated that age of initial exposure to estrogen was critical 
for rapid induction of cataracts and that the lens was most sensitive to the effects of 
ERΔ3 repressor in a small window of time prior to or at puberty in ERΔ3 mouse. Hence, 
for rapid cataract onset in this study, both male and female ERΔ3 mouse of pre-pubertal 
age (i.e., 19 days old) were treated with different doses of estradiol (E2) once a day for 6 
days, starting at day 19 to day 25, as day 25 typically corresponds to the age at which 
these mice reach puberty. Since the endogenous estrogen produced post-puberty could 
cause spontaneous cataracts and confound the results, the female mice were 
ovariectomized prior to treatment. Male mice were left intact as they do not develop 
cataracts from endogenous estrogen exposure. 
In this study, the effect of E2 route of delivery (ophthalmic vs. systemic), E2 
doses, and gellan gum concentration in the in situ gel-forming E2 eye drops on the 
incidence of cataracts in ERΔ3 mice was investigated by gross observations and lens 
histopathology. In addition, all ERΔ3 mice were observed for any signs of ocular 
irritation (i.e., redness, swelling or watering of eyes) and gross cataracts over time with 
the naked eye. The incidence of observed gross cataracts in these mice is listed in Table 
V.7. Incidence is considered when at least one of the eyes per animal appears cataractous. 
The results indicated that cloudiness, characteristic of the ERΔ3-induced cataract (see 
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Figure V.3), were observed only in the eyes of ERΔ3 mice treated with E2 by ocular as 
well as systemic route, but not in the mice treated with vehicle controls by either means 
of delivery (see in Table V.7). These results suggest that estrogen was required to 
interfere with the estrogen signaling mechanism in ERΔ3 mice and cataract induction 
was a result of expression and activation of the ERΔ3 inhibitor. In addition, no signs of 
ocular irritation were observed in any of the estradiol-treated or vehicle-treated mice, 
indicating the safety of the developed formulations (see in Table V.7). However, further 
testing of potential for ocular irritation in rabbits is required as it is the official method for 
evaluation of acute ocular irritation of ophthalmic products and also it is the only reliable 
model for predicting human responses in the eye.  
 
Table V.7. Gross observation for ocular irritation and cataract incidence in ERΔ3 mice 
Treatment 
Kelcogel
®
 
CG-LA 
E2 dose 
(μg/kg) 
n 
Ocular 
Irritation 
Gross Cataracts Incidence (%) 
4 weeks 6 weeks 8 weeks 
Ocular 
eye drops 
0.1%w/v 
0 8 No 0 0 0 
4 8 No 37.5 % 37.5 % 62.5% 
40 9 No 11.1 % 33.3 % 77.8 % 
100 8 No 25 % 37.5 % 100 % 
0.3%w/v 
0 9 No 0 0 0 
4 9 No 44.4 % 77.8 % 100 % 
40 8 No 87.5 % 100 % 100 % 
100 8 No 100 % 100 % 100 % 
sc 
injection 
----- 
0 4 No 0 0 0 
4 4 No 0 % 25 % 50 % 
40 8 No 12.5 % 37.5 % 100 % 
400 6 No 50 % 66.7 % 100 % 
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The variability chart and bar graph in Figure V.1 and V.2 illustrate the effect of E2 
dose and delivery route on the incidence of cataracts at different time points post- 
treatment. Cataracts were induced by all 3 E2 doses by ophthalmic (i.e., of 4, 40, and 100 
μg/kg) or systemic (i.e., of 4, 40, and 400 μg/kg) delivery. The ophthalmic dose was 
determined based on delivery to both eyes, with each eye receiving half the injected E2 
dose.  By both means of E2 route of delivery, the number of animals with gross cataracts 
and percent gross cataract incidence increased with E2 doses and duration of time. Higher 
cataract incidence with increasing E2 dose is expected because higher doses are required 
for ERΔ3 repressor to be activated and dimerize to block estrogen action and to cause 
cataracts. Accordingly, the increase in cataract incidence and severity with time suggest 
that the cascade of events that lead up to the noticeable morphological changes in lens 
pathophysiology (i.e., cataracts) post-activation of ERΔ3 repressor by E2 is a time- 
dependent or kinetic phenomenon. However, when compared at equivalent E2 
dose/mouse (i.e., μg/kg) and same time post-treatment, the percent gross cataract 
incidence remained higher in the case of ocular eye drop formulations containing 
0.3%w/v gellan gum relative to systemic injection treatments (see Figure V.1 and V.2). 
The increase in incidence is most noticeable with all 3 E2 doses at 4 and 6 weeks post-
treatment. Higher estrogen responsiveness observed in the lens with topical delivery at 
half of the systemically administered doses demonstrates the efficiency of topical 
delivery in supplying sufficient estrogen levels to the lens compared to systemic delivery. 
In the later case, higher doses are required to show similar response in the lens as the 
drug administered has to bypass blood-retinal barrier and vitreous humor before reaching 
the avascular lens tissue.  
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Lens opacities were observed by gross examination as early as 4 weeks with the 
ocular E2 treatments at all investigated doses and gellan gum concentrations, but with the 
systemic sc injection treatments, cataracts were not observed at E2 dose of 4 µg/kg (see 
Table V.7). In addition, 100% incidence was observed by 4 weeks with higher E2 dose 
(100 μg/kg) and gellan gum concentration (0.3%w/v) only by the ophthalmic delivery 
(see Table V.7). At 40 μg/kg E2 dose, cataracts were evident in both eyes by 6 wks post-
treatment in all 8 animals with the eye drop formulation containing 0.3 %w/v gellan gum, 
with 6 of the mice having strong cataracts (as shown in Figure V.3). However, none of 
the mice treated with this E2 dose using either eye drops containing 0.1 %w/v gellan gum 
polymer or systemic sc injection had strong cataracts, but 3 of 8 had opacities in both 
eyes by 6 wks post-treatment. These data demonstrate that ophthalmic delivery of E2 with 
in situ gel-forming eye drops containing 0.3 %w/v gellan gum polymer concentration 
results in an earlier cataract onset vs. eye drops containing 0.1 %w/v gellan gum polymer 
concentration or systemic treatment. The better efficacy with ophthalmic in situ gel-
forming eye drops containing higher polymer concentration (i.e., 0.3%w/v Kelcogel
®
 
CG-LA) is likely due to its better gelling (shown in Table IV.10) and sustained drug 
release behavior (shown in Table IV.11).  
 167 
 
Figure V.1: Schematic showing variability in percent cataract incidence by gross 
examination in ERΔ3 mice across different treatments and time intervals. The 
incidence at each time point in weeks, post-treatment of the 6 daily treatments by either 
delivery route, is shown for each estradiol dose, polymer concentration, and delivery 
route.  (O) ophthalmic delivery and (Inj) for subcutaneous injection delivery.  Two 
polymer concentrations were tested, 0.1% (0.1) and 0.3% (0.3) at 3 estradiol doses, 4, 40, 
40, and 400 
ocular delivery route. 
 
A few mice in some treatment groups did not show develop grossly detectable 
cataracts by maximum time of 2 months post-treatment (see in Figure V.1). In the case of 
ophthalmic treatments (shown in Table V.7), 100% gross cataract incidence was 
observed with formulations containing 0.3% w/v polymer at all E2 doses; whereas using 
0.1% w/v polymer formulations, the incidence increased with E2 dose: 62.5% (4 μg/kg), 
77.8% (40 μg/kg), and 100% (100 μg/kg). Similarly, the incidence of cataracts in ERΔ3 
mice 2 months post-treatment increased with E2 dose in injection treatments: 50% (4 
μg/kg), 100% (40 μg/kg), and 100% (400 μg/kg) by gross observation (shown in Table 
V.7).  These data as well as data obtained at earlier time points comparing the ocular 
formulation containing 0.1% w/v gellan gum and systemic delivery especially for the 
highest E2 dose, suggest that the eye drops formulation containing 0.1% w/v gellan gum 
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polymer may have a similar or lesser efficacy to the systemic injection.  Estrogen dose 
dependency in the incidence of cataracts was also reported by Davis and colleagues in 
their previous studies using ERΔ3 mouse model (Davis et al., 2000). Such dose 
dependency underscores the need for sufficient levels of estrogen in the eye tissues to 
activate the ERΔ3 repressor and cause morphological changes in the lens 
pathophysiology leading to its opacification and cataract formation. However, the lack of 
detectable gross cataracts in some mice may be due to decrease in severity of the cataract 
(i.e., cataract has not progressed to be visible by the unaided eye); therefore, the lack of 
gross cataracts does not rule out the possibility of immature cortical cataracts. To confirm 
the presence or lack of cataracts, eyes from all the mice were also examined by 
histopathology at the end of 2 months. Representative microscopic images of lens 
histological sections obtained from ERΔ3 mice subjected to the different treatments are 
shown in Figures V.4 –V.7.  Histopathology on lenses from E2-treated ERΔ3 mice at 2 
months of age, confirmed gross observations with the presence of cortical vacuoles in the 
lenses of all mice treated with E2. In contrast, no abnormalities were observed in the 
lenses of ERΔ3 mice treated with either the ophthalmic or injection vehicles up to 2 
months after the 6 days of treatment (Figure V.4).  
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Figure V.2: Percent cataract incidence by gross examination in ERΔ3 mice across 
different treatments and time intervals. The incidence at each time point in weeks, 
post-treatment of the 6 daily treatments by either delivery route, is shown for each 
estradiol dose, polymer concentration, and delivery route.  (O) ophthalmic delivery and 
(I) for subcutaneous injection delivery.  Two polymer concentrations were tested, 0.1% 
into both eyes).  Injected estradiol doses were 4
injected dose for the highest dose compared to the ocular delivery route. 
 
 
    
Vehicle drop      E2 drop 
Figure V.3: Grossly detectable cataracts in ER3 mice after ophthalmic E2 
administration. Daily treatments were given for 6 days in immature males and females 
(ovariectomized prior to puberty to prevent the endogenous estrogen‘s ability to induce 
cataracts).  Photograph in the right panel shows an example of a strong cataract with E2 
drops compared to the vehicle drops (left panel) > 6 weeks after treatment.  
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The severity of the histologically-detected cataracts (i.e., qualitative estimate of 
the number or area of the lens covered by the cortical vacuoles or globules) was greater 
with increasing E2 doses (Figures V.5 - V.7).  In accordance with gross observations, the 
ERΔ3 mice treated with ophthalmic formulations containing 0.3%w/v Kelcogel® CG-LA 
showed stronger and more severe cataracts compared to formulations containing 0.1% 
w/v polymer as well as injection treatments due to reasons previously discussed 
(representative lens histopathology images are shown in Figures V.5 - V.7). Thus, these 
results demonstrate that a) ophthalmic delivery resulted in earlier onset of cataracts in 
ERΔ3 mouse compared to systemic delivery, presumably due to the availability of 
sufficient levels of E2 in the eye tissues and lens to activate the ERΔ3 repressor and b) 
ophthalmic formulations containing 0.3%w/v Kelcogel
®
 CG-LA and higher E2 doses 
accelerated the onset of gross cataracts and resulted in more severe cataracts compared to 
0.1%w/v Kelcogel
®
 CG-LA, indicating higher ocular bioavailability to induce the dose- 
dependent ERΔ3 cataracts due to the demonstrated stronger gel structure and sustained 
drug release behavior (discussed in Section(s) IV.C.4.2 and IV.C.4.3) in the eye.   
Considering the significant influence the Kelcogel
®
 CG-LA concentration in the 
formulation has on the strength of the in situ gel structure obtained in the presence of tear 
fluid (as shown in Table IV.10) and, the efficacy in inducing rapid and severe known 
estrogen responses in the eye (as shown in Table V.7), patients suffering from dry eyes 
would need to be considered. This is because with the insufficient tear fluid, the in situ 
gel-forming solution eye drop formulation medium could provide an environment that 
would supplement the insufficient tear fluid. Since the apparent viscosity of the 
developed in situ gel-forming solution (as shown in Table IV.9) are higher than that of 
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water (as shown in Table IV.9), it could still be effective in prolonging drug‘s contact 
time and providing higher ocular drug absorption compared to conventional ophthalmic 
solutions. Since use of tear substitutes is a common practice in patients with dry eyes, 
pre-administration of the tear substitutes before the use of the developed in situ gel-
forming eye drops may maintain the treatment efficacy. Future formulation consideration 
could include a blend of polymers that would alleviate the dry eye condition while still 
providing in situ gel formation for delivery of estrogen. 
   
Figure V.4: Representative lens histological sections of ERΔ3 mice treated with 
vehicle controls.  Tissue sections are from mice treated with A) Injection control B) In 
situ gel-forming eye drops control, shown at 40X (left panels) and 400X (right panels) 
magnification. The box in the right panel represents the clear areas of the cortical region 
of the lens. All histological sections were stained using hematoxylin and eosin stain 
(H&E) in formalin-fixed eyes. 
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Figure V.5: Representative lens histological sections of ERΔ3 mice treated with 
estradiol (E2) sc injections. Tissue sections are from mice treated with sc injection of  A) 
4 μg/kg E2 dose B) 40 μg/kg E2 dose, and C) 400 μg/kg E2 dose shown at 40X (left 
panels) and 400X (right panels) magnification. The box in the right panel represents the 
cortical region of the lens where ERΔ3-induced cortical vacuoles are observed.. As E2 
dose increases cataracts progress and greater area of lens is involved.  
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Figure V.6: Representative lens histological sections of ERΔ3 mice treated with 
estradiol (E2) in situ gel-forming eye drops containing 0.1 %w/v Kelcogel
®
 CG-LA. 
Tissue sections are from mice treated with eye drops of A) 4 μg/kg E2 dose B) 40 μg/kg 
E2 dose, and C) 100 μg/kg E2 dose, shown at 40X (left panels) and 400X (right panels) 
magnification. The box in the right panel represents the cortical region of the lens where 
ERΔ3-induced cortical vacuoles are observed and as E2 dose increases cataracts progress 
and greater area of lens are involved.  
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Figure V.7: Representative lens histological sections of ERΔ3 mice treated with 
estradiol (E2) in situ gel-forming eye drops containing 0.3 %w/v Kelcogel
®
 CG-LA. 
Tissue sections are from mice treated with eye drops of A) 4 μg/kg E2 dose B) 40 μg/kg 
E2 dose, and C) 100 μg/kg E2 dose, shown at 40X (left panels) and 400X (right panels) 
magnification. The box in the right panel represents the cortical region of the lens where 
ERΔ3-induced cortical vacuoles are observed. Notice increase in vacuoles and the area of 
lens affected at higher E2 doses indicating more severe cataracts.  
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V.C.2. Gene Expression Study 
Davis and colleagues, in their previous studies, implemented cDNA microarray 
analysis to identify the gene expression changes with potential to be related to lens 
pathology observed in the ERΔ3 transgenic mouse model. They reported that pax6, sox2 
and six6 among other genes were differentially expressed in the lens of immature (i.e., 21 
day-old) ERΔ3 female mice at 6 hr post-treatment treatment with 1000 μg/kg E2 sc 
injection (results not shown). Gene analysis in the lens was performed at 6 hr post-
treatment based on an estimate of time it may take for the systemically administered drug 
to cross blood-retinal barrier and vitreous humor before reaching the avascular lens tissue 
to elicit its effects. Gene analysis provides a rapid and short-term approach to examine 
early changes or effects of estrogen treatments in the lens as a result of likely estrogen 
actions via lenticular ER receptors. Hence, in the current study, differential expression of 
the above mentioned genes in the ERΔ3 mouse lens was examined as a valuable tool to 
compare the effect of different estrogen treatments (i.e., ophthalmic vs. systemic) and 
relate it to their ability to induce rapid estrogen-dependent responses in the lens. 
Accordingly, immature ERΔ3 mice were treated with the vehicles or different doses of E2 
by ophthalmic or systemic routes and the lenses harvested at 6-hrs post-treatment. The 
ophthalmic dose was determined based on delivery to both eyes, with each eye receiving 
half the injected E2 dose.  The gene expression in the lens was measured by real-time RT-
PCR analysis. In the case of ophthalmic treatments, in situ gel-forming eye drops 
containing only 0.1%w/v Kelcogel
®
 CG-LA are used to verify if 6 hr post-treatment 
represents a suitable time course for differential expression of genes involved in ERΔ3-
induced cataracts in the mouse lens. Based on the results obtained, future studies can then 
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investigate the effect of different polymer concentrations in the topical in situ gel-forming 
eye drops on the estrogen-induced gene expression in the ERΔ3 mouse lens.  
 
Table V.8. Relative expression levels of candidate genes in premature ERΔ3 lenses 
Mouse 
Gene 
Ophthalmic Treatments (n=4/gene/treatment) 
0.4 μg/kg 
(Mean ± SEM) 
4 μg/kg 
(Mean ± SEM) 
40 μg/kg 
(Mean ± SEM) 
pax6 0.90 ± 0.07 1.14 ± 0.14 *2.32 ± 0.18 
sox2 1.00 ± 0.20 1.33 ± 0.35 2.80 ± 0.92 
six3 1.10 ± 0.18 1.20 ± 0.41 1.64 ± 0.50 
Mouse 
Gene 
Injection Treatments (n=4/gene/treatment) 
0.4 μg/kg 
(Mean ± SEM) 
4 μg/kg 
(Mean ± SEM) 
40 μg/kg 
(Mean ± SEM) 
pax6 1.15 ± 0.05 1.38 ± 0.10 1.29 ± 0.10 
sox2 1.40 ± 0.38 1.23 ± 0.36 1.50 ± 0.52 
six3 1.27 ± 0.31 1.10 ± 0.18 1.29 ± 0.35 
*p<0.05 
The relative expression levels (i.e., ΔCt) of these candidate genes in the lens of 
ERΔ3 mice obtained in response to different treatments are summarized in Table V.8. 
The relative expression levels of pax6 gene, shown in Table V.8 and Figure V.8, indicate 
that at 6 hr post-treatment, only mice treated with higher E2 dose of 40 μg/kg ophthalmic 
eye drops showed significant upregulation of pax6 in the lens compared to control and 
equivalent dose of sc injection treatments (p<0.05). The ophthalmic dose was determined 
based on delivery to both eyes, with each eye receiving half the total body dose and 
equivalent to half the injected E2 dose. Since the systemically delivered E2 gets 
distributed to other tissues in the body and only small amounts may cross the blood-
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retinal barrier and reach the avascular lens tissue to induce estrogen responses, lack of 
significant upregulation at sc injection dose of 40 μg/kg is expected. Therefore, this data 
concur with previous studies by Kirker and Davis demonstrating that significant 
upregulation of pax6 gene in the ERΔ3 mouse lens by sc delivery requires high E2 doses 
(~ 1000 μg/kg). These results reinforce our earlier suppositions that a) E2 delivered 
locally to the eye (i.e. ophthalmic delivery) can act directly on the lens by binding to 
specific estrogen receptors localized in the cells of the lens and/or retina and regulate the 
expression of genes involved in its growth and maintenance and b) high E2 doses are 
required for ERΔ3 repressor to activate and dimerize to block estrogen action and cause 
differential expression of lenticular genes likely involved in cataracts. Based on the pax6 
gene expression results obtained with eye drops containing 0.1%w/v Kelcogel
®
 CG-LA 
(Table V.8), and cataract onset data (shown in Table V.1) for both  it can be expected 
that, future investigations of E2-regulated gene expression in ERΔ3 mice using in situ 
gel-forming eye drops containing 0.3%w/v Kelcogel
®
 CG-LA will result in significant 
upregulation of pax6 gene at much lower E2 doses (i.e., < 40 μg/kg), due to stronger gel-
structure (as shown in Table IV.10), sustained drug release (as shown in Table IV.11) and 
better drug disposition in the ocular tissues. 
In the case of sox2 and six3 genes, no significant difference in their expression 
levels relative to vehicle controls was observed in the ERΔ3 mouse lenses treated with 
either ocular or systemic E2 treatments (shown in Figure V.9 and V.10). Lack of 
significant upregulation of these genes could be because the 6 hr time point may not be 
the time of peak gene responses for the ophthalmically vs. systemically delivered E2. This 
time point was chosen based on the previous studies in the laboratory by Davis, where 
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significant upregulation of all three genes was observed when mice were administered 
with very high systemic E2 dose of 1000 μg/kg. Since the E2 doses used in this study was 
25 to 250-fold lower, significant upregulation of all the genes may require a higher dose 
for either delivery method and/or different times for gene analysis post-treatment for 
comparing ocular vs. systemic delivery.  
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Figure V.8: Expression of estrogen-responsive pax6 gene in ERΔ3 mouse lens. 
Expression of pax6 was evaluated in RNA prepared from mouse lenses 6 hr after sc 
injection (I) and ophthalmic (O) eye drops containing 0.1%w/v Kelcogel
®
 CG-LA 
treatments using real-time RT-PCR T values reflect higher expression 
levels. The relative expression was calculated by the 2
-
 method. Expression of pax6 
was increased 2.3 fold over the vehicle control (refer to Table V.8).  * indicates 
significance compared to all the other groups (1-way ANOVA, p=0.0003; it was 
significantly different than sc E2 treatments and both control groups by Tukey‘s test, 
n=4). 
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Figure V.9: Expression of estrogen-responsive sox2 gene in ERΔ3 mouse lens. 
Expression of sox2 was evaluated in RNA prepared from mouse lenses 6 hr after 
ophthalmic (O) and injection (I) treatments using real-time RT- T 
values reflect higher expression levels. Data was graphed as mean ± SEM (n=4). There 
was no significant difference in sox2 expression as a result of E2 treatment. (GraphPad
®
 
Prism, 1-way ANOVA, Tukey‘s test, p=0.3759).  
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Figure V.10: Expression of estrogen-responsive six3 gene in ERΔ3 mouse lens. 
Expression of six3 was evaluated in RNA prepared from mouse lenses 6 hr after 
ophthalmic (O) and injection (I) treatments using real-time RT- T 
values reflect higher expression levels. Data was graphed as mean ± SEM (n=4). There 
was no significant difference in six3 expression as a result of E2 treatment. (GraphPad
®
 
Prism, 1-way ANOVA, Tukey‘s test, p=0.9123). 
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 V.C.3. Uterotropic Assay in Mice and Rats 
   Unopposed systemic estrogen is associated with an increased risk of endometrial 
cancer in women (Naunton et al., 2006; Johnson et al., 2005). Hence, estradiol 
formulations intended for chronic use should reduce the amount of drug systemically 
available to minimize estrogen-induced side effects on estrogen-responsive tissues (i.e., 
endometrium). The rodent uterotrophic assay has been traditionally used to establish the 
estrogenic activity of sex steroids and suspected environmental estrogens because of the 
sensitivity of uterus to the exposed estrogen (Evans et al., 1941; Reel et al., 1996; Markey 
et al., 2001). As exposure to estrogen results in uterine stimulation, change in wet uterine 
weight is measured as a marker of systemic E2 exposure.  Since in situ gel-forming 
estradiol eye drops are specifically designed to maximize ocular drug absorption and 
minimize system bioavailability low to no uterine stimulation is expected with the topical 
eye drops. Hence, in this study, rodent uterotrophic assay was performed to verify if low 
amounts of estrogen are systemically absorbed from the developed topical eye drops 
compared to systemic treatments and to identify an estrogen dose that doesn‘t result in 
any uterine stimulation, but provides E2 action in the lens.  
  After 3 daily treatments with E2 by injection (sc) or ophthalmic drops, in 
immature ERΔ3 female mice, uterine wet weight (normalized to body weight) was 
measured on day 4.  Uterotropic response (i.e., change in uterine wet weight) obtained 
with different estrogen (E2) doses by ophthalmic or systemic routes of delivery was 
compared and summarized as dose-response curve (shown in Figure V.11). The 
sigmoidal shape of the dose-response curve obtained with systemic as well as ophthalmic 
treatments indicate that, at smaller E2 doses (i.e., <0.4 μg/kg), the uterine stimulation was 
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minimal and comparable with the control treatments; and, with increases in the E2 dose, 
the stimulation increased linearly and reached a maximum or plateau at E2 doses of ≥ 40 
μg/kg. At all the tested E2 doses, higher uterine response or greater change in uterus wet 
weight was observed in mice treated with systemic estrogen treatments compared to 
ophthalmic treatments and vehicle controls. In the case of ophthalmic E2 treatments using 
in situ gel-forming eye drops, only the two higher E2 doses (4 and 40 μg/kg) significantly 
increased the wet uterine weight compared to vehicle-treated mice (p<0.05) (see Figure 
V.12). However, with the 4 μg/kg ophthalmic E2 dose, the level of stimulation was 
significantly reduced compared to the equivalent dose delivered by systemic route (see 
Figure V.13).  In addition, the 0.4 μg/kg E2 ophthalmic dose did not cause any uterine 
stimulation, unlike the same dose administered by sc injection. Since the uterine response 
to E2 treatment was measured as a marker of the amount of E2 available in the systemic 
circulation upon treatment, no (i.e. with ≤0.4 μg/kg E2 dose) to low (i.e. with 4 μg/kg E2 
dose) uterine stimulation observed with ophthalmic treatments suggest that they result in 
little to no systemic estrogen-related side effects compared to systemic estrogen 
treatments. Mice are highly sensitive to low levels of E2 due to the lack of peripheral 
aromatization; therefore, the systemic E2 
topical dose of in situ gel-forming eye drops may not result in a similar effect in women.  
However, in the mice, 0.4 μg/kg E2 dose did not cause uterine stimulation and it may be 
an effective dose in humans for cataract prevention.  
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Figure V.11: Dose-response curve showing the effect of E2 on uterine stimulation in 
immature ERΔ3 female mice. After 3 daily treatments with different E2 doses by 
injection (sc) or ophthalmic drops containing 0.1% w/v gellan gum polymer, in immature 
ERΔ3 female mice, uterine wet weight (normalized to body weight) was measured on 
day 4.  Vehicle (I) used for sc injection contained corn oil; where as vehicle (O) for 
ocular drops was similar in contents to the E2 eye drops except the drug.   
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Figure V.12: Uterine stimulation of estrogen ophthalmic and systemic treatments in 
immature ERΔ3 female mice.  All three doses of E2 administered by sc injection (I) 
resulted in significant uterine stimulation; whereas, only the two higher doses delivered 
to the eye significantly increased uterine weight compared to vehicle-treated mice. 
Vehicle (I) used for sc injection contained corn oil; where as vehicle (O) for ocular drops 
was similar in contents to the E2 eye drops except the drug.  No uterine stimulation is 
evident with 0.4 g/kg E2 dose by ocular eye drops (GraphPad
®
 Prism, 1-way ANOVA, 
p<0.0001, * indicates significance vs. vehicle by Tukey‘s test).   
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Figure V.13: Comparing the effect of systemic and ophthalmic estrogen treatments 
on the uterine stimulation in immature ERΔ3 female mice. Vehicle (I) used for sc 
injection contained corn oil; where as vehicle (O) for ocular drops was similar in contents 
to the E2 eye drops except the drug.  Significantly lower uterine weights are evident only 
at the 4 μg/kg E2 dose with ophthalmic eye drops vs. sc injection (GraphPad
®
 Prism, 1-
way ANOVA p<0.0001, * indicates significance vs. sc treatments by Tukey‘s test).   
 
In addition to the effects of E2 dose and delivery method in mice, influence of 
Kelcogel
®
 CG-LA concentrations in the in situ gel-forming eye drops on the uterine 
stimulation as a measure of the amount of drug systemically absorbed was evaluated in 
immature female Sprague-Dawley rats. Rats were used instead of mouse primarily due to 
their availability and also to understand species-related differences on systemic drug 
absorption upon ocular drug delivery. The normalized uterine weight data obtained with  
different E2 doses ( 4, 10, and 40 μg/kg) and eye drop formulations (i.e., containing either 
0.1% w/v or 0.3% w/v gellan gum polymer) indicate that unlike in the mice where both 4 
and 40 μg/kg E2 dose resulted in significant stimulation compared to vehicle treatments  
(see Figure V.12), only rats treated with 40 μg/kg E2 dose of 0.3%w/v Kecogel
®
 CG-LA 
formulations resulted in significant uterine stimulation compared to vehicle treatments 
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(p<0.05) (Figure V.14). Also, the uterine stimulation in rats treated with 4 and 10 μg/kg 
E2 using eye drops containing higher polymer concentration (i.e., 0.3% w/v gellan gum) 
was not significant (p>0.05) compared to the uterine stimulation obtained with eye drops 
containing 0.1 %w/v gellan gum, except at 40 μg/kg E2 dose. In addition, the magnitude 
of the normalized uterus weight/ body weight in response to same E2 topical ocular 
concentrations are lower in case of rats compared to the mice (see Figures V.12 and 
V.14). These results indicate that rats are less sensitive to similar systemic estrogen 
concentrations compared to mice or the systemic E2 bioavailability from the topical eye 
drops differs between the species. 
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Figure V.14: Comparing the effect of ocular estrogen treatments on the uterine 
stimulation in immature female Sprague-Dawley rats. (0.1) and (0.3) represents eye 
drops containing 0.1% w/v and 0.3% w/v gellan gum concentrations. Vehicle (O) for 
ocular drops was similar in contents to the E2 eye drops except the drug.  Significantly 
higher uterine weights are observed only at the 40 μg/kg E2 dose with ophthalmic eye 
drops containing 0.3% w/v gellan gum polymer. (GraphPad
®
 Prism, 1-way ANOVA 
p<0.0001, * indicates significance vs. vehicle treatments by Tukey‘s test).   
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In addition to the effects of E2 dose, influence of E2 route of delivery was 
evaluated for 4 μg/kg E2 dose in immature female Sprague-Dawley rats using ophthalmic 
eye drops containing either 0.1% w/v or 0.3%w/v gellan gum or sc injection. Only a 
single E2 dose was investigated due to the limited availability of animals. Since the E2 
dose of 4 μg/kg was the only dose in previous studies in mice uterotrophic assay that 
resulted in significant uterine stimulation between ocular and systemic estrogen 
treatments (Figure V.13), the same dose was tested and compared again as the most likely 
dose to be able to identify differences between the polymer concentrations and systemic 
delivery in the rats. The normalized uterine wet weights obtained with ocular as well as 
injection treatments at 4 μg/kg  E2 dose indicated that only the injection treatment 
resulted in higher and significant uterine stimulation compared to vehicle treatments 
(p<0.05). Unlike in the mice where the ocular treatment at the 4 μg/kg E2 dose resulted in 
significant uterine stimulation compared to vehicle-treatment (p<0.05) (see Figure V.12), 
the uterine stimulation in the rats at 4 μg/kg  E2 dose with eye drops containing different 
gellan gum concentrations was not statistically significant compared to vehicle treatment 
(p>0.05) (Figure V.15). This result indicate that rats are less sensitive to similar estrogen 
concentrations and the amount of drug systemically absorbed upon ocular delivery is 
lower and results in lower systemic estrogen-related side effects (i.e., uterine stimulation) 
compared to systemic E2 delivery.    
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Figure V.15. Uterine stimulation by E2 ophthalmic and systemic treatments in 
immature female Sprague-Dawley rats. An uterotropic assay in immature Sprague 
Dawley rats compared the ocular treatments containing 0.1% and 0.3% polymer 
concentrations with the sc injection treatment for the same E2 dose (4 g/kg). As a 
vehicle treatment, the animals were given an ocular eye drop not containing drug as well 
as an injection of corn oil.  Neither formulation containing E2 resulted in significant 
stimulation of the uterus compared to the vehicle, unlike the 4 g/kg E2 sc injection 
(GraphPad
®
 Prism, 1-way ANOVA, p<0.03, * indicates significance vs. vehicle 
treatments by Tukey‘s test).   
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V.D. CONCLUSIONS 
Cloudiness or lens opacities, characteristic of the ERΔ3-induced cataracts were 
observed by gross examination only in the eyes of ERΔ3 mice treated with E2 by ocular 
as well as systemic route, but not in the mice treated with vehicle controls by either 
means of delivery (Table V.7). These results suggest that estrogen was required to 
interfere with the estrogen signaling mechanism in ERΔ3 mice and cataract induction 
was a result of expression and activation of the ERΔ3 inhibitor as previously reported. 
Cataracts are observed in ERΔ3 mice in all treatments groups (i.e., at E2 doses of 4, 40, 
and 100 μg/kg). But, the severity and percent gross cataract incidence varied depending 
on the particular estrogen treatment dose and delivery route, as sufficient estrogen levels 
were required in the lens to activate and dimerize ERΔ3 repressor and block estrogen 
action to cause cataracts. The percent gross cataract incidence was found to be higher in 
the case of ophthalmic treatments compared to systemic treatments; especially strong 
cataracts were observed at all tested E2 doses with in situ gel-forming eye drops 
containing 0.3%w/v Kelcogel
®
 CG-LA polymer (Table V.7 and Figure V.3). Also, no 
signs of ocular irritation were noticed by gross observations in any of the estradiol-treated 
or vehicle-treated mice, indicating the safety of the developed formulations (Table V.7). 
However, further testing of potential for ocular irritation in rabbits is required as it is 
more reliable model for predicting human responses in the eye.  
Histopathology on the lenses from ERΔ3 mice at 2 months post-treatment 
confirmed gross incidence of cataracts in different treatment groups and cortical vacuoles 
characteristic of ERΔ3-induced cataracts, were present only in the estrogen-treated mice. 
The lens, however, remained transparent without any abnormalities in the case of vehicle-
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treated ERΔ3 control mice up to the maximum time of 2 months post-treatment (Figure 
V.4). Histological analysis also confirmed that the severity of the cataracts (i.e., estimated 
qualitatively based on the area of the lens that appeared cataractous) was highest in mice 
treated with ophthalmic in situ gel-forming eye drops containing 0.3%w/v Kelcogel
®
 CG-
LA compared to eye drops containing 0.1%w/v Kelcogel
®
 CG-LA due to stronger gel 
structure and sustained drug release in the eye (Figure V.7).  
Gene analysis provided a rapid and short-term approach to examine early changes 
in the lens as a result of likely estrogen actions via lenticular ER receptors. At 6 hr post-
treatment, only ERΔ3 mice treated with higher E2 dose of 40 μg/kg ophthalmic eye drops 
(i.e., each eye received half the total body dose and equivalent to half the injected E2 
dose) showed statistically significant upregulation of the pax6 gene relative to the vehicle 
controls or equivalent dose of sc injection (Figure V.8). The short-term gene expression 
studies demonstrated that a) E2 delivered by ophthalmic route using in situ gel-forming 
eye drops was able to permeate the cornea and induce a known, rapid estrogen response 
in the lens at much lower doses compared to systemic doses (1000 μg/kg ) as previously 
reported (unpublished data), and b) higher ocular E2 doses (i.e., 40 μg/kg) were required 
in the short-term studies to provide sufficient estrogen levels in the lens to rapidly 
activate ERΔ3 repressor and cause early changes in the expression of a lenticular gene. 
Therefore, in the future long-term gene expression studies (i.e., upon multiple 
administration of eye drops for several days), significant upregulation of estrogen-
regulated lenticular genes and known estrogen actions in the lens may likely be induced 
at much lower E2 ocular doses (i.e., 0.4 or 4 μg/kg) using in situ gel-forming eye drops 
containing 0.3%w/v Kelcogel
®
 CG-LA. 
 189 
Uterotrophic assay in mice indicated that uterine stimulation in immature ERΔ3 
female mice is a function of systemic exposure to estrogen. The sigmoidal shape of the E2 
dose-uterine response curve (Figure V.11) suggested existence of a minimum through 
maximum dose range for the uterine stimulation as reported in the literature (Evans et al., 
1941; Reel et al., 1996; Markey et al., 2001). At all the investigated E2 doses (0.4, 4, and 
40 μg/kg), uterine stimulation was lower with ocular treatments compared to systemic 
treatments (Figure V.11). These results indicated that the amount of drug that could 
potentially be absorbed into systemic circulation and cause systemic estrogen related side 
effects was minimal with in situ gel-forming eye drops. Significant lower wet uterine 
weights were observed in mice treated with 4 μg/kg ophthalmic dose compared to 
equivalent systemic (sc) injection dose (Figure V.13). Whereas, in the case of the mice 
treated with 0.4 μg/kg E2 dose, in situ gel-forming eye drops did not increase the uterine 
weight, unlike the same dose administered by sc injection (Figure V.12). Hence, this dose 
may be used as an effective dose in humans for cataract prevention and to prevent 
systemic estrogen-induced side effects on non-ocular estrogen-responsive tissues.  
Uterotrophic assay in immature female Sprague-Dawley rats indicated that, unlike 
in the mice, where ocular treatment at 4 μg/kg E2 dose resulted in significant uterine 
stimulation, the uterine stimulation in the rats at the same dose using in situ gel-forming 
eye drops containing different gellan gum concentrations was not statistically significant 
compared to vehicle treatments, unlike systemic delivery (Figure V.15). These results 
suggest that rats are less sensitive to similar systemic estrogen concentrations compared 
to mice or the systemic E2 bioavailability from the topical eye drops differs between the 
species. 
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In summary, these findings indicate that the developed in situ gel-forming E2 eye 
drops are effective in inducing known estrogen responses in the eyes of ERΔ3 mice and 
can be used in future testing for cataract prevention in preclinical models (such as MNU-
induced cataracts model in rats) and clinical trials. At the lowest E2 dose of 0.4 μg/kg in 
ERΔ3 mice, the ophthalmic eye drops containing 0.3%w/v polymer did not stimulate the 
uterus; but, were not tested for cataract induction. Therefore, additional testing is needed 
to determine if sufficient estrogen levels can be delivered to the eye to influence a known 
estrogen response in the lens without evidence of systemic bioavailability and identify 
ocular E2 therapeutic concentrations for cataract prevention. However, as the ophthalmic 
E2 dose of  4 μg/kg did not stimulate uterus in rats and induced cataracts in ERΔ3 mice, 
this dose may not result in systemic bioavailability in humans while still protecting the 
lens. These data suggest that estrogen in situ gel-forming eye drops could be given to 
women and men without the adverse side effects similar to what would be observed in 
systemic delivery, such as feminization of males or stimulation of non-ocular estrogen 
target tissues in women.  
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CHAPTER VI 
 
IN VIVO EVALUATION OF OCULAR SAFETY AND PHARMACOKINETICS 
OF OPTIMIZED IN SITU GEL-FORMING E2 OPHTHALMIC FORMULATION 
IN RABBITS 
 
VI. A. INTRODUCTION 
 Pharmaceutical preparations intended for ocular administration should be safe 
and non-irritating to the eye upon multiple administrations. Hence assessment of the 
potential for ocular irritation and toxicity of ophthalmic solutions represents an extremely 
important step in the development of a commercially acceptable ophthalmic drug 
product. Modified Draize eye irritation test in rabbits was widely used for this purpose as 
it is the official method for the evaluation of acute ocular irritancy (Draize, 1944 and 
1955; York and Steiling, 1998; Bruner et al., 1991 and 1992). Also, it is the only reliable 
model that captures the full complexity of the eye and the ocular response of its intricate 
biochemical and physiological processes. The primary goal of this study is to establish 
ocular safety of the developed product so that it can be used in future testing in humans. 
Since most of the excipients in the formulation are GRAS (generally regarded as safe) 
listed and previously used in approved commercial ophthalmic products, we expected the 
optimized formulation to be safe and non-irritating to the eye.  
 
 Upon ocular administration, drug in the formulation simultaneously remains in 
contact with three absorptive membranes; the cornea, the conjunctiva and the nasal 
mucosa to cause ocular as well as systemic drug absorption. Corneal pathway via the 
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aqueous humor is the major route for ocular absorption; whereas, drug uptake via 
nasolacrimal drainage and conjunctival sclera route contributes to systemic absorption, 
which, when solution eye drops are used, can be up to 70-100% of the instilled dose 
(Zignani et al., 1995). Adverse systemic side effects induced by ocular administration are 
often observed and several cases of such side effects are reported in the literature 
(McMahon et al., 1979; Kumar et al., 1986; Chang et al., 1987; Urtti et al., 1984).  As E2 
is a potent hormone with wide range of systemic effects on various organs and tissues of 
the body (e.g., breast and endometrium), measurement of ocular and systemic estrogen 
concentrations is critical.  
In this chapter, the ocular irritation potential of the optimized in situ gel-forming 
E2 formulation (Formulation K0.3-High E2 in Section IV.C.4) was evaluated in rabbits. 
The primary goal is to establish ocular safety of the developed product so that it can be 
used in future testing in humans. Since most of the excipients in the formulation are 
GRAS listed and previously used in approved commercial ophthalmic products, the 
formulation is expected to be safe and non-irritating to the eye. Further, estradiol (E2) 
pharmacokinetics upon ocular and systemic estrogen delivery in rabbits was studied and 
the absolute bioavailability of E2 from the optimized in situ gel formulation was 
estimated.  The pharmacokinetic studies (PK) that reveals maximal ocular and minimal 
systemic drug absorption will underscore the utility of in situ gel-forming E2 delivery 
system. 
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VI. B. EXPERIMENTAL AND METHODS 
VI. B.1. Animals 
All procedures were designed to minimize animal suffering in accordance with 
the Animal Welfare Act. All experiments were carried out under veterinary supervision 
and were approved by the Institutional Animal Care and Use Committee (IACUC) at 
Duquesne University. Specific pathogen-free (SPF), 6 weeks-old, New Zealand white 
male rabbits were purchased from Myrtle‘s Laboratory Inc. (Thompsons Station, TN) for 
this study. Each rabbit was tattooed with a serial number on their ear for easy 
identification. The rabbits were housed in individual cages with free access to food 
(Purina ProLab Diet) and water in a well ventilated controlled environment; with 
temperatures ranging from 22-25°C; with humidity between 50-75%; and with a standard 
12hr:12hr light:dark cycle. All rabbits were acclimatized to laboratory conditions for 3-5 
days prior to the beginning of experiments.  
 
VI. B.2. Ocular Irritation in Rabbits: Modified Draize Test 
Six male, pathogen-free New Zealand white rabbits, each weighing 1.0–2.0 kg, 
were used in this study. The animals were evaluated prior to treatment to ensure their 
eyes were normal. After screening, the rabbits were randomly assigned one eye as the test 
eye and the contra-lateral eye as the matched control (i.e., untreated). Therefore, six eyes 
were used for treatment and the other six eyes as control. Fixed volume (30 μl) of the 
optimized in situ gel-forming E2 eye drops (Formulation K0.3-High E2 in Section IV.C.4) 
was instilled into the lower cul-de-sac of the treatment eye of each animal via a 
micropipette twice a day for 3 days; whereas, the control eye was left untreated. This 
 194 
optimized formulation will be used henceforth and will be referred as the optimized in 
situ gel-forming eye drops. Immediately after administration, the upper and lower eyelids 
of the treated eye were gently held closed for 10 seconds to maximize drug cornea 
contact. 
Pre-and post treatment, observation of ocular tissue (i.e., cornea, iris, and 
conjunctiva) was performed at 0.25, 1, 2, 3, 6, and 7 days after the initial treatment for 
signs of irritation such as redness, swelling, or discharge. Any observed ocular irritation 
was graded according to the modified Draize scale of weighted scores (shown in Table 
VI.1). The total ocular irritation scores for each rabbit were calculated by adding the 
weighted sum of irritation scores for the cornea, iris, and conjunctiva. The maximum 
mean total score (MMTS) of eye irritation was obtained by dividing the maximum total 
score obtained for any rabbit at any time point by the total number of rabbits used in the 
study (i.e., n=6). The test formulations were then classified for their ocular irritation 
potential based on the eye irritation score (i.e., MMTS), according to Table VI.2. 
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Table VI.1. Draize scale for scoring ocular irritation/toxicity/lesions in rabbits using the 
optimized in situ gel-forming eye drops 
I. Cornea Score 
A. Opacity-degree of density  
No Opacity 0 
Scattered or diffuse area, details of iris clearly visible 1 
Easily discernible translucent areas, details of iris slightly obscured 2 
Opalescent areas, no details of iris visible, size of pupil barely discernible 3 
Opaque, iris invisible 4 
B. Area of cornea involved  
One quarter (or less) but not zero    1 
Greater than one quarter, but less than half 2 
Greater than half, but less than three quarters 3 
Greater than three quarters, up to whole area 4 
A×B×5                                 Total Maximum = 80  
II. A. Iris Score 
Normal 0 
Folds above normal, congestion, swelling, iris still reacting to light 1 
No reaction to light, hemorrhage, gross destruction 2 
A×5                                     Total Maximum = 10  
III. Conjunctivae Score 
A. Redness 0 
Vessels normal 1 
Vessels definitely injected above normal 2 
More diffuse, deeper crimson red, individual vessels not easily discernible 3 
Diffuse beefy red 4 
B. Chemosis  
No swelling 0 
Any swelling above normal 1 
Obvious swelling with partial eversion of lids 2 
Swelling with lids about half-closed 3 
Swelling with lids about half-closed to completely closed 4 
C. Discharge  
No discharge 0 
Any amount different from normal (does not include small amounts observed in 
inner canthus of normal animals) 
1 
Discharge with moistening of the lids and hairs just adjacent to lids 2 
Discharge with moistening of the lids and hairs, and considerable area around 
the eye 
3 
(A+B+C) ×2                      Total Maximum = 20  
Total Maximum Score: 110  
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Table VI.2. Classification of formulations based on irritation score 
MMTS Classification Symbol 
0.0 – 0.5 Non-irritating N 
0.6 – 2.5 Practically non-irritating PN 
2.6 – 15.0 Minimally irritating M1 
15.1 – 25.0 Mildly irritating M2 
25.1 – 50.0 Moderately irritating M3 
50.1 – 80.0 Severely irritating S 
80.1 – 100.0 Extremely irritating E 
100.1- 110.0 Maximally irritating Mx 
 
VI.B.3. Estimation of Ocular and Systemic E2 Bioavailability from the Optimized In 
situ Gel-forming Eye Drops 
VI.B.3.1. Pharmacokinetics of Intravenous Estradiol in Rabbits  
Six male, pathogen-free New Zealand white rabbits were used in this study. E2 
stock solution of 20 μg/mL concentration was prepared in polysorbate 80 (0.32 %w/v) 
and sterilized by filtering through 0.22 μm sterile filter (FiltrareTM). Each rabbit was pre-
weighed and administered an E2 dose of 7.5 μg/kg by an IV bolus injection of sterile 
stock solution in a fixed volume through marginal ear-vein using a 25-gauge needle and 
sterile disposable syringe. Each rabbit was pre-treated with topical lidocaine 15-30 min 
prior to sampling or injection to reduce pain. Also, each rabbit was restrained 
individually using a towel to provide warmth and comfort during injection or blood 
collection.  
Blood samples were withdrawn from each rabbit at time zero (i.e., before E2 
injection) and at fixed time points of 0.25, 0.5, 1, 2, 3, 4 hr post-administration via one or 
more of the blood sampling sites (i.e., central artery of the ear, the marginal ear vein, the 
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jugular vein, the cephalic vein, lateral saphenous vein). 1-2 mL of the blood was 
immediately transferred to microcentrifuge tubes containing serum-gel clotting activator 
(Sarstedt Inc., Newton, NC) and placed on ice. The centrifuge tubes were then stored in 
the refrigerator for 24 hr to allow clotting and clot retraction for serum collection. At the 
end of this period, these tubes were centrifuged at 13,000 rpm for 5 min to separate serum 
and stored at -20ºC until the time of measurement. E2 concentration in the serum samples 
were determined by radioimmunoassay (RIA) using Coat-A-Count
®
 Estradiol kit 
(Siemens Healthcare Diagnostics Inc., Deerfield, IL) according to the manufacturer‘s 
recommended procedure (described below). RIA was used in this study as it provides 
simple and rapid approach for estimation of E2 in the biological fluids as opposed to other 
existing spectroscopic techniques such as GC/MS (Dickinson et al., 1997; Setnikar et al., 
1997) and LC-ESI-MS (Msagati and Nindi, 2006; Shivprakash et al., 2006) which 
requires complex sample processing and expensive instrument.  
   Using serum RIA data, E2 concentration-time profiles were generated and PK 
parameters such as maximum serum E2 concentration (Cmax), area under the 
concentration–time curves (AUC) from zero to the last time point (AUC0-t), the time to 
reach Cmax (Tmax), the time taken for serum E2 to be reduced by 50% (t1/2),  and the 
fraction of E2 eliminated per unit time or elimination constant (Ke) were calculated by 
non-compartmental model-independent analysis using WinNonlin Professional
®
 (version 
5.2) software (Phasrsight Corporation, Mountain View, CA). 
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RADIOIMMUNOASSAY (RIA) 
Coat-A-Count
®
 Estradiol kit (Siemens Healthcare Diagnostics, USA) is a no-
extraction solid-phase 
125
I radioimmunoassay kit used for the quantitative estimation of 
estradiol in serum. In this procedure, fixed volume of 
125
I-labeled estradiol solution was 
added to rabbit serum or aqueous humor sample in a polypropylene tube coated with 
rabbit antibodies to estradiol.  The mixture was then allowed to incubate for 3 hrs at room 
temperature, during which known amount of 
125
I-labeled estradiol competes with 
unknown quantity of estradiol in the sample for antibody sites on the antibody-coated 
tubes. After incubation, the tubes were decanted to separate bound from free estradiol. 
The tubes were then counted for radioactivity in a gamma counter, the counts being 
inversely related to the amount of estradiol present in the test sample. The amount of 
estradiol in the sample was determined by comparing the counts to a calibration curve. 
The RIA kit had a sensitivity of 8 pg/mL and a range of 20 to 3600 pg/mL. The intra-and 
inter-assay coefficients of variance were between 4-8%. The recovery of the added 
standards was between 93-101%.  
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VI.B.3.2. Pharmacokinetics of E2 in Aqueous Humor and Serum upon Topical 
Delivery of In situ Gel-Forming Eye Drops  
A total of 18 male, pathogen-free, New Zealand white rabbits, including the six 
rabbits previously tested in the ocular irritation and E2 pharmacokinetic study, were used 
in this study.  Prior to this experiment, these rabbits were given 7-10 days of washout 
period to eliminate the previously administered exogenous estrogen. All the rabbits were 
weighed and divided into 6 different groups, each containing 3 rabbits, in order that the 
average body weight of each group was similar. In this study, each rabbit in 5 of the 6 
groups was administered a 30 μL of the optimized in situ gel-forming E2 eye drops 
(Formulation K0.3-High E2 in Section IV.C.4) into the lower cul-de-sac of both the eyes 
(~ 7.5 μg/kg) using a micropipette. Although E2 dose/body weight of the rabbit was 
similar to IV treatment, each eye of the rabbit received only half of the total body dose. 
Immediately after administration, the upper and lower eyelids of the treated eyes were 
gently held closed for 10 seconds to maximize drug cornea contact. Rabbits in the 
untreated group served as a control for baseline E2 levels.  
 Post-instillation, at fixed time point‘s of 0, 0.25, 1, 2, and 4 hr, three rabbits per 
group were anesthetized by intramuscular injection of ketamine (44 mg/kg) and 
acepromazine (1 mg/kg), 10-15 minutes prior to euthanasia. The rabbits were euthanized 
by intra-cardiac puncture using sodium pentobarbital (100 mg/kg). Post euthanasia, 3-5 
mL of the blood was withdrawn by intra-cardiac puncture using 20-G needle, and 
transferred to microcentrifuge tubes containing serum-gel clotting activator (Sarstedt Inc., 
Newton, NC) and frozen on dry-ice. After blood collection, 150-200 µL of the aqueous 
humor was withdrawn from both the eyes by inserting a 25-G needle attached to a 
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tuberculin syringe through the corneoscleral junction and slightly upward into the 
anterior chamber, and the pooled sample was transferred to plain microcentrifuge tubes, 
frozen on dry ice and stored at -80ºC until the time of measurement. At the end of the 
experiment, the centrifuge tubes containing blood samples were stored in the refrigerator 
for 24 hr to allow serum formation. At the end of this period, these tubes were 
centrifuged to separate serum, and stored at -20ºC until analyzed. E2 concentration in the 
serum as well as aqueous humor at different time points was determined by 
radioimmunoassay (RIA) using Coat-A-Count
®
 Estradiol kit (Siemens Healthcare 
Diagnostics Inc., Deerfield, IL) according to the procedure described earlier. 
 Based on the RIA assay data, E2 absorption from the eye drops at different time 
points was calculated and concentration-time profiles in aqueous humor as well as serum 
were generated. Relevant PK parameters (i.e., Cmax, Tmax, AUC, Ke, and t1/2) were then 
calculated from the group mean concentrations by standard noncompartmental method of 
analysis (NCA) with extravascular input using WinNonlin Professional
®
 (version 5.2) 
software (Phasrsight Corporation, Mountain View, CA). Absolute systemic 
bioavailability of E2 from the optimized in situ gel-forming eye drops was calculated 
according to Eq. VI.1 below, using the administered E2 dose and serum AUC0-t obtained 
upon ocular and systemic E2 delivery. 
  
Absolute Bioavailability (F) = 100
Dose
Dose
AUC
AUC
ocular
iv
iv
ocular    Equation VI.1 
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VI.C. RESULTS AND DISCUSSION 
VI. C.1. Ocular Irritation Study in Rabbits: Modified Draize Test 
Rabbits in this study were treated with 30 μL of the optimized in situ gel-forming 
eye drops; this volume was found to be the maximum fluid that the rabbit eye could hold 
without overflowing in the preliminary trials using the formulation control. Additionally, 
this volume falls within the practical range of volumes that can be administered by a 
typical eye dropper in humans (i.e., 30-50 μL) (Lang et al., 2002). During the 7 days of 
the study, rabbits did not show any clinically relevant signs of irritation in their treated 
eyes relative to the control or untreated eyes (Table VI.3). Representative pictures of the 
treated eye and untreated eye in one rabbit at different times post-treatment are shown in 
Figure VI.1. No visible ocular damage or clinically abnormal signs were observed in the 
cornea or iris (i.e., scores of 0) of the rabbits. These results are in complete agreement 
with previous studies (Mazuel and Rozier et al., 1989) that gellan gum containing 
solution eye drops are well tolerated.  
Table VI.3. Draize ocular irritation score of the optimized formulation in rabbits 
Ocular Tissue Irritation Score 
I. Cornea  
A. Opacity-degree of density 0 
B. Area of cornea involved 0 
A×B×5  0 
II. A. Iris 0 
A×5                                      0 
III. Conjunctivae  
A. Redness 0 
B. Chemosis 0 
C. Discharge 2 
(A+B+C) ×2                       4 
Total Maximum Score: I+II+III 4 
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However, at some time points, white conjunctival discharge with moistening of 
the lids and hairs just adjacent to lids was observed in few of the rabbits and resulted in a 
maximum irritation score of 4 out of 110 according to Draize scale (Table VI.3). Since, 
the total number of rabbits used in this study was 6; the maximum mean total score 
(MMTS) obtained was 0.7. According to Draize classification in Table VI.2, this score 
corresponds to the formulation that is practically non-irritating to the eyes. Such excellent 
ocular tolerance was expected as the excipients used in the optimized in situ gel-forming 
formulation are GRAS (generally regarded as safe) listed and has been previously used in 
FDA approved drug products. Lack of ocular irritation upon repeated administrations in 
the rabbits also indicates that E2 concentration in the formulation did not have any 
harmful effects on the ocular tissues and is safe to be delivered by the ophthalmic route. 
Since rabbits are used as the predictors for human response (Lang et al., 2002), it can be 
expected that the optimized in situ gel-forming E2 solution eye drops will be safe and 
non-irritating to the patients in future clinical testing. 
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Figure VI.1. Lack of ocular irritation upon administration of the optimized in situ 
gel-forming E2 eye drops in a male New Zealand white rabbit. Panels in A, B, C, and 
D illustrate representative ocular irritation in control eye (left panel) and treatment eye 
(right panel) at fixed time points of 0.25, 1, 3, and 7days, respectively, from one of the 
six rabbits tested. Treated eyes were given 30 μL of Formulation K0.3-High E2 and 
control eyes were untreated. 
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VI.C.2. Pharmacokinetics of Intravenous Estradiol in Rabbits 
 Investigation of E2 pharmacokinetics upon intravenous bolus injection in rabbits 
was performed as only limited reports of E2 pharmacokinetics in rabbits exist in the 
literature.  Moreover, the PK data obtained would serve as a reference that would allow 
for accurate estimation of absolute bioavailability of E2 upon ocular delivery. 
 Serum E2 concentrations after single bolus dosing (7.5 μg/kg) in rabbits was 
measured at different time points using radioimmunoassay (shown in Table VI.4). RIA 
was used as it is simple and more sensitive for estimation of low systemic concentrations 
of estradiol. The bolus treatment resulted in a rapid spike in serum estradiol levels within 
15 min after administration with mean peak serum E2 concentration (Cmax) of 1136 ± 201 
pg/mL (Figure VI.2 and Table VI.5).  But, within 2 hr the detectable serum levels drop to 
levels approaching the 0 time point and return to baseline levels by 4 hr (Figure VI.2). 
The bolus treatment resulted in the total drug exposure (i.e., mean area under the serum 
concentration time curve (AUC0-t)) of 1014 hr.pg/ml. The serum E2 elimination rate 
constant (Ke) and elimination half-life (t1/2) upon bolus treatment was estimated to be 
1.63/hr and 26 min, respectively (shown in Table VI.5). These data indicate E2 is rapidly 
eliminated in serum due to extensive hepatic metabolism and has a short half-life, as has 
been previously reported (i.e., 15-30 min) (Tremblay et al., 1977; Dickinson et al., 1997; 
White et al., 1998; Bawarshi-Nassar et al., 1988; Hussain, et al., 1988). Since E2 was 
administered intravenously, its bioavailability (i.e., fraction of administered dose of 
unchanged drug that reaches the systemic circulation) is 100%. Hence, in this study, the 
AUC obtained reflects the measure of total systemic drug exposure upon treating with 7.5 
μg/kg of E2. This AUC and dose information will be used according to Eq. VI.1 to 
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measure the absolute bioavailability of E2 from the optimized topical in situ gel-forming 
eye drops in the next section.  
 
Table VI.4. Serum E2 concentration-time data after single IV bolus injection of 7.5 μg/kg 
E2 in rabbits 
Time 
(hr) 
Mean Serum E2  
Conc. (pg/ml) 
SEM 
0 29.3 7.02 
0.25 1136.3 201.80 
0.5 445.8 25.02 
1 127.5 11.55 
2 56.3 5.92 
3 33.4 8.93 
4 30.6 13.00 
 
 
Figure VI.2. Serum E2 concentration-time profile after single IV bolus injection of 
7.5 μg/kg E2 in rabbits. The levels of E2 in the serum rapidly drop to base line levels 
within 2 hr after injection. Serum concentration is shown as mean ± SEM (n=6). 
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Table VI.5. Serum pharmacokinetic parameters of E2 after single IV bolus injection of 
7.5 μg/kg E2 in rabbits 
PK parameter Value 
Cmax 1136 pg/mL 
tmax 0.25 hr 
Ke 1.63/hr  
AUC0-t  1014 (hr.pg/mL)  
t1/2 26 min 
 
VI.C.3. Pharmacokinetics of E2 in Aqueous Humor and Serum upon Topical 
Delivery of In Situ Gel-Forming Eye Drops 
 For the drug delivered by ophthalmic route to reach the lens, it must permeate the 
cornea and acquire detectable levels in the aqueous humor (AH). Hence, the purpose of 
this study was to determine if E2 from the topical in situ gel-forming eye drops permeates 
the cornea, if higher levels reach the aqueous humor compared to systemic circulation, if 
drug levels in AH remains higher for longer periods due to the in situ gel not being 
washed out of the eye, and to compare the systemic drug absorption with IV treatment at 
equivalent dose/rabbit and estimate absolute drug bioavailability.  
 In this study, rabbits were administered 30 L of the optimized in situ gel-
forming eye drops in both eyes with the total body dose (7.5 μg/kg) equivalent to the IV 
dose given to each rabbit in earlier study (VI.B.3.1). Serum and aqueous humor E2 
concentrations achieved from topical eye drops in rabbits were measured at different time 
points using radioimmunoassay (results shown in Table VI.6). E2 concentration-time 
profiles in AH and serum (shown in Figure VI.3 and VI.4) indicate that topical 
ophthalmic delivery result in a rapid spike in estradiol levels in AH and serum within 15 
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min after administration causing maximum E2 concentrations (Cmax) of 188.2 ± 63.3 
ng/mL, and 176.8 ± 83.6 pg/mL, in aqueous humor and serum, respectively. The peak E2 
concentration (Cmax) in serum at 15 min was 1000-fold lower than the AH (note the 
difference in concentration units). Such a rapid spike in aqueous humor E2 levels (i.e., 
188.2 ng/mL) compared to base levels (i.e., 0.006 ng/ml or 6 pg/ml) initially was likely 
due to the lag-time for gel-formation during which large amounts of drug probably leaked 
out in the eye and got rapidly absorbed into the aqueous humor owing to its high corneal 
permeability (logP-3.5). Faster ocular drug absorption immediately upon administration 
is highly beneficial in topical therapies to cause rapid onset of therapeutic effect and 
relieve patients of immediate disease symptoms. Within 30 min of topical administration, 
E2 concentration decreased rapidly to 6.3 ± 2 ng/mL (~30-fold decrease from Cmax) in AH 
compared to 89.8 ± 3 pg/ml in serum (~2-fold decrease from Cmax) (shown in Figure VI.3 
and VI.4). Such rapid decrease in E2 concentrations in AH was likely due to; a) drainage 
of the instilled drug solution from the conjunctival sac and nasolacrimal duct, b) the 
turnover of AH and the rapid distribution of E2 into the posterior tissue of the eye, and/or 
c) the gel that was formed sustained the drug (E2) release and subsequent absorption into 
the AH. But, within 2 hr the detectable serum E2 levels drop to levels approaching the 0 
time point and returns to baseline levels by 4 hr (see in Figure VI.4) causing the total 
systemic drug exposure (i.e., mean area under the serum concentration time curve (AUC0-
t)) of 219.5 hr.pg/mL. In contrast, E2 levels drop more slowly in the aqueous humor and 
are still ~30-fold higher (i.e., 200 pg/mL) compared to its low baseline levels (i.e., 6 
pg/mL) at the end of 4 hr (see in Figure VI.3) resulting in the total ocular drug exposure 
(i.e., area under the serum concentration time curve (AUC0-t)) of 53.1 hr.ng/mL. High E2 
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levels in AH at the end of 4 hr suggest that E2 contact time in the eye was prolonged and 
the drug release from the in situ gel was sustained. Based on the obtained data, the E2 
elimination rate constant (Ke) and elimination half-life (t1/2) was estimated to be 1.0/hr 
and 42 min in AH and 0.8/hr and 51 min, respectively (shown in Table VI.7). Faster E2 
elimination in AH was likely due to rapid distribution into the posterior tissues of the eye. 
The large difference (~250-fold) in the total drug exposure in AH (i.e., AUC0-t of 53.1 
hr.ng/mL) and serum (AUC0-t of 219.5 hr.pg/mL) upon topical ophthalmic E2 delivery 
indicates 1) that the drug was able to permeate cornea and was preferentially absorbed 
into the eye and 2) only low drug levels are systemically absorbed compared to the high 
levels that are present in the aqueous humor.  
 Due to the effective delivery of high E2 doses to the aqueous humor (Cmax of 
188.2 ng/mL vs. 0.006 ng/ml base levels) of the male rabbits using the optimized in situ 
gel-forming eye drops, future studies should investigate lower doses and identify 
minimum effective therapeutic E2 aqueous humor concentrations. These levels would not 
result in detectable serum levels and still be effective in inducing estrogen-regulated 
responses and in protecting lens transparency. 
 
 
 
 
 
 
 
Table VI.6. Serum and aqueous humor E2 concentration-time data after topical 
administration of 30 μL of the optimized in situ gel-forming eye drops in rabbits 
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Time 
(hr) 
Serum  Aqueous Humor  
Mean E2 
(pg/ml) 
SEM 
Mean E2 
(ng/ml) 
SEM 
0 29.3 7.02 0.006 0.001 
0.25 176.8 83.6 188.23 63.3 
0.5 89.8 2.99 6.32 2.1 
1 81.2 6.76 3.76 2.9 
2 34.9 5.51 0.44 0.07 
4 28.4 4.49 0.20 0.05 
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Figure VI.3. Aqueous humor E2 concentration-time profile after topical 
administration of 30 μL of the optimized in situ gel-forming eye drops in rabbits. 
The levels of E2 in the aqueous remain elevated up to 4 hr after ophthalmic delivery. 
Aqueous humor concentration is shown as mean ± SEM (n=5).  
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Figure VI.4. Serum E2 concentration-time profile after topical administration of 30 
μL of the optimized in situ gel-forming eye drops in rabbits. The levels of E2 in the 
serum drop to base levels within 3 hr after ophthalmic delivery. Serum concentration is 
shown as mean ± SEM (n=5).  
   
 Serum E2 levels in the rabbits treated with ophthalmic drops were substantially 
lower compared to animals receiving the IV injection at equivalent dose/rabbit (i.e., 7.5  
μg/kg); plus, these levels also decline to baseline levels within the 4 hr test period (see in 
Figure VI.5). In both cases, the serum E2 concentrations spike in 15 min and peak 
concentrations (Cmax) upon ophthalmic delivery (i.e., 177 ± 84 pg/mL) was 
approximately 7-fold lower compared to IV treatment (i.e., 1136 ± 201 pg/mL).  In 
addition, E2 delivery by ophthalmic route (i.e., AUC - 219.5 hr.pg/mL) resulted in 5-fold 
lower total systemic drug exposure compared to IV injection (AUC of 1014 hr.pg/mL). 
Since low systemic E2 doses resulted in lower uterine stimulation in previous studies in 
mice and rats (shown in Section V.C.3), lower systemic E2 exposure observed in the 
rabbits using topical in situ gel forming eye drops will similarly minimize systemic E2 
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related side effects on estrogen-responsive tissues.  Using the administered E2 treatment 
dose and observed systemic drug exposure (AUC0-t) data upon topical and systemic E2 
treatments, the absolute systemic E2 bioavailability (BA) was estimated (using Eq.VI.1). 
The absolute bioavailability of E2 from the optimized in situ gel-forming eye drops was 
found to be 20% of the administered E2 dose. The result concurs with previous studies 
where low systemic BA was similarly observed with ophthalmic formulations containing 
gel-forming agents or viscosity enhancing agents (Kumar et al., 1986; Kyyronen and 
Urtti, 1990; Urtti et al., 1993; Folk et al., 1996; Wei et al., 2007). Using conventional 
solution eye drops 50-100% of the administered dose is systemically absorbed 
(Nanjawade et al., 2007; Martens-Lobenhoffer and Banditt, 2002). Thus, low systemic E2 
BA observed in this study was likely due to the in situ gel formation that increased the 
viscosity of the preparation in the eye and reduced its mucociliary clearance or drainage 
through the nasolacrimal duct.  
 
Table VI.7. Pharmacokinetic parameters of E2 in serum and aqueous humor after topical 
administration of 30 μL of the optimized in situ gel-forming eye drops in rabbits 
PK parameter 
Value  
Serum  Aqueous humor 
Cmax 176.8 pg/mL 118.2 ng/mL 
tmax 0.25 hr 0.25 hr 
Ke 0.82/hr  1.0/hr 
AUC0-t  219.5(hr.pg/mL)  53.1 (hr.ng/mL) 
t1/2 51 min 42 min 
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Figure VI.5. Serum E2 concentration-time profiles after topical (■) and systemic 
delivery (♦) of 7.5 μg/kg E2 in rabbits. Serum E2 levels at 15 min after IV injection was 
10-fold higher compared to eye drops. E2 levels rapidly drop to base levels within 3 hr 
after administration by either method. Serum E2 concentration is shown as mean ± SEM. 
 
 
 
%20100
DoseAUC
DoseAUC
F
iv




oculariv
ocular
 213 
VI.D. CONCLUSIONS 
 The optimized in situ gel-forming E2 eye drops (Formulation K0.3-High E2) was 
well tolerated and did not show any clinically relevant signs of irritation or toxicity in the 
eyes or other ocular tissues in rabbits. Based on the Draize irritation score in rabbits, the 
developed in situ gel-forming eye drops formulation can be classified as practically non-
irritating. The radioimmunoassay was found to be sensitive enough to monitor the 
changes in the serum levels and aqueous humor E2 concentrations during the study.  
Following a single IV bolus injection, E2 was rapidly eliminated from the body with 
serum half-life of 26 min. Upon ocular instillation of the optimized in situ gel-forming 
eye drops, large amounts of E2 was preferentially absorbed into the aqueous humor of the 
eye and resulted in the area under the curve (AUC) that was 250-fold higher than in case 
of E2 in the systemic circulation or serum. Additionally, the E2 concentrations in the 
aqueous humor of the eye remained ~30-fold above the base levels at the end of 4 hr 
suggesting that the drug contact time in the pre-corneal area was prolonged and the drug 
release from the in situ gel was sustained. However, the E2 concentrations in serum 
reached the base levels within 2 hr due to rapid hepatic metabolism and resulted in 
absolute bioavailability (BA) of 20% of the administered dose. Such low observed BA 
using in situ gel-forming solution eye drops was a result of viscoelastic nature of the gel 
formed that reduced drug drainage through nasolacrimal duct and minimized systemic 
drug absorption. Lower systemic E2 levels will reduce the incidence of harmful side 
effects on estrogen-responsive tissues (i.e., breast, endometrium). Due to the effective 
delivery of high doses to the aqueous humor, future studies should investigate lower 
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doses that do not result in detectable serum levels, yet will be effective in inducing 
estrogen-regulated responses in the lens and preserve lens transparency. 
 In summary, the studies in rabbits demonstrated that the optimized in situ gel-
forming E2 solution eye drop formulation is practically non-irritating to the eyes with 
maximum ocular drug absorption and minimal systemic drug bioavailability.   
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CHAPTER VII 
 
STABILITY TESTING OF THE OPTIMIZED IN SITU GEL-FORMING E2 
OPHTHALMIC SOLUTION 
 
VII. A. INTRODUCTION 
Stability of a pharmaceutical drug product is performed to gather evidence on 
how the quality of a drug substance or drug product varies with time under the influence 
of a variety of environmental factors, such as temperature, humidity, and light, and to 
establish a retest period for the drug substance or a shelf life for the drug product and 
recommended storage conditions (FDA, 1987; ICH Q1A (R2), 2003a). Stability testing 
also allows evaluation of the impact of short-term excursions outside the labeled storage 
conditions that might occur during shipping and for predicting the shelf-life under normal 
storage conditions. Further, the U.S. Food and Drug Administration (FDA) requires that a 
tentative shelf life (i.e., expiration dating period) be indicated for every human drug and 
biologic drug product prior to their testing in humans. 
For the purpose of worldwide stability testing, USA is geographically classified 
into Zone II (i.e., subtropical with possible high humidity climatic) based on the prevalent 
annual climatic conditions. For drug products intended for storage in this climatic zone, 
its stability should be evaluated at long-term (25°C ± 2°C/60% ± 5% RH), intermediate 
(30°C ± 2°C/ 65% ± 5% RH) and accelerated conditions (40°C ± 2°C/75% ± 5% RH). 
Exposing the product to such exaggerated storage conditions will accelerate the reaction 
rate and allow a) identification of likely drug degradation products and elucidate the 
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mechanism of the drug‘s degradation pathway b) establishment of relationships between 
the kinetic parameters, such as drug degradation rate and storage conditions, and c) 
predictions of drug product shelf-life by extrapolation of the degradation rate at market 
place storage conditions. 
In the present work, stability of the optimized in situ gel-forming eye drops 
(Formulation K0.3-High E2 in Section IV.C.4) that previously demonstrated acceptable in 
vitro and in vivo product performance characteristics will be evaluated at the conditions 
pre-defined in the ICH Q1A (R2) guideline on stability testing of new drug substances 
and drug products (see Section VII.B.2).  
 
VII.B. EXPERIMENTAL AND METHODS 
VII.B.1. Stability-Indicating HPLC Assay Method Development & Validation  
As part of developing a stability indicating analytical assay, forced degradation 
studies were carried out to induce possible estradiol degradation products, to elucidate 
degradation mechanism, and to detect the degradation products. The optimized in situ 
gel-forming formulation containing E2 (0.01%w/v), Kelcogel CG-LA (0.3%w/v) along 
with other excipients was prepared (procedure described in III.B.3.1) and subjected to: a) 
thermal degradation at 70°C for a week and b) being autoclaved at 120°C and 15psi 
pressure for 30 min. At the end of this study, samples were withdrawn and analyzed 
using HPLC. To identify and confirm the formation of a particular estradiol degradation 
product, USP reference standards of drug and other related substances were used.  
The US Pharmacopoeial regulations recommend monitoring of estrone, an 
oxidative degradation product of estradiol that has the potential to cause cancers 
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(Nygaard et al., 2004).  In addition, literature evidence indicated estriol to be one of the 
major hydrolytic degradation products of estradiol (Mazellier et al., 2008; Shareef et al., 
2006). Hence, a UV based stability-indicating gradient-HPLC method was developed for 
accurate measurement of E2 in the presence of E1 and E3 in the solution. The developed 
method was validated for specificity, linearity, accuracy and precision, limit of detection 
(LOD), and quantitation (LOQ) according to ICH Q2 (R1) guidelines as described below. 
Further, the drug samples from forced degradation studies were analyzed using the 
developed method to demonstrate its stability-indicating nature and also to confirm the 
formation of estrone and estriol as potential drug degradation products in the formulation.  
 
Instrumentation 
The HPLC system consisted of a Waters Alliance (Waters Corporation, Milford, 
MA, USA) equipped with a Waters 2690 separation module and Waters 2475 
fluorescence detector. Data acquisition was performed by the Empower
TM
 2 Pro software. 
Analysis was carried out at UV absorption wavelength of 280 nm with a Luna C18 (2) 
reversed-phase column of 250 mm  4.6mm i.d., 5 m dimensions (Phenomenex, 
Torrance, CA, USA) at ambient temperature. The mobile phase consisted of a gradient of 
acetonitrile and water 35:65 (v/v) ratios from 5.5 min to acetonitrile and water 50:50 
(v/v) ratios in 18 min set at a flow rate of 1mL/min. 
 
Preparation of Solutions 
Standard stock solutions of 30 μg/mL of Estradiol (E2), Estrone (E1), and Estriol 
(E3) were prepared by dissolving accurately weighed amounts in ethanol. Calibration 
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standards were then prepared at concentrations of 1, 1.5, 2, 2.5 and 3 μg/mL from the 
respective standard solution by appropriate dilution with ethanol. 
 
Linearity and Range 
The calibration curves were constructed for E2 and its impurities E1 and E3 in the 
range of 1-3 μg/mL. The UV absorbance units of the solutions were considered for 
plotting the linearity graph. The linearity was evaluated by linear regression analysis, 
which was calculated by least square regression method.  
 
Specificity  
Specificity of the developed method was evaluated to accurately measure E2 in 
the presence of related substances E1 and E3. Six replicates of the test sample containing 
theoretical concentration of 2 μg/mL were used for the analysis. Specificity was reported 
as the mean peak retention times along with standard deviation.  
 
Accuracy and Precision  
Accuracy and precision of the assay method were evaluated for both intra-day and 
inter-day variations at three different concentrations (i.e., 1, 2, and 3 μg/mL) for three 
consecutive days. Accuracy and precision were expressed in terms of percent mean 
recovery and percent relative standard deviation (%RSD or %CV), respectively. 
Repeatability or intra-assay precision refers to the variations in the recovery values 
obtained upon analyzing the above samples within the laboratory over a short period of 
time during the same day. Whereas, intermediate precision represents inter-assay 
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variations measured across different days (i.e., 3 days). Analysis of variance (ANOVA) 
was used to identify statistical differences in the intra- and inter-day recovery values.  
 
Limit of Detection and Quantitation 
LOD and LOQ were calculated based on the standard deviation of the response 
(σ) and slope (S) of the calibration curve obtained from multiple calibration curves. LOD 
being given by the 3.3σ/S and LOQ given by 10σ/S: Where σ is the standard deviation of 
the intercept of the calibration curves and S is the mean slope of the calibration curves. 
 
VII.B.2. Stability of the Optimized In Situ Gel-Forming E2 Eye Drops 
Formulation Preparation and Testing 
The optimized formulation containing E2 (0.025%w/v), Kelcogel CG-LA 
(0.3%w/v), mannitol (4.75%w/v), potassium sorbate (0.3%w/v), EDTA (0.03%w/v) 
(Formulation K0.3-High E2 in Section IV.C.4) was prepared and sterilized according to 
the procedure previously described in III.B.3.1. 20 mL of the sterile formulation was then 
aseptically transferred into sterile glassvials under the laminar fume hood and sealed. The 
vials containing the optimized formulation were evaluated for drug stability at the storage 
conditions (shown in Table VII.1.) defined in ICH Q1A (R2) guideline on stability testing 
of new drug substances and drug products. The summary of product performance 
characteristics, the time points at which they were tested, and specifications of the 
parameters estimates monitored during storage are listed in Table VII.2.  
The procedures for testing the characteristics such as pH, osmolality, clarity, and 
antimicrobial efficacy were previously discussed in Section III.B.3.2. Whereas, the 
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procedures for rheological characterization and drug release testing are outlined in 
Section IV.B.4.2. However, drug potency during storage was measured using the 
validated stability-indicating HPLC method discussed earlier in this chapter.  
 
Table VII.1. Storage conditions used in stability study of the optimized in Situ gel-
forming E2 eye drops 
Storage Condition Temperature Relative Humidity 
Accelerated (ACC) 40°C ± 2°C 75% ± 5% 
Intermediate (INT) 30°C ± 2°C 65% ± 5% 
Long Term (Real-Time) 25°C ± 2°C 60% ± 5% 
 
Data Analysis and Interpretation 
The parameter estimates obtained for different product performance 
characteristics at different time points and storage conditions were compared with 
specifications and analyzed for statistical significance by ANOVA. The significance level 
(α) for all analyses was ≤0.05. 
In case of E2 potency, drug degradation upon storage at different temperatures at 
different time points was characterized by treating the data to zero and first order reaction 
kinetic models. The integral forms of the zero-order and first-order reaction rates are 
shown in Eq. VII.1 and VII.2.   
tKCC oot        Equation VII.1. 
tKClnCln ot        Equation VII.2. 
Where Co and Ct are the concentrations at initial time and at time t. Ko and K are 
the zero-order and first-order reaction rate constants in units of concentration/time and 
(1/time), respectively. Accordingly, based on the order of the reaction, the shelf-life 
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defined as the time taken to reach 90% of the initial drug concentration or time taken for 
10% drug degradation was given by: 
For zero-order reaction, shelf life (t90%) = 0.1Co/Ko  Equation VII.3. 
For first-order reaction, shelf-life (t90%) = 0.105/K  Equation VII.4. 
In case of drug release testing, the drug release data was characterized using the 
power-law model proposed by Korsemeyer-Peppas in Eq. IV.4 and the t20 and t80 were 
compared for statistical significance using ANOVA. Also, the differences in the drug 
release profiles at different storage conditions and times during storage were analyzed by 
computing similarity factor, f2 proposed by Moore and Flanner (1996). The similarity 
factor is a statistic that measures the closeness of between two dissolution profiles and is 
given by Equation VII.5. 
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Where n is the number of time points, Rt is the dissolution value of the reference product 
at time t, and Tt is the dissolution value of the test product. The larger the value of f2 or 
the closer the value of f2 is to 100, the smaller is the difference between the two curves. 
The FDA suggests that the two dissolution profiles are considered to be similar if the f2 
similarity factor is between 50 and 100 (SUPAC-IR, 1995). The lower acceptable value 
(i.e., 50) corresponds to 10% average absolute difference between a reference product 
and a test product at each time point. 
 
 
 
 222 
Table VII.2. List of product characteristics monitored for stability during storage 
Formulation 
Characteristic 
Acceptable Value 
Testing Frequency 
(months) 
A. pH 6-7 0, 2, 4, 6 
B. Osmolality 275-325 mOsm/kg 0, 2, 4, 6 
C. Clarity 
Visually clear (or) light transmittance 
>85% at 490 nm using water as reference 
0, 2, 4, 6 
D. E2 Potency 90-110% assay 0, 2, 4, 6 
E. Anti-microbial 
efficacy 
Compliance with USP for Class-I products 0, 3, 6 
F. Rheology   
a) Flow behavior Apparent viscosity (μ)< 50cps at 100 s-1 0, 2, 4, 6 
b) Viscoelasticity G‘>>G‖, and δ<45° 0, 2, 4, 6 
G. Drug Release t20% ≤ 0.5 hr  and t80% in 6-12 hr and 0, 2, 4, 6 
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VII.C. RESULTS AND DISCUSSION 
VII.C.1. Stability-Indicating HPLC Assay Method Development & Validation  
The least squared regression analysis of the calibration curve data of E1, E2, and 
E3 in the range of 1-3 μg/mL was shown in Figure VII.1. The observed high correlation 
coefficient (r
2
=1) indicated good agreement and linearity between increasing levels of E1, 
E2, and E3, and their corresponding peak areas. The appearance of well resolved peaks for 
E1 (peak retention time (RT) of 15.1±0.3), E2 (peak RT of 11.4±0.7) and E3 (peak RT of 
5.5±0.5) in the overlay of the chromatograms of the calibration standards in Figure VII.2 
demonstrated the specificity of the developed gradient-HPLC method for accurate 
estimation of E2 in the presence of its impurities E1 and E3. The stability-indicating nature 
of the developed method was confirmed as the method accurately identified both the drug 
degradation products E1 and E3 along with E2 in the forced degradation samples shown in 
Figure VII.3 and VII.4. Based on the results, it was observed that estrone (oxidative 
degradation product of E2) was the prominent impurity upon thermal degradation; 
whereas, estriol (hydrolytic degradation product of E2) was found to be the significant 
drug degradation product upon steam sterilization of the drug product in the autoclave.  
The gradient-HPLC method was further validated in compliance with ICH Q2 
(R1) guidelines. The results of validation studies are shown in Table VII.3. It was 
observed that the developed method was accurate (% mean recovery: 99.2 ± 0.7, 99.1 ± 
1.5, 97.9 ± 0.9 for E1, E2, and E3, respectively), precise (CV :< 0.7 %,< 1.5%, and <0.9% 
for E1, E2, and E3, respectively) and highly reproducible with low intra-day (CV: <1.2%, 
<2.4%, and <2.4% for E1, E2, and E3, respectively) and inter-day variation (CV: <2.6%, 
<3.3%, <3.4% for E1, E2, and E3, respectively). Two-way ANOVA analysis indicated no 
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significant differences between the intra- and inter-day recoveries at different analyte 
(i.e., E1 or E2 or E3) concentrations (p>0.05). The limits of detection were found to be 
0.2, 0.1, and 0.1 μg/mL for E1, E2, and E3, respectively. Similarly, the limits of 
quantitation of E1, E2 and E3 using the developed method were found to be 0.6, 0.4, and 
0.4 μg/mL, respectively. 
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Figure VII.1. Regression plots of calibration standards of E1, E2 and E3 
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Figure VII.2. Overlay of HPLC chromatograms of E1, E2 and E3 calibration standards 
 
 
 
 
Figure VII.3. HPLC chromatogram of E2 (2 g/mL) upon forced degradation at 70C  
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Figure VII.4. HPLC chromatogram of E2 (2 g/mL) upon autoclave at 120C and 15 psi 
for 30 minutes  
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Table VII.3. Validation parameters of stability-indicating E2 gradient-HPLC assay 
method 
Lineari
ty and 
Range 
E1 1 - 3μg/ml (r
2-0.99) 
E2 1 - 3μg/ml (r
2-0.99) 
E3 1 - 3μg/ml (r
2-0.99) 
Specifi
city 
E1 2μg/ml solution of E1  has retention time (RT) of 15.1 ± 0.3 min 
E2 2μg/ml solution of E2  has retention time (RT) of 11.4 ± 0.7 min 
E3 2μg/ml solution of E3  has retention time (RT) of 5.5 ± 0.4 min 
 
Accura
cy and 
Precisi
on 
Con
c. 
(μg/
ml) 
E1 E2 E3 
Intra-day Inter-day Intra-day Inter-day Intra-day Inter-day 
Accu
racy 
Preci
sion 
Accu
racy 
Preci
sion 
Accu
racy 
Preci
sion 
Accu
racy 
Preci
sion 
Accu
racy 
Preci
sion 
Accu
racy 
Preci
sion 
1 
99.5 
± 1.1 
1.1 
98.7 
± 2.2 
2.2 
100.1 
± 0.7 
0.7 
98.1 
± 1.9 
1.9 
98.6 
± 1.1 
1.1 
96.8 
± 2.9 
3.0 
2 
98.3 
± 0.9 
1.0 
100.2 
± 2.6 
2.6 
101.5 
± 2.4 
2.4 
97.3 
± 3.2 
3.3 
97.9 
± 2.4 
2.4 
97.8 
± 3.4 
3.4 
3 
99.2 
± 1.2 
1.2 
99.5 
± 1.1 
1.1 
99.3 
± 2.2 
2.2 
98.2 
± 0.7 
0.7 
97.2 
± 1.6 
1.6 
99.2 
± 1.9 
1.9 
Limit 
of 
Detecti
on 
(LOD) 
E1 0.2μg/ml 
E2 0.1μg/ml 
E3 0.1μg/ml 
Limit 
of 
Quantit
ation 
(LOD) 
E1 0.6μg/ml 
E2 0.3μg/ml 
E3 0.3μg/ml 
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VII.C.2. Stability of the Optimized In Situ Gel-Forming E2 Eye Drops  
pH, clarity and osmolality: The summary of critical product performance characteristics 
of the optimized in situ gel-forming E2 solution eye drops obtained during storage at 
different conditions and time points are summarized in Table VII.4.  
 The pH of the formulation during stability study was well within the specification 
limits and varied between 6.35-6.36 units. Storage conditions had no significant 
influence on the corresponding pH of the preparation at different time points 
(p>0.05, one-way ANOVA).  
 The clarity of the solution eye drops remained clear throughout the study period. 
The percent light transmittance of the eye drops in the visible range, at 490 nm 
wavelength, was >95% at all storage conditions and time points (Table VII.4).  
 The osmolality of the optimized formulation during storage as shown in Table 
VII.4 was within the acceptable range of 275-325 mOsm/Kg. Analysis of the 
osmolaity data obtained at different time points during storage at different 
conditions using one-way ANOVA indicated no significant differences (p>0.05). 
 
Antimicrobial Efficacy: The results of USP antimicrobial efficacy of the optimized in 
situ gel-forming E2 solution eye drops are summarized in Table VII.4. The optimized 
formulation was found to be antimicrobially effective against the test microorganisms - 
Pseudomonas aeruginosa, Escherichia coli, and, Staphylococcus aureus throughout the 
study duration.  The sterility of the formulation was maintained during storage for 6 
months at room temperature, intermediate, and accelerated storage conditions. The 
observed evidence of antimicrobial efficacy demonstrated that the preservative mixture 
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composed of potassium sorbate and EDTA at the concentrations used in the formulation 
was optimum.    
 
Table VII.4. Summary of critical characteristics of the optimized in situ gel-forming E2 
eye drops at different storage conditions 
pH (units) 
Storage Condition 0 2 month 4month 6month 
Long Term (RT) 6.36±0.01 6.36±0.02 6.35±0.01 6.36±0.02 
Intermediate (INT) 6.36±0.01 6.36±0.02 6.35±0.03 6.36±0.03 
Accelerated (ACC) 6.36±0.01 6.36±0.02 6.35±0.03 6.35±0.04 
Osmolality (mOsm/Kg) 
Storage Condition 0 2 month 4month 6month 
Long Term (RT) 289±3 291±2 289±2 290±4 
Intermediate (INT) 289±3 289±4 287±3 288±4 
Accelerated (ACC) 289±3 288±4 292±5 291±5 
Clarity (%UV transmittance) 
Storage Condition 0 2 month 4month 6month 
Long Term (RT) 97±2 96±2 96±3 95±2 
Intermediate (INT) 96±1 95±2 96±2 95±2 
Accelerated (ACC) 96±2 95±3 97±2 95±2 
Antimicrobial efficacy 
Storage Condition 0 3month 6month 
Long Term (RT) Yes Yes Yes 
Intermediate (INT) Yes Yes Yes 
Accelerated (ACC) Yes Yes Yes 
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Apparent Viscosity:  
The apparent viscosity of the optimized formulation measured at the shear rate of 
100s
-1 
during storage was summarized in Table VII.5. The apparent viscosity of the 
formulation varied in the range of 12.5-23.2 cps depending upon the storage condition. 
The viscosity of the formulation decreased with increases in the storage temperature. 
However, the apparent viscosities were within the acceptance criteria (i.e., <50cps at 
100s
-1
) through out the study duration. Statistical one-way ANOVA analysis of the 
viscosity data using Prism
®
 indicated that long-term storage conditions of  25°C/60%RH 
did not have statistically significant (p>0.05) influence on the apparent viscosity of the 
formulation. Whereas, intermediate and accelerated storage conditions of 30°C/65%RH 
(INT) and 40°C/75%RH, respectively, showed statistically significant influence on the 
apparent viscosity of the formulation at 4 and 6 months (p<0.05). But, the apparent 
viscosities were still within the specification limits, and hence, formulations are 
considered stable. The influence of storage condition on the rheological flow curve of the 
optimized formulation at day 0 and day 180 (6 months) was shown in Figure VII.5. The 
decrease in apparent viscosities with increases in the applied shear rate confirmed that the 
shear thinning or pseudoplastic nature of the formulation was conserved during storage.  
 
Table VII.5. Apparent viscosity of the optimized in situ gel-forming E2 eye drops at 
different time points during storage at different conditions  
Apparent Viscosity (cps) at 100s
-1
  
Storage Condition 0 2 month 4 month 6 month 
Long Term (RT) 23.2±1.2 22.7±0.5 21.6±0.9 21.0±1.1 
Intermediate (INT) 23.2±1.2 21.9±0.3 *20.4±0.2 *19.6±0.3 
Accelerated (ACC) 23.2±1.2 20.9±0.3 *15.7±0.3 *12.5±0.6 
 *p<0.05; n=3 in all cases 
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Figure VII.5. Flow curves showing the effect of storage conditions on apparent viscosity 
of the optimized in situ gel-forming formulation 
 
Viscoelasticity: 
 Frequency sweep plots of the optimized in situ gel-forming E2 solution eye drops 
measured in the presence of STF (30:7 v/v ratios) at different time points during storage 
at real-time and accelerated conditions are shown in Figure.VII.6 and VII.7, respectively. 
The power-law rheology model fitting parameters and the viscoelastic parameter 
estimates of the optimized formulation obtained during storage are similarly summarized 
in Table VII.7. The optimized formulation showed evidence of phase transition and in 
situ gel-structure formation in the presence of STF at all time points during storage as 
G‘>G‘‘, δ<45° (shown in Table VII.6). Further, the frequency sweep plots at room 
temperature and accelerated storage conditions (Figure VII.6 and VII.7) showed 
moderate to weak dependency of elastic modulus (G‘) on angular frequency according to 
power-law rheology model with the model exponent ―n‖ values in the range of 0.3-0.4 
(Table VII.7). The n value in this range further confirms the nature of the material formed 
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to be viscoelastic and that it corresponds to a gel state according to the acceptance 
criteria.  
 The magnitude of viscoelastic parameter estimates (i.e., G‘ and G‘‘) decreased 
with change in storage condition as well as length of storage (Table VII.4). The modulus 
of elasticity (G‘) values reflective of the strength of the gel structure formed varied in the 
range of 0.85-0.92 Pa and 0.92-0.66 Pa during storage for 6 months at long-term (RT) 
and accelerated (ACC) conditions, respectively. Statistical one-way ANOVA analysis of 
the elastic modulus data using Prism
®
 indicated that long-term storage conditions of  
25°C/60%RH did not have statistically significant (p>0.05) influence on the gel strength 
or viscoelasticity of the formulation throughout the study duration.  In contrast, storage at 
accelerated conditions of 40°C/75%RH, resulted in statistically significant decrease in the 
gel strength or elastic modulus of the formulation at 4 and 6 months (p<0.05). Such 
decrease in gel strength of the formulation upon accelerated storage indicate the 
susceptibility of the polymer in the formulation to physically degrade and lose capacity to 
form stronger gel structures in the presence of simulate tear fluid at higher temperature 
and relative humidity (i.e., > 40°C/75%RH). 
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Table VII.6. Summary of viscoelastic parameter estimates and power-law rheology 
model fitting parameters of the optimized in situ gel-forming E2 eye drops at different 
accelerated storage conditions 
Storage 
Condition 
Time 
(month) 
Viscoelastic Indices Model-fitting Parameters 
G‘ (Pa) G‖ (Pa) δ (°) n r2 
--- 0 0.92±0.01 0.49±0.01 27.7±0.5 0.3 0.99 
RT 2 0.92±0.07 0.50±0.01 28.5±2.1 0.3 0.99 
ACC 2 0.84±0.01 0.46±0.02 28.7±1.3 0.3 0.99 
RT 4 0.85±0.02 0.40±0.01 25.2±0.2 0.4 0.96 
ACC 4 *0.77±0.01 0.40±0.01 27.2±0.1 0.3 0.99 
RT 6 0.84±0.01 0.46±0.02 28.7±1.3 0.3 0.99 
ACC 6 *0.66±0.01 0.33±0.01 26.6±0.2 0.3 0.99 
   *p<0.05 (1-wayANOVA); n=3 in all cases  
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Figure VII.6. Effect of storage at 25°C/60%RH on the frequency dependency of the 
elastic modulus of the optimized in situ gel-forming E2 solution eye drops  
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Figure VII.7. Effect of storage at 40°C/75%RH on the frequency dependency of the 
elastic modulus of the optimized in situ gel-forming E2 solution eye drops.  
 
Potency of E2: 
 The results of potency of E2 in the in situ gel-forming solution eye drops during 
storage at RT, INT, and ACC conditions are summarized in Table VII.7. E2 potency at 
day 0 and day 180 varied in the range of 100.3%-99.3%, 100.3%-97.7%, and 100.3%-
96.6% at RT, INT, and ACC storage conditions, respectively.  The change in E2 potency 
with time at different storage conditions was illustrated in Figure VII.8. At any tested 
condition, the degradation was <5% and no degradation products were detected using the 
stability indicating assay, suggesting the stability of the optimized formulation.    
Statistical one-way ANOVA analysis (using GraphPad Prism
®
 Version 5) of the potency 
data obtained for the optimized formulation at different storage conditions indicated that 
only at 6 months storage at accelerated storage condition of 40°C/75%RH, the E2 potency 
was statistically significant (p<0.05) compared to the observed potency at day 0 (Figure 
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VII.9). Although significant, the E2 potency values of the formulation were within the 
specification limit of 90-110% throughout the study duration at all tested storage 
conditions, and hence considered highly stable and desirable. 
 
Table VII.7. Potency of E2 at different time points in the optimized in situ gel-forming 
solution eye drops stored at different conditions. 
Storage Time 
E2 Potency (Mean % ± SD) 
Storage Condition 
RT INT ACC 
Zero/Initial 100.3 ± 1.2 --- --- 
1-Month 99.4 ± 0.7 99.9 ± 1.1 100.0 ± 3.3 
2-Month 99.1 ± 0.9 99.1 ± 2.4 97.8 ± 2.6 
3-Month 99.0 ± 1.9 98.9 ± 1.6  98.4 ± 1.2 
4-Month 99.7 ± 3.2 98.3 ± 1.9 97.9 ± 1.4 
6-Month 99.3 ± 1.5 97.7 ± 1.5 *96.6 ± 1.2 
          *p<0.05(1-wayANOVA)  
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Figure VII.8. Effect of storage conditions on the potency of E2 in the optimized in situ 
gel-forming solution eye drops at different time points 
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Figure VII.9. E2 potency (Mean ± SD) in the optimized in situ gel-forming solution eye 
drops stored at 40°C/75% RH at different time points. 
  
 The E2 degradation in the solution eye drops followed zero-order kinetics at all 
tested storage conditions (Figure VII.10-VII.12). The degradation rate constant at real-
time (RT) storage condition was 0.003%/day and the estimated shelf-life (t90) was 3323 
days or 9.1 years (Table VII.8). The degradation rate constant at intermediate (INT) 
storage condition was 0.015%/day and the estimated shelf-life (t90) was 668 days or 1.8 
years (TableVII.8). The degradation was relatively faster at accelerated (ACT) storage 
condition with rate constant of 0.02%/day and estimated shelf-life (t90) of 500 days or 1.4 
years (TableVII.8). Such long shelf-life at ACC storage conditions indicates acceptable 
stability of the formulation. ICH guidelines recommend a tentative shelf-life of 2 years at 
room temperature if the product remains stable and drug potency varied within the 
specification limits of 90-110% at accelerated storage condition for 6 months (ICH Q2 
(R1), 1996; ICH Q1A (R2), 2003a). Accordingly, a tentative shelf-life of 2 years was 
assigned for the optimized in situ gel-forming E2 solution eye drops for storage at room 
temperature. 
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Table VII.8. Summary of zero-order degradation rate constants of the optimized E2 in 
situ gel-forming solution upon storage at different conditions for 6 months  
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Figure VII.10. Zero-order degradation kinetics of E2 in the optimized in situ gel-forming 
solution eye drops stored at 25°C/60% RH for 180 days 
Storage Condition 
RT INT ACC 
Ko(%/day) t90(days) Ko(%/day) t90(days) Ko(%/day) t90(days) 
0.003 3323 0.015 668 0.020 500 
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Figure VII.11. Zero-order degradation kinetics of E2 in the optimized in situ gel-forming 
solution eye drops stored at 30°C/65% RH for 180 days 
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Figure VII.12. Zero-order degradation kinetics of E2 in the optimized in situ gel-forming 
solution eye drops stored at 40°C/75% RH for 180 days 
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Drug Release Characterization: 
The cumulative E2 release profiles from the optimized in situ gel-forming solution 
eye drops at different time points during storage at real-time (RT) and accelerated (ACC) 
conditions are shown in Figure VII.13 and VII.14, respectively. The drug release was 
found to be sustained with 80% of the drug released in 6-12 hr. Burst release of the drug 
from in situ gel-forming solutions was also observed with 20% of the drug released (i.e. 
t20%) in 0.4-0.5 hr. 
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Figure VII.13. Dissolution Profiles of E2 in the optimized in situ gel-forming solution 
eye drops at different time points during storage at 25°C/60% RH. 
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Figure VII.14. Dissolution Profiles of E2 in the optimized in situ gel-forming solution 
eye drops at different time points during storage at 40°C/75% RH 
 
The model fitting parameters and drug release estimates (i.e., t20% and t80%) 
obtained upon treating the drug release data to Korsemeyer-Peppas Model are 
summarized in Table VII.9. The release rate constant (K) was in the range of 27.4- 
28.4(%h
-n
) at real-time (RT); whereas for the accelerated storage (ACC) condition, it was 
in the range of 27.4-31.8 (%h
-n
). The magnitude of the release exponent n was in the 
range of 0.50-0.51 at real-time storage condition; whereas for the accelerated storage 
(ACC) condition, it was in the range of 0.48-0.52. The cut-off value of n for a purely 
Fickian diffusion mechanism in case of gel systems with aspect ratio of 3.6 (i.e., 2a = 
21.34mm and l = 5.96mm) was 0.45 (Figure IV.17). The n values >0.45 suggest that a) 
E2 release from the gels during storage was function of drug diffusion from the polymer 
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gel matrix as well as polymer relaxation, and b) E2 release kinetics or mechanism of drug 
release was not significantly influenced by the storage conditions.  
As shown in Table VII.9, the time for 20% or 80% of the drug to be released 
(t20%) or   (t80%) respectively, decreased with storage condition and storage time. At room 
temperature, t80% decreased from 8.1 hr at day 0 to 7.9 hr at 6 months; whereas for the 
accelerated storage condition, t80% decreased from 8.1 hr at day 0 to 6.8 hr at 6 months. 
Faster drug release at accelerated condition was due to concomitant decrease in the 
strength of the gel-structure (i.e., G‘) at higher temperature (i.e., 0.94 Pa at day 0 vs. 0.66 
Pa at day 180 at accelerated condition). Although, the drug release was little faster upon 
storage at accelerated condition, the drug release parameter estimates are well within the 
acceptable criteria (Table VII.2).  
 
Table IV.9. Summary of model fitting parameters and drug release estimates of E2 in the 
optimized in situ gel-forming solution eye drops during storage. 
Storage 
Time 
Storage 
Condition 
K n r
2
 
t20 
(hr) 
t80 
(hr) 
Zero 25°C/60%RH 27.4±0.3 0.51±0.01 0.98 0.54±0.02 8.12±0.04 
2-month 
25°C/60%RH 27.4±0.6 0.51±0.01 0.99 0.54±0.03 8.15±0.05 
40°C/75%RH 27.4±0.1 0.52±0.01 0.99 0.54±0.01 7.93±0.06 
4-month 
25°C/60%RH 27.7±0.2 0.51±0.01 0.98 0.53±0.01 8.08±0.02 
40°C/75%RH 30.1±0.2 0.49±0.01 0.99 0.43±0.01 7.49±0.11 
6-month 
25°C/60%RH 28.4±0.1 0.50±0.01 0.99 0.51±0.02 7.85±0.04 
40°C/75%RH 31.8±0.3 0.48±0.01 0.99 0.38±0.01 6.84±0.06 
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Table VII.10. Comparison of dissolution profiles of E2 in situ gel-forming eye drops 
during storage using similarity factor (f2). 
Storage 
Time 
Similarity Factor  (f2) Difference Factor (f1) 
25°C/60%RH 
(RT) 
40°C/75%RH 
(ACC) 
25°C/60%RH 
(RT) 
40°C/75%RH 
(ACC) 
2-month 93 91 1 2 
4-month 94 74 1 6 
6-month 82 62 3 11 
 
The similarity factor (f2) was used to compare E2 dissolution profiles from the 
optimized in situ gel-forming solution at day 0 and at different time points during storage 
at 25°C/60% RH (RT) as well as 40°C/75%RH (ACC). The f2 results are summarized in 
Table VII.10. The f2 values for E2 drug release upon storage at RT at 2, 4, and 6 months 
was 93, 94, and 82, respectively. Similarly, the f2 values for E2 drug release upon storage 
at accelerated condition at 2, 4, and 6 months was 91, 74, and 62, respectively. The f2 
values in the range of 50-100 at each time point and storage condition suggest that the 
drug release profiles are statistically similar (SUPAC-IR, 1995). However, the larger the 
value of f2 or the closer the value of f2 is to 100, the smaller is the difference between the 
two curves. Hence, it can be concluded that the differences in the drug release profiles 
upon storage at 25°C/60% RH (RT) were smaller compared to storage at 40°C/75%RH 
(ACC).  
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VII.D. CONCLUSIONS 
Forced degradation of the prototype E2 in situ gel-forming formulation indicated 
estrone (E1) and estriol (E3) to be the major E2 degradation products. The stability 
indicating HPLC-method was successfully developed and validated to accurately 
measure E2 concentration in the presence of its impurities. The developed method was 
found to be simple, precise and accurate and reproducible 
Analysis of the optimized formulation during storage at 25°C/60%RH (RT), 
30°C/65%RH (INT), and 40°C/75%RH (ACC) for six months indicated acceptable in 
vitro product performance characteristics throughout the study duration.  
The critical product characteristics such as pH, clarity and osmolality remained 
stable within the specification limits at all tested conditions. The optimized formulation 
was sterile and the antimicrobial efficacy was preserved during storage. Therefore, the 
formulation is considered stable and highly desirable. 
The formulation was found to be shear thinning as alone and viscoelastic in the 
presence of simulated tear fluid at all temperatures and storage conditions. The 
rheological parameter estimates (i.e., apparent viscosity/ gel strength) were within the 
specification limit throughout storage. However, increase in temperature from room 
temperature to intermediate or accelerated conditions resulted in statistically significant 
decrease in the apparent viscosity and elastic modulus of the optimized formulation at 4 
and 6 months of storage.   
Effect of storage on drug degradation was found to be minimal as the potency 
remained >97% throughout the stability study. As the degradation was <5%, 2 years 
tentative shelf-life period was assigned to the product. Similarly, storage conditions did 
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not show significant influence on the drug release estimates of the optimized in situ gel-
forming solution eye drops. Further, comparison of the E2 release data using similarity 
factor (f2) indicated the drug release profiles to be similar throughout the study duration. 
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CHAPTER VIII 
 
SUMMARY 
 
Cataracts are very common, with the highest risk in aging women.  Currently, 
there are no therapies that can delay or prevent cataract development.  Studies on 
estrogen in women and animal models indicate it has promise to protect the lens from 
developing cataracts. The prospect of the lens being responsive to estrogens opened the 
possibility that age-related cataracts can be delayed or prevented with estrogen 
replacement therapy. Knowing estrogen directly influences the lens presented the option 
of topical treatments, which may provide a means to minimize negative side effects of 
systemically administered estrogen (i.e., risk of endometrial cancer).  Hence, the focus of 
this dissertation was to develop an ophthalmic estrogen therapy that can be instilled 
directly to the eye with prolonged contact time and with minimal systemic absorption to 
locally supplement estrogen levels that decline with age without the need for systemic 
hormone therapy.  The project is the first to investigate the potential of a topical 
ophthalmic estrogen delivery system to prevent or delay the onset of age-related 
cataracts.  
 
As described in Chapter III, SBE 7 was used as the aqueous solubility enhancing 
agent of estradiol because of its well established safety and extended hydrophobic cavity. 
In the presence of SBE 7, the aqueous solubility of E2 was significantly enhanced due to 
inclusion of E2 aromatic ring into the hydrophobic SBE 7 cavities. The inclusion complex 
was thermodynamically stable, as E2 inclusion into the SBE 7 cavity displaced the 
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enthalpy-rich water causing the release of energy that favored the formation of inclusion 
complex. The stoichiometry of 1:1 between E2 and SBE 7 was observed in the complex. 
Pre-formulation studies identified excipients that provided desirable characteristics to the 
ophthalmic preparations, such as osmolality, clarity, sterility, etc. Deacetylated gellan 
gum (Kelcogel
®
 CG-LA) was used as a suitable vehicle for in situ gel-forming systems as 
its solutions were visibly clear and remained liquid in vitro, but formed a gel on contact 
with the mono (Na
+
, K
+
) and divalent cations (Ca
2+
) in the tear fluid. The mechanism of 
gelation involved reduction in electrostatic repulsions between the carboxyl groups of the 
gellan gum chains in the presence of cations; which promoted a coil-to-helix transition 
followed by helix aggregation to form a gel network. Rheological characterization 
illustrate that the hydrogel formed was viscoelastic in nature with potential to increase 
contact time in the eye and provide improved drug absorption and increased duration of 
therapeutic effect. Mannitol was used as a tonicity adjusting agent in the formulation to 
adjust its osmolality and make it isotonic with physiological fluids. Quaternary 
ammonium preservative, benzalkonium chloride, was used in the formulation because of 
its established efficacy against both gram positive and gram negative microorganisms and 
extensive use in commercial ophthalmic preparations. But, in the presence of other 
anionic excipients (i.e., gellan gum and SBE 7) in the formulation, its efficacy in 
inhibiting the growth of microorganisms was lost due to low amounts of free preservative 
available as a result of excipient-excipient columbic interactions.  
In order to overcome the challenge of preservative inefficacy of the prototype in 
situ gel-forming formulation, in Chapter IV, use of a non-ionic drug solubilizing agent 
and new preservative system was described. Polysorbate 80 was used as a non-ionic 
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solubilizing agent to increase the aqueous solubility of estradiol. A preservative system 
composed of potassium sorbate (0.3%w/v) and disodium-EDTA (0.03%w/v) was used to 
achieve USP anti-microbial efficacy. EDTA binds to the essential minerals in the 
microbial cytoskeleton and disorganizes its assembly, thereby to enhance the 
permeability of potassium sorbate and to provide a synergistic anti-microbial effect. 
Using this new preservative mixture and non-ionic polysorbate 80, the excipient-
excipient ionic interactions were minimized and the formulations demonstrated USP 
antimicrobial efficacy. Gellan gum, being a polysaccharide, has shown potential to 
support microbial growth in the formulation. Pre-optimization studies illustrate the need 
for adjusting preservative concentrations with the gellan gum concentration in the 
formulation. Also, with the preservatives being the salts of potassium and sodium, they 
displayed the tendency to interact with anionic gellan gum polymer and, at higher 
polymer concentrations (i.e., 0.5% w/v Kelcogel
®
 CG-LA), resulted in formulations that 
are too viscous to flow. Therefore, formulations containing lower concentrations between 
0.1-0.3% w/v Kelcogel
®
 CG-LA were used for further testing.   
Analyses of statistically designed formulations illustrated the significant influence 
of polymer and drug concentrations on the product performance characteristics of the in 
situ gel E2 formulations. The drug release from in situ gel followed non-Fickian 
mechanism, with which drug release is a function of its diffusion from the gel matrix as 
well as polymer relaxation. The deviation from purely Fickian mechanism was attributed 
to the reason that the formulations during gelation imbibe large amount of dissolution 
media leading to a swollen state of the gel. Formulations containing 0.1-0.3%w/v 
Kelcogel
®
 CG-LA and 0.001-0.025%w/v E2 concentrations demonstrated acceptable 
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characteristics of in situ gel-forming ophthalmic solutions and, hence, were used for 
further in vivo evaluation of product safety and efficacy in animal models.  
As described in Chapter V, estrogen delivered by ophthalmic route was able to 
induce known estrogen responses in the eye. In pre-pubertal ERΔ3 mice, gross cataracts 
were observed as early as 2 weeks post-treatment with ophthalmic in situ gel-forming E2 
eye drops. No lens abnormalities were observed in mice treated with the vehicles, as 
estrogen was required to interact with the estrogen receptors in the lens and other ocular 
tissues and activate ERΔ3 repressor to result in cataract formation in this mouse model. 
The onset and severity of gross cataracts were found to be function of polymer and 
estradiol (E2) concentration in the ophthalmic eye drops, which suggests that increasing 
estrogen levels to the eye for longer periods would enhance ERΔ3 repressor activity and 
accelerate the lenticular changes observed with cataracts. At the same E2 dose/mouse, 
ophthalmic delivery of E2 using in situ gel-forming eye drops containing 0.3%w/v 
polymer concentration resulted in an earlier cataract onset vs. eye drops containing 0.1% 
polymer or systemic treatment. The better efficacy with the higher polymer content was a 
result of better gelling behavior and longer contact time in the eye.  
Similarly, at the same E2 dose/mouse (i.e., 40 μg/kg), ophthalmic treatment 
resulted in a significant increase in expression of pax6, a gene known to influence 
cataract development and which is increased in the ERΔ3 lens after short-term E2 
exposure vs. vehicle, unlike the same systemic dose (sc). Also, the estrogen-induced 
uterine stimulation due to systemic E2 absorption was lower with ophthalmic eye drops 
compared to systemic estrogen therapy at all tested E2 doses in pre-pubertal 
ovariectimized ERΔ3 female mice. At the lowest E2 dose of 0.4 μg/kg in ERΔ3 mice, the 
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ophthalmic eye drops containing 0.3%w/v polymer did not stimulate the uterus; but, were 
not tested for cataract induction. Therefore, additional testing is needed to determine if 
sufficient estrogen levels can be delivered to the eye to influence a known estrogen 
response in the lens without evidence of systemic bioavailability. However, as the 
ophthalmic E2 dose of 4 μg/kg did not stimulate uterus in rats and induced cataracts in 
ERΔ3 mice, this dose may not result in systemic bioavailability in humans while still 
protecting the lens.  These data suggest that the in situ gel-forming E2 eye drops 
containing 0.3%w/v Kelcogel CG-LA is an optimum formulation for future testing in 
pre-clinical models such as MNU-induced cataracts model in rats as a long-term 
treatment for cataract prevention. 
As described in Chapter VI, the optimized in situ gel-forming E2 eye drop 
formulation was well tolerated and did not show any clinically relevant signs of irritation 
or toxicity in the eyes or other ocular tissues in rabbits. Based on the Draize irritation 
score in rabbits, the optimized formulation was classified as practically non-irritating to 
the eyes. Upon ocular administration in rabbits, E2 from the optimized in situ gel-forming 
eye drop was able to rapidly permeate cornea and achieve maximum concentration in as 
early as 15 minutes. E2 was preferentially absorbed into the aqueous humor of the eye 
and resulted in the area under the curve (AUC) that was 250-fold higher than in the 
systemic circulation (serum). E2 concentrations in the aqueous humor were sustained due 
to sustained release nature of the drug from the in situ gel-matrix formed, and/or low E2 
metabolism due to lack of sufficient levels of drug metabolizing enzymes relative to 
systemic circulation.  
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Serum levels in the rabbits treated with the ophthalmic drops were substantially 
lower compared to animals receiving the same dose by IV injection; plus, these levels 
also decline to baseline levels within the 2 hr test period due to viscoelastic nature of the 
formed gel that reduced drug drainage through nasolacrimal duct and minimized systemic 
drug absorption. The systemic bioavailability (BA) of E2 upon topical administration of 
the in situ gel-forming eye drops was found to be 20%.  These data indicate that only low 
levels are systemically delivered compared to the high levels that are present in the 
aqueous humor.  Due to the effective delivery of high doses to the aqueous humor using 
the optimized in situ gel-forming eye drops, future studies using lower doses that do not 
result in detectable serum levels and yet provide sufficient levels in the ocular tissues to 
influence a known estrogen response will likely be sufficient to protect lens transparency. 
As described in Chapter VII, the optimized formulation was stable and storage 
conditions and duration had no significant influence on the product performance 
characteristics. The critical product characteristics such as pH, clarity, and osmolality 
remained stable within the specification limits at all tested conditions. The optimized 
formulation was sterile and the antimicrobial efficacy was conserved during storage. As 
the drug degradation was <5%, a tentative 2 year shelf-life period was assigned to the 
product for storage at room temperature. 
 
The results demonstrated in individual chapters illustrate that the optimized in situ 
gel-forming E2 eye drop formulation was stable and non-irritating to the eyes. It delivers 
sufficient estrogen to the lens and increases its contact time in the eye to induce known 
estrogen responses, which could occur with little to no effects on other non-ocular, 
estrogen-responsive tissues, such as the uterus. Although the optimized formulation was 
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very effective at inducing cataracts in ERΔ3 model, this model cannot demonstrate the 
protective influences of the ocular formulation on cataract development or progression.  
Therefore, in future studies the formulation will be tested for cataract prevention in 
animal models without the ER3 repressor and in which cataracts can be induced (such 
as MNU induced cataracts model in rats).  Once its efficacy in prevention is verified with 
limited to no uterine stimulation to confirm the minimal systemic exposure, the 
formulation can be tested in humans.   
The work described within this dissertation is significant in that it facilitates 
future testing in pre-clinical animal models and humans on the benefits of long-term 
treatment of topical estrogen in delaying cataract development. As delaying cataract 
development by one decade could reduce the number of cataract surgeries by almost half, 
this topical ophthalmic therapy could provide a significant health benefit to the elderly 
and, accordingly, reduce the substantial medical costs associated with these surgeries.   
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